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 Introduction ⏐11 
Non-dystrophic myotonic syndromes (NDMs) belong to the group of muscle disorders. 
The clinical approach to a patient with a suspected muscle disorder starts with a 
careful history and physical examination. Common presenting symptoms of a muscle 
disorder are negative muscle features like hypotonia, atrophy and muscle weakness. 
Examples of muscle diseases characterised by such negative features are the muscular 
dystrophies (e.g. dystrophinopathies), the congenital myopathies (e.g. nemaline and 
myotubular myopathy), and the inflammatory myopathies (among which polymyositis 
and dermatomyositis). Generally, less attention is paid to muscle diseases with 
positive muscle features like muscle cramps, involuntary muscle contractions, rippling 
muscles or myotonia, such as McArdle disease, rippling muscle disease and NDMs like 
myotonia congenita. Although myotonia is the main clinical feature in NDMs, several 
other clinical features can be distinguished (see Clinical box 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1a The skeletal muscle ion channelopathies, consisting of the non-dystrophic myotonic 
syndromes and periodic paralyses. 
 
 
 
 
 
 
 
 
Figure 1.1b Overexcited and/or inactive: the spectrum of myotonia and paresis in skeletal muscle ion 
channelopathies. 
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CLINICAL BOX 1 
 
Clinical features in non-dystrophic myotonic syndromes (NDMs) 
Myotonia is a clinical phenomenon that refers to a delayed muscle relaxation after voluntary or evoked 
muscle contraction1, which patients experience as muscle stiffness. It is a cardinal feature in myotonic 
disorders including NDMs.2 A clinical examination of patients with a suspected NDM almost always reveals 
action myotonia and/or percussion myotonia. Both phenomena are most commonly and easily tested in 
the hand and arm muscles: 
1. Action myotonia will be confirmed by a forceful grip after which the ability to relax the grip is 
abnormally delayed (Figure 1.2). 
2. Percussion myotonia may be confirmed by mechanical stimulation: a tap with the percussion hammer 
on the thenar muscles, for example, will make these muscles contract for a prolonged period of time.  
The first phenomenon may also be provoked in the eyelid muscles and both phenomena in leg muscles. 
 
In NDM patients a voluntary muscle contraction may also provoke transient paresis, i.e., a transient 
decline in muscle force.3 Myotonia as well as transient paresis may improve with continuing exercise, 
which is known as the warm-up phenomenon.4,5 Both phenomena are best examined in the biceps 
muscle,5 although the warm-up phenomenon may also be detectable in the eyelid muscles and both 
phenomena in the leg-muscles. Since both the warm-up phenomenon and the transient paresis may 
disappear after repetitive contractions, patients should be tested for these phenomena after a period of 
rest (e.g. after a 10 minute interval). 
 
In contrast to the warm-up phenomenon, myotonia may also worsen after repetitive contractions, which 
phenomenon is called paramyotonia, a bastardisation of paradoxical myotonia.6 In paramyotonia the 
muscle stiffness is already detectable after several contractions and subsequently worsens after 
additional repetitive contractions. Paramyotonia should, however, not be confused with “exercise-
induced delayed-onset myotonia”, in which the myotonia only appears after a prolonged period of 
exercise.7 
 
 
                                                                             
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  Myotonia of the right hand from a patient with recessive myotonia congenita. The patient was 
asked to make a maximum voluntary contraction for three seconds, subsequently he was asked 
to relax the muscles of the hand as fast as possible. It took six seconds to totally relax the hand-
muscles. 
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Pathophysiologically, NDMs belong to the skeletal muscle ion channelopathies. 
Skeletal muscle ion channels are voltage-gated ion channels that regulate the 
excitability of the skeletal muscle membrane (sarcolemma; see Clinical box 2). These 
ion channels are encoded by skeletal muscle ion channel genes. The skeletal muscle 
ion channelopathies are characterised by transient sarcolemma hyperexcitability 
(myotonia), hypoexcitability (paresis or paralysis) or both. This way of distinguishing 
the main symptoms corresponds well to the types of skeletal muscle ion 
channelopathies: 1. congenital myotonias without paralysis (chloride 
channelopathies) 2. congenital diseases with exclusively myotonia, exclusively 
paralysis or a combination of both (sodium channelopathies) and 3. congenital 
paralysis without myotonia (calcium channelopathies). The skeletal muscle ion 
channelopathies with their different types of symptoms and diseases are depicted in 
Figures 1.1a and 1.1b. 
 
CLINICAL BOX 2 
 
Muscle physiology 
Striated muscles are organs specialised for a rapid generation of motion and force. They have the ability 
to shorten rapidly and efficiently, and to switch on and off in milliseconds. The activation of the 
contractile apparatus of striated muscles is the result of a cascade of events in response to an electrical 
signal received from the motor nerve: motor neuron activity transfers via the neuromuscular junctions to 
the sarcolemma, where action potentials propagate from the motor endplate zone along the muscle fibre 
towards each tendon (see Figure 1.3 for a schematic overview). Subsequently, the excitation spreads 
along the transverse tubular system into the depth of the muscle fibres, which is necessary for a 
contraction. This process is initiated by intracellular calcium release brought about by direct interaction of 
channel proteins of the transverse tubular system and the sarcoplasmic reticulum.  
 
Inside the muscle cell, the electric potential is negative relative to its exterior. This so-called resting 
membrane potential, which is about -70 to -90 mV, sustained across the thin barrier of the sarcolemma, 
which has specific electrical properties for the maintenance of this potential. The basis of these properties 
lies in ion channels, which activate in response to ligands, transmitters, or voltage changes and inactivate 
by intrinsic inactivation processes. Voltage-gated ion channels are essential for the generation and 
modification of action potentials. The sarcolemma contains voltage-gated sodium, chloride, potassium 
and calcium channels. De- and repolarisations of the sarcolemma are regulated by fast moving ions that 
pass through these channels. With the membrane in rest, the Na gates of the Na channel are closed, the K 
gates of the K channels are closed and the Cl gates of the Cl channels are open. The normal resting 
membrane potential serves to keep the ion channels in an activatable state to accommodate for newly 
generated action potentials. An action potential is a transient reversal of the membrane potential caused 
by an alteration in the membrane’s permeability. In the case of an action potential, Na channels open up, 
allowing Na+ ions to enter the cell, causing a depolarisation. This action potential (with opening Na 
channels) is transmitted all along the sarcolemma. When the action potential has elapsed, the Na gates 
close and the K gates open, thus terminating the action potential. Shortly after, the K gates close and the 
Na-K pump in combination with the Cl channels will subsequently restore the resting membrane potential. 
In conclusion, a proper function of all these voltage gated ion channels is essential for a normal muscle 
contraction and relaxation. 
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Figure 1.3 Schematic overview of the neuromuscular junction and the skeletal muscle fibre membrane 
(sarcolemma) with different ion channels. Enlarged is a sodium-channel during depolarisation. 
The action-potential is propagated along the sarcolemma. During depolarisation the 
sarcolemma is intracellular positively loaded and extracellular negatively loaded. 
 
History of NDMs 
Clinical features 
Originally, a diagnosis of NDMs was based on clinical characteristics in combination 
with the hereditary pattern. In 1876 Thomsen, a Danish physician who suffered from 
the disease himself, was the first to describe the dominant form of myotonia 
congenita (DMC).8 He chronicled the manifest stiffness (myotonia), which was most 
pronounced in the leg muscles, the reduction of stiffness through repetitive muscle 
contractions, which he coined the warm-up phenomenon, and dominant inheritance 
of the disease.8 He also noted that the warm-up phenomenon was transient, 
diminishing after a few minutes of inactivity.  
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In 1957 Becker first described a recessive form of myotonia congenita (RMC) with a 
more generalised myotonia and the combination of myotonia and transient paresis.9 
Both symptoms improved with sustained exercise, which he also called the warm-up 
phenomenon.5 The distribution pattern of RMC is reported as generalised: “ [..] leg 
muscles are often severely affected and the muscles of the head, arms and hands are 
usually also involved”.10 As a rule, myotonia is first noticed in the legs,11 which is why 
it is also called ‘the ascending type of myotonia congenita’.2 Since myotonia is defined 
as painless muscle stiffness, pain is reportedly uncommon.10 The prevalence of RMC 
and DMC varies in different studies between 2 to 7.3 per 100,000.3,12,13 The classical 
clinical picture of a patient with RMC is described in Clinical box 3.  
 
 
CLINICAL BOX 3 
 
Clinical picture of a patient with recessive myotonia congenita (M. Becker) 
A 35-year-old road worker presented with a 30-year history of skeletal muscle stiffness. He occasionally 
experienced fell when attempting to rise from a chair or walk or run rapidly. He described his symptoms 
as follows: “It is often impossible for me to get up from a chair. When I get up quickly, my leg muscles 
seize up and remain contracted (consistent with myotonia) followed by a brief sensation of weakness  
(compatible with transient paresis). Every attempt at moving forward is difficult and I even fall at times. 
When I contract my muscles several times in succession, they become less stiff and strength returns 
(analogous to the warm-up phenomenon). After a few minutes I will be as strong and flexible as other 
people.” He continued: “At work I have to keep moving all the time, especially before crossing the street, 
to prevent myself from falling or to make sure it won’t take me longer to cross the street than planned.” 
The leg stiffness had become more pronounced over the years, with stiffness in the hands having first 
become manifest 15 years ago. There was no family history of any similar disorder and the clinical and 
electromyographic evaluations of his parents were completely normal.  
 
Clinical examination of the patient revealed pronounced muscular hypertrophy, especially in the legs, 
thighs, and shoulders. There was no eyelid myotonia, but a marked handgrip myotonia (action myotonia). 
On arising from a chair the patients gait was stiff-legged with a minor weakness lasting approximately 10 
to 15 seconds. Percussion myotonia was easily elicited from the thenar and large muscles of the legs. The 
other results of the physical examination were all normal.  
 
Needle-electromyography (EMG) showed continuous myotonic discharges in almost all skeletal muscles 
examined. Figure 1.4 shows a myotonic discharge in the patient’s left biceps. Direct nucleotide sequence 
analysis yielded two different mutations: c.501C>G; p.F167L and c.1238T>G; p.F413C in the CLCN1-gene 
(compound heterozygous). The patient’s father appeared to be a carrier of the F413C and his mother a 
carrier of the F167L mutation.   
 
Treatment with mexiletine 3 dd 200 mg diminished the myotonic symptoms. 
 
 
Paramyotonia congenita (PC) was first described by Von Eulenburg in 1886.6 This 
dominant disease differs from myotonia congenita in various aspects. First, the 
myotonia worsens after repetitive contractions (paramyotonia). Second, it tends to be 
provoked and exacerbated by low temperatures.6 Third, patients with PC may show 
muscle weakness provoked by prolonged exercise or low temperatures. Contrary to 
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transient paresis, muscle weakness in PC may persist for hours. In general, muscles 
are bilaterally and symmetrically affected.10 In his original report, Eulenburg described 
a predilection of myotonia for facial, tongue, throat and hand muscles.6 Streib later 
confirmed this.14 Also in PC pain is uncommon.10 The prevalence of PC has been 
estimated at 1 per 356,000.15 
 
Hyperkalemic periodic paralysis (hyperPP) is a dominant condition, which formally 
belongs to the periodic paralyses. It was first described in the 1950s.16,17 However, it 
forms a continuum with PC: patients with hyperPP may show some paramyotonia 
while patients with PC may be accompanied by sequences of minor attacks of periodic 
paralysis. HyperPP is mainly characterised by episodes of generalised muscle 
weakness. Often, but not always, an increase in serum potassium can be established 
during an attack of generalised muscle weakness. Potassium-rich meals, a period of 
rest after exercise, emotions/stress, pregnancy and cold environment tend to trigger 
or exacerbate the attacks.18 The condition has a prevalence of approximately 1 in 
200,000.10 
Pathophysiology of and genes implicated in NDMs 
In 1969 Bryant was the first to provide initial insight into the pathophysiological 
mechanism underlying myotonia by showing that the membrane resistance of 
myotonic goat muscle fibres was considerably elevated at rest, which he later found 
to be due to a strongly diminished sarcolemmal chloride conductance.19,20 Two 
decades later Rüdel confirmed this diminished sarcolemmal chloride conductance in a 
mouse model.21 The same phenomenon was also shown to underlie DMC and RMC in 
humans.22-25 DMC and RMC are thus caused by a permanent reduction of the resting 
chloride conductance of the sarcolemma.23,24 A normal chloride conductance is 
necessary for a fast repolarisation of the sarcolemma and a strongly reduced chloride 
conductance will result in a lack of functional chloride channels, which, in turn, results 
in a higher resting membrane potential rendering the sarcolemma vulnerable to 
depolarisations.26 A 30% reduction in chloride conductance may cause the overexcited 
sarcolemma to produce repetitive depolarisations (myotonia).27 When the resting 
membrane potential is much higher, the sarcolemma may temporarily become 
inexcitable, forming the basis for transient paresis.  
 
In the 1980s in vitro electrophysiological studies with skeletal muscle fibres of PC 
patients uncovered a disturbed fast inactivation (impaired repolarisation) of sodium 
channels.28-30 Accordingly, PC is caused by a long-lasting depolarisation of the 
sarcolemma due to an inactivation defect of the sodium channel.29,31 When the 
preceding depolarisation is limited, the already recovered sodium channels can be 
reactivated immediately after their repolarisation, which leads to an overexcited 
sarcolemma with repetitive depolarisations (myotonia).26 However, when the 
Thesis_Trip_v13.pdf
 Introduction ⏐17 
preceding depolarisation is strong, the inactivated state of the sodium channels is 
prolonged, leading to an inexcitable sarcolemma resulting in periodic paralysis.27 
 
In the early 1990s genetic studies of both forms of myotonia congenita were linked to 
the skeletal muscle chloride channel gene (CLCN1), mapped to chromosome 7q35. 
This gene encodes the chloride channel (ClC-1;voltage-gated chloride channel, type 1) 
in the sarcolemma (Figure 1.3).32-34 Subsequent molecular genetic studies 
demonstrated the first point mutations in this gene.32,35-37 So far, approximately 80 
different mutations have been associated with myotonia congenita.38,39 
 
In the same period, different research teams independently linked PC and HyperPP to 
the SCN4A gene, which was genetically mapped to chromosome 17q23-25.40-43 This 
gene encodes the pore-forming α-subunit (hSkM1) of the skeletal muscle sodium 
channel (NaV1.4; voltage-gated sodium channel, type 4A) in the sarcolemma (Figure 
1.3).44 By identifying different point mutations in SCN4A it was established that this 
was the disease causing gene.45-48 Yet, at least 30 different missense mutations 
underlying these three groups of sodium channel disorders have meanwhile been 
identified.49,50  
Reclassification of NDMs 
Following the advances in DNA-analysis a third group of disorders associated with 
myotonia and caused by a disturbed, fast inactivation of sodium channels was 
uncovered that was most likely formerly diagnosed as DMC, i.e., potassium-
aggravated myotonias (PAM).7,51-53 PAM is a collective term for unusual myotonias 
resulting from potassium sensitivity, i.e., myotonia fluctuans (fluctuating myotonia), 
myotonia permanens (permanent myotonia), and acetazolamide responsive myotonia 
congenita.7,54 Typical of myotonia fluctuans is its erratic muscle stiffness.7 Another 
hallmark of this condition is the so-called “exercise-induced delayed onset myotonia”, 
in which the muscle stiffness only appears after prolonged exercise. Myotonia 
permanens is characterised by a serious and continuous myotonia, which may 
clinically be difficult to differentiate from myotonia congenita. Finally acetazolamide-
responsive myotonia congenita is a painful PAM that responds well to 
acetazolamide.54 There are several other PAMs that have also been associated with 
painful myotonia.2,55,56 None of the PAMs involve cold sensitivity or muscle weakness. 
Rüdel et al. suggested to refere to PAM diagnosed without a potassium-loading test as 
a sodium-channel myotonia (SCM), 57 which term we will use in this thesis. 
 
Over the past decade, combined, the pathophysiological and genetic studies 
described above have led to a reclassification of the NDMs.58-60 NDMs are now 
categorised as two important groups consisting of chloride and sodium 
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channelopathies (Figure 1.5). Chloride channelopathies (ClCh) comprise autosomal-
recessive (RMC; M. Becker) and autosomal-dominant myotonia congenita (DMC; M. 
Thomsen), while sodium channelopathies (NaCh) include paramyotonia congenita 
(PC), potassium-aggravated myotonias (PAM) and hyperkalemic periodic paralysis 
with (para)myotonia (HYPP).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Concentric needle-EMG of the left biceps brachii, showing a myotonic discharge. 
Ancillary investigations 
Needle EMG almost invariably show myotonic discharges in patients with a NDM, 
which audible discharges are especially triggered by insertion or manipulation of the 
needle and typically wax and wane in frequency and amplitude (Figure 1.4). The 
characteristic sound, that of an accelerating motorcycle, is caused by the changes in 
frequency.61 These myotonic discharges are detectable in almost all skeletal 
muscles.62,63 Analysing electrical and mechanical phenomena of myotonia in patients 
with myotonia congenita, Wagner found a correlation between myotonic muscle fibre 
discharges and mechanical findings depending on the frequency of stimulation and 
the force of contraction.62 Comparing ClCh and NaCh, Fournier detected no 
differences in the quantity of myotonic discharges.63  
Transient paresis can be indirectly confirmed by means of neurophysiological tests.5,64-
66 A strong correlation has been reported for transient paresis and the overall 
decrement of the compound muscle action potential (CMAP) after repetitive nerve 
stimulation (RNS).64,65 However, a certain decrement can be found in all types of 
myotonia.66 On the other hand, some NDM subtypes may be distinguished by the 
differences in CMAP output after short or long exercise tests.67,68 Fournier described 
three EMG patterns, each correlating with a subgroup of mutations.69 Furthermore, 
transient paresis can be measured and explained using force measurements and high-
density surface EMG.5 
Lastly, although DNA analysis for NDMs became available in the 1990s, procedures 
may be complex and complicated. In some countries screening for CLCN1 or SCN4A 
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mutations may take up to an entire year. Moreover, 25 to 60% of the DMC and RMC 
patients lacked any identifiable CLCN1 mutation.70-72 To date, comparable studies in 
patients with PC, PAM or HYPP have not yet been performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Non-dystropic myotonic syndromes devided in chloride and sodium channelopathies. 
 
Differential diagnoses 
Myotonia 
The principal differential diagnosis of myotonia consists of the dystrophic myotonic 
syndromes like myotonic dystrophy type 1 (DM1) and type 2 (DM2). DM1 is more 
frequent than NDMs and DM2. Furthermore, DM1 is an autosomal, dominant disease 
in which the pathology is not only limited to the sarcolemma itself. It is a multi-system 
disorder, which is accompanied by a characteristic distribution of progressive muscle 
weakness (initially in the muscles of the face, throat, neck, and distal limbs, with 
severer symptoms developing in the proximal limb muscles in a later stage of the 
disease), and the involvement of different organs, i.e., the heart (conduction defects 
and arrhythmias), the eyes (cataract), smooth muscles (gastro- intestinal complaints), 
lungs (aspiration pneumonia), and the brain (mental retardation and hyper-
somnolence).73 
DM2, also denoted as proximal myotonic myopathy (PROMM), is a disease mimicking 
DM1.74 The main distinction between DM1 and DM2 is that patients with DM2 show 
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pronounced proximal muscle weakness in combination with myalgia. Contrary to DM1 
there is hardly any cognitive impairment, hypersomnia, ptosis, muscle wasting or 
respiratory insufficiency. The two disorders can be distinguished via DNA analysis. 
Periodic paralyses 
It is important to differentiate hypokalemic periodic paralysis and thyrotoxic periodic 
paralysis from hyperkalemic periodic paralysis. Hypokalemic periodic paralysis mimics 
the hyperkalemic variant, except that during a generalised attack of muscle weakness 
a decreased serum potassium is measured. Moreover, the syndrome will never show 
myotonia or myotonic discharges. Like the other two diseases, thyrotoxic periodic 
paralysis is characterised by identical attacks of generalised muscle weakness and 
there may also be a low serum potassium. At the time of the first attack the clinical 
thyrotoxic symptoms may go undetected.10 Thus, in cases of periodic paralyses, 
especially in hypokalemic periodic paralysis, it is recommended to always check the 
patient’s thyroid function.  
Treatment 
Treatment of NDMs is, to date, purely symptomatic. Myotonia may respond to drugs 
reducing or blocking the sodium channels of the sarcolemma.75-77 These agents 
alleviate myotonia by reducing the hyperexcitability of this membrane in both ClCh 
and NaCh. The first pharmacological treatment for myotonia was published by Wolf in 
1936 who treated four patients with myotonia congenita with quinine, an anti-
arrhythmic drug.78 Other authors later reported favourable effects for procainamide, 
tocainide, and phenytoin.75,76,79-82 Nevertheless, expert opinion suggests mexiletine as 
the drug of choice.10,12 However, the effects of mexiletine in patients with myotonia 
has so far only been tested in some case reports,83-85 one study with a heterogeneous 
population,75 and one with an electrophysiological evaluation.86 Finally, the usefulness 
of acetazolamide, a carbonic anhydrase inhibitor, in the treatment of myotonia has 
been described for some sodium channelopathies.87,88 In conclusion it needs to be 
pointed out that none of the mentioned regimes is an established or evidence-based 
treatment for myotonia. 
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Thesis rationale 
To summarise, NDMs were considered a separate clinical entity for more than a 
century. In the pre-genetic era, clinical features were already described thoroughly, 
most particularly by Thomsen, Eulenburg and Becker.3,6,8 In the seventies and eighties 
of the previous century researchers detected chloride conductance disturbances in 
the sarcolemma of myotonic goats. In vitro electrophysiological studies with skeletal 
muscle fibres of patients diagnosed with PC, moreover, uncovered sodium 
conductance disturbances. Subsequently, the responsible genes, CLCN1 and SCN4A, 
were identified. Since then, scientific research in this field has been chiefly dedicated 
to the molecular and genetic pathophysiology of the syndromes. Subsequently, 
several independent authors reported genotype-phenotype mismatches.56,57,89,90 The 
warm-up phenomenon had, for instance, always been assumed to be a typical 
symptom for chloride channelopathies. However, instead of an expected chloride 
channel defect, several researchers detected a mutation in the skeletal muscle sodium 
channel gene in patients and families displaying this phenomenon.56,89,90 It hence 
became apparent that existing, assumed genotype-phenotype correlations were 
imprecise and that the clinical pictures of the various NDM subtypes as presented in 
the literature could be inaccurate. Obviously, the genotype is necessary to redefine 
the pure clinical phenotypes of NDMs, 2,57,89,91-93 which has now become feasible 
thanks to the current DNA analysis technology that allows us to compose 
homogeneous groups of patients characterised either by chloride or sodium channel 
abnormalities. However, to date, the literature on phenotypic characteristics of a 
group of NDM patients with genetically confirmed ClCh and NaCh is scarce. Recently, 
Fialho et al. were the first to report on a large cohort with genetically confirmed ClCh, 
while Matthews and colleagues described a cohort of genetically confirmed NaCh 
cases.94,95  
Building on these preliminary findings, the aim of the present thesis is to describe the 
phenotypes of NDMs on basis of their genetics, to provide clinicians with rules of 
thumb for focussed genetic testing, and to create a better strategy to detect genetic 
mutations. Lastly, we would like to create better circumstances for the development 
of double-blind randomised clinical trials (RCTs).  
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Synopsis 
Drug therapy to treat myotonia (delayed muscle relaxation after contraction) in muscle diseases such as 
myotonic dystrophy and myotonia congenita. 
 
Myotonia is an abnormal relaxation of muscles after contraction. It is a key symptom in a number of muscle 
diseases called myotonic disorders. It can be mild or severe, interfering with daily activities such as walking, 
climbing stairs or opening and closing the eyelids. It can be worse after periods of rest or triggered by cold 
or fatigue. People with mild myotonia can manage their disease without medication but in severe cases 
treatment is usually necessary. Drugs that have been used to treat myotonia include sodium channel 
blockers such as procainamide, phenytoin and mexiletine; tricyclic antidepressant drugs such as 
clomipramine or imipramine; benzodiazepines; calcium antagonists; taurine and prednisone. This review 
describes ten randomised controlled trials which tested the effectiveness of twelve different drug 
treatments. The ten trials included a total of 143 patients of which 113 had myotonic dystrophy and 30 had 
myotonia congenita. The trials were generally small and of poor quality. Meta-analysis was not possible due 
to a lack of appropriate trials and data. Two small studies indicated that clomipramine and imipramine had 
a short-term beneficial effect on the myotonia in myotonic dystrophy and one small study indicated that 
taurine had a long-term beneficial effect on the myotonia in myotonic dystrophy. Minor side effects such as 
dry mouth and dizziness were reported with clomipramine and imipramine, but not with taurine. Based on 
the evidence from the ten trials included in this review, it was not possible to determine whether drug 
treatment is safe and effective for myotonia in people with a myotonic disorder. Larger, well-designed 
randomised controlled trials are needed. 
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Abstract 
Background 
Abnormal relaxation of skeletal muscles, known as myotonia, can cause disability in myotonic disorders. 
Sodium channel blockers, tricyclic antidepressive drugs, benzodiazepines, calcium-antagonists, taurine and 
prednisone may be of use in reducing myotonia. 
 
Objectives 
To consider the evidence from randomised controlled trials on the efficacy and tolerability of drug 
treatment in patients with clinical myotonia due to a myotonic disorder. 
 
Search strategy 
We searched the Cochrane Neuromuscular Disease Group trials register (July 2009), MEDLINE (January 1966 
to July 2009) and EMBASE (January 1980 to July 2009). Grey literature was hand-searched and reference 
lists of identified studies and reviews were examined. Authors, disease experts and manufacturers of anti-
myotonic drugs were contacted.  
 
Selection criteria 
We considered all (including quasi) randomised trials of participants with myotonia treated with any drug 
treatment versus no therapy, placebo or any other active drug treatment. 
The primary outcome measure was reduced clinical myotonia using two categories: (1) no residual 
myotonia or improvement of myotonia or (2) no change or worsening of myotonia. 
Secondary outcome measures were: (1) clinical relaxation time; (2) electromyographic relaxation time; (3) 
stair test; (4) presence of percussion myotonia; and (5) adverse events. 
 
Data collection & analysis 
Two authors extracted the data independently onto standardised extraction forms and disagreements were 
resolved by discussion. 
 
Main results 
Ten randomised controlled trials were found comparing active drug treatment versus placebo or another 
active drug treatment in patients with myotonia due to a myotonic disorder. Included trials were double-
blind or single-blind crossover studies involving a total of 143 patients of whom 113 had myotonic 
dystrophy type 1 and 30 had myotonia congenita. The studies were of poor quality. Therefore, we were not 
able to analyse the results of all identified studies. Two small crossover studies without a washout period 
demonstrated a significant effect of imipramine and taurine in myotonic dystrophy. One small crossover 
study with a washout period demonstrated a significant effect of clomipramine in myotonic dystrophy. 
Meta-analysis was not possible. 
 
Reviewers' conclusions 
Due to insufficient good quality data and lack of randomised studies, it is impossible to determine whether 
drug treatment is safe and effective in the treatment of myotonia. Small single studies give an indication 
that clomipramine and imipramine have a short-term beneficial effect and that taurine has a long-term 
beneficial effect on myotonia in myotonic dystrophy type 1. Larger, well-designed randomised controlled 
trials are needed to assess the efficacy and tolerability of drug treatment for myotonia. 
 
Thesis_Trip_v13.pdf
30⏐Chapter 2 
Background 
Myotonia is a clinical phenomenon, which refers to an abnormal muscle relaxation 
after voluntary or evoked muscle contraction.1 It is a cardinal feature in myotonic 
disorders including the dystrophic myotonic syndromes and the non-dystrophic 
myotonic syndromes. Myotonia may be present in every skeletal muscle. Clinical 
examination reveals action myotonia and/or percussion myotonia both of which are 
best tested in the hand muscles: following a forceful grip, the ability to relax the grip is 
delayed (action myotonia or grip myotonia); or mechanical stimulation, for example a 
blow with the percussion hammer on the thenar muscles, will also contract the 
muscle for a few seconds (percussion myotonia). Furthermore, an acute muscle 
contraction may give a transient decline in muscle force (transient paresis).2,3 
Repeated muscle contraction and relaxation may improve myotonia as well as muscle 
force, which is called the 'warm-up' phenomenon. However, in a condition called 
paramyotonia, the myotonia worsens after repetitive contractions (paradoxical 
myotonia). 
 
A number of conditions are associated with an abnormal relaxation of muscles in a 
way that resembles myotonia but they do not have the characteristic 
electrophysiological features of true myotonia (pseudomyotonia).4 Because such 
pseudomyotonia may have a different physiological basis from true myotonia, we 
excluded these conditions from our review. These conditions include McArdle's 
disease (Glycogenosis type V), Hoffman's disease (myotonia in hypothyroidism), 
Brody's disease (sarcoplasmic reticulum-Ca2+ATPase deficiency), neuromyotonia, 
neuroleptic malignant syndromes and tetanus. Schwartz-Jampel syndrome 
(chondrodystrophia myotonia) was also excluded because myotonic activity in this 
disease persists during general anesthesia, which does not happen in true myotonia.5 
The true myotonic syndromes included in this review are discussed below. 
Dystrophic myotonic syndromes 
Myotonic dystrophy type 1 is an autosomal-dominant disorder in which myotonia is 
accompanied by a characteristic pattern of muscle weakness and by the involvement 
of several organs.6-8 This condition is caused by an expanded CTG (cytosine-thymine-
guanine) trinucleotide repeat in the DMPK-gene on chromosome 19q.9,10 The 
inheritance is characterised by anticipation, that is the earlier and more severe onset 
of the disease in successive generations.11 The prevalence of myotonic dystrophy type 
1 varies from 2 to 12 per 100,000.12 Myotonia is clinically detectable in almost every 
symptomatic patient. Recently, myotonic dystrophy type 2 was described, which 
differs from type 1 in its predominant proximal muscle weakness. It was, therefore, 
originally named proximal myotonic myopathy (PROMM).13,14 Myotonic dystrophy 
type 2 is caused by an increased CCTG repeat in the ZNF9 gene on chromosome 3. We 
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have included patients with clinical myotonia due to both types of myotonic 
dystrophy. 
Non-dystrophic myotonic syndromes 
Clinically non-dystrophic myotonic syndromes have myotonia with or without periodic 
paralysis.15 Recently the molecular basis of these disorders has been discovered. No 
obvious genotype-phenotype correlations exist.16-18 Over the past decade, a 
combination of electrophysiological and molecular biological studies have led to a 
reclassification of this group of diseases.2,15,19,20 They are now classified as chloride 
(ClCh) or sodium channelopathies (NaCh). 
 
There are two forms of ClCh: autosomal-recessive myotonia congenita (RMC; M. 
Becker)21,22 and autosomal-dominant myotonia congenita (DMC; M. Thomsen).23 Both 
diseases are characterised by clinical myotonia. Autosomal-recessive myotonia 
congenita also shows transient paresis.2,3 The disorders are caused by a mutation in 
the skeletal muscle chloride channel gene (CLCN1) on chromosome 7q.24-26 The 
prevalence of ClCh varies in different studies between 2 to 7.3 per 100,000.22,27,28 We 
included all patients with dominant and recessive myotonia congenita in our review. 
 
NaCh are all autosomal-dominantly inherited or sporadic and are divided into 
paramyotonia congenita (PC), potassium-aggravated myotonia (myotonia fluctuans, 
myotonia permanens and acetazolamide responsive myotonia congenita) and 
hyperkalemic periodic paralysis (hyperPP).29-33 The NaCh are caused by a mutation in 
the skeletal muscle sodium channel gene (SCN4A) on chromosome 17q encoding for 
SkM1, the alpha-subunit of the sodium channel.24,34 The exact prevalence of sodium 
channel diseases is not known although the prevalence of PC has been estimated at 
1 per 356,000.21 HyperPP can occur with myotonia or paramyotonia and sometimes 
without either. We excluded HyperPP without (para)myotonia and included all other 
sodium channel disorders in our review. 
 
The pathophysiological mechanisms in the several myotonic disorders are different. 
Recent publications suggest that the expanded CTG-repeat in myotonic dystrophy 
triggers aberrant splicing of chloride channel mRNA but it is also possible that the 
myocytes in myotonic dystrophy display an abnormal Na+ channel activity.35-37 Thus, 
the exact pathophysiological mechanism leading to myotonia in myotonic dystrophy is 
unknown.  
 
The ClCh are caused by a permanent reduction of the resting chloride conductance of 
the sarcolemma.38,39 Normal chloride conductance is necessary for a fast 
repolarisation of the sarcolemma, otherwise the sarcolemma tends to stay 
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depolarised causing myotonia or becomes hyper-depolarised causing a loss of 
excitability and thereby a transient paresis.40  
 
NaCh are caused by a long-lasting depolarisation of the sarcolemma due to an 
inactivation defect of the sodium channels.41,42 These can initiate successive action 
potentials, which is the basis for myotonia.40  
 
Many people with mild myotonia can manage their disease without medication. 
Severe myotonia can interfere with daily activities and in these individuals treatment 
is often necessary. No treatment for the cause of myotonia is available, so treatment 
is merely symptomatic. In general drugs that block the sodium channels, independent 
of the disease process involved, may diminish myotonia. These agents reduce the 
excitability of the cell membrane of the skeletal muscle and include local anesthetics 
and cardiac agents such as anti-arrhythmic drugs. 
 
The first treatment for myotonia was published by Wolf in 1936 who treated four 
patients with myotonia congenita with quinine, an anti-arrhythmic drug.43 The 
literature also suggests that procainamide, tocainide and phenytoin have favourable 
effects.44-49 However, procainamide and tocainide could have serious long-term side 
effects. Expert opinion suggests that mexiletine is the agent of first choice.28 However, 
the published evidence basis for this opinion is unclear. There are some case reports, 
one study with a heterogeneous population and an electrophysiological evaluation on 
the use of mexiletine in patients with myotonia.45,50-53 Acetazolamide is a carbonic 
anhydrase inhibitor traditionally thought of as a diuretic, but it has been described as 
useful for myotonia in some NaCh.54,55 
 
A crucial aspect to this review is how to quantify myotonia because it can be difficult 
to standardise this as highlighted by a report of an experimental protocol to quantify 
myotonia.56 The problems include the variability of the myotonia between patients 
and within a given patient at different times of the day, and how to take account of 
the warm-up phenomenon. Furthermore, there is the usual problem of inter-rater 
variability. A possible solution for the last item might be the use of specific devices 
with a computerised protocol.1,57 At the moment, one of the most used parameters of 
myotonia is the relaxation time after maximum voluntary contraction (MVC) as 
measured by stopwatch, special technical equipment or computerised protocols. A 
related measure is the electromyographic variant, the electromyographic (EMG) 
relaxation time after MVC. Another used parameter is to record the presence or 
absence of percussion myotonia. These parameters measure the impairment, but not 
the functional effect of myotonia. The stair test (time needed to climb ten stairs) is 
possibly the best available method for measuring approximate functional benefit. 
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No systematic reviews of drug treatment for myotonia are known. Two non-
systematic reviews of therapy for the myotonic disorders have been published.58,59 
This systematic review aims to provide the evidence on which to base treatment. 
Objectives 
To consider the evidence from randomised controlled trials on the efficacy and 
tolerability of drug treatment in people with clinical myotonia due to a myotonic 
disorder. 
Criteria for considering studies for this review 
Types of studies 
We included all randomised and quasi-randomised (alternate or other systematic 
treatment allocation) trials of any drug treatment in people with clinical myotonia due 
to one of the myotonic disorders described below. 
Types of participants 
Participants of all ages with clinical myotonia caused by myotonic disorders, such as 
the dystrophic myotonic syndromes and the non-dystrophic myotonic syndromes, 
were included. It is now possible to diagnose the myotonic disorders by DNA-analysis. 
This was not possible at the time when the included studies were performed, so DNA-
analysis was not an inclusion criterion in our review. 
We excluded people with McArdle's disease (Glycogenosis type V), Hoffman's disease 
(myotonia in hypothyroidism), Brody's disease (sarcoplasmic reticulum-Ca2+ATPase 
deficiency), neuromyotonic diseases, neuroleptic malignant syndromes, tetanus and 
Schwartz-Jampel syndrome. For trials or treatment groups including people with 
dystrophic myotonic syndromes and non-dystrophic myotonic syndromes we 
described the different diseases and the degree of myotonia separately, if this was 
possible. 
Types of interventions 
We included any drug treatment (given either singly or in combination) versus no 
therapy, placebo or another active drug treatment. The list of potential drugs included 
quinine, procainamide, tocainide, phenytoin, mexiletine and acetazolamide, but this 
list was not exclusive. 
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Types of outcome measures 
Primary outcome 
As there is no consensus regarding the best measure of myotonia leading to disparate 
outcome measures in each of the randomised controlled trials, we devised a measure 
using a categorisation of the changes in clinical myotonia after drug treatment for 
each trial based on the conclusion of the original authors as follows: 
(1) improvement of myotonia with no residual clinical myotonia; 
(2) improvement of myotonia but still clinically detectable; 
(3) no change of myotonia; 
(4) worsening of myotonia. 
Secondary outcomes 
(1) Relaxation time: the time taken to fully open the hand after a maximum voluntary 
contraction (MVC) (hand-grip myotonia). This might be determined manually by 
stopwatch or by computerised protocols. When using a computerised hand-grip 
myometer the decline in maximum voluntary contraction from 90 to 5% during 
relaxation is frequently used to measure the relaxation time. However, some 
researchers have used 50%, 75% or 100% decline from peak MVC as the relaxation 
time. We included all such protocols. 
(2) Electromyographic (EMG) relaxation time: the phenomenon of myotonia can be 
recorded with an electromyographic needle electrode and is seen as positive waves, 
so called myotonic discharges or after-discharges. After MVC these myotonic or 
afterdischarges wax and wane and finally stop. The duration of these after-discharges 
is also called EMG relaxation time. For example after-discharges can be recorded from 
the opponens pollicis muscle. 
(3) Stair test: time needed to climb ten stairs. 
(4) Presence of percussion myotonia: percussion myotonia is myotonia occurring after 
a mechanical stimulus; for example tested using percussion of the thenar muscles of 
the hand with a reflex hammer. 
(5) The occurrence of one or more adverse events during treatment with the different 
agents. We specified the adverse events. 
For all outcome measures we used a minimum treatment duration of one week and a 
maximum treatment duration of one year and where necessary planned to adjust for 
different follow-up periods.  
Search strategy for identification of studies 
See: Cochrane Neuromuscular Disease Group search strategy. 
The Cochrane Neuromuscular Disease Group trials register was searched for 
randomised controlled trials using: "myotonia", "myotonic dystrophy"', "non-
dystrophic myotonias", "myotonia congenita", "Morbus Thomsen", "Morbus Becker", 
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"potassium-aggravated myotonia", "myotonia fluctuans", "myotonia permanens", 
"paramyotonia congenita", "hyperkalemic periodic paralyses", "relaxation" AND 
"muscle" and "treatment" OR "therapy" as the primary search items (July 2009). We 
adapted this strategy to search MEDLINE (January 1966 to July 2009) and EMBASE 
(January 1980 to July 2009) for other randomised controlled trials. Grey literature 
such as neuromuscular text books and abstracts from international neuromuscular 
congresses were hand-searched and we checked the reference lists of the identified 
literature and reviews concerning myotonia. We also contacted authors, disease 
experts and manufacturers of anti-myotonic drugs. 
Electronic search strategies 
EMBASE strategy 
((randomised controlled trial or clinical trial or multicenter study or controlled study 
or crossover procedure or double blind procedure or single blind procedure or 
randomisation or major clinical study or placebo or meta analysis) or (phase 2 clinical 
trial or phase 3 clinical trial or phase 4 clinical trial) or (clin* and trial*) or (( singl* or 
doubl* or tripl* or trebl*) and (blind* or mask*)) or placebo* or random* or control* 
or (meta?analys* or systematic review*) or (cross?over or factorial or sham? or 
dummy) or ABAB design*) not (animal) 
AND 
((myotonia OR myotonic dystrophy OR myotonic disorders OR non-dystrophic 
myotonia OR myotonia congenita OR morbus Thomsen OR morbus Becker OR 
potassium aggravated myotonia OR myotonia fluctuans OR myotonia permanens OR 
paramyotonia congenita OR hyperkalemic periodic parlalysis) OR (muscle AND 
relaxation) AND (treatment OR therapy)) 
MEDLINE strategy 
(randomised controlled trial [PT] OR randomised controlled trials OR controlled 
clinical trial [PT] OR controlled clinical trials OR random allocation OR double-blind 
method OR single-blind method OR clinical trial [PT] OR exp clinical trials OR (clin* 
AND trial*) OR (( singl* OR doubl* OR trebl* OR tripl*) AND (blind* OR mask* OR 
dummy)) OR placebos OR placebo* OR random* OR research design OR (clinical trial 
phase I OR clinical trial phase ii OR clinical trial phase iii OR clinical trial phase iv [PT]) 
OR multicenter study [PT] OR meta analysis [PT] OR prospective studies OR 
intervention studies OR cross-over studies OR meta-analysis OR (meta?analys* OR 
systematic review*) OR control*) NOT (Animal [MESH] NOT (Human [MESH] AND 
Animal [MESH])) AND ((myotonia OR myotonic dystrophy OR myotonic disorders OR 
non-dystrophic myotonia OR myotonia congenita OR morbus Thomsen OR morbus 
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Becker OR potassium aggravated myotonia OR myotonia fluctuans OR myotonia 
permanens OR paramyotonia congenita OR hyperkalemic periodic paralysis) OR 
(muscle AND relaxation) AND (treatment OR therapy)) 
Methods of the review 
Selecting trials for inclusion 
Two authors (JT and CGF) independently reviewed the titles and abstracts from the 
electronic search to identify relevant trials for full review. The full text of all 
potentially relevant studies was obtained for assessment. The authors decided which 
trials fitted the inclusion criteria and graded their methodological quality. 
Disagreement was resolved by discussion. Review authors were not blinded to trial 
authors' names, institutions and the journals of publication. 
Assessment of methodological quality 
Two independent authors (JT and CGF) assessed randomised trials for methodological 
quality with respect to the following items: allocation concealment, patient blinding, 
observer blinding, explicit diagnostic inclusion and exclusion criteria and explicit 
outcome measures. These items were assessed according to the Cochrane approach: 
A - adequate, B - unclear, C - inadequate, D - not done. Disagreement was resolved by 
discussion. 
Data extraction 
Data extraction on participants, methods, intervention, outcomes and adverse events 
was performed by two independent authors (JT and CGF) using a data extraction 
form. We attempted to obtain missing data from the trial authors if this was 
necessary. For the primary outcome we had created a special scoring system: (1) no 
residual clinical myotonia; (2) improvement of myotonia but still clinically detectable; 
(3) no change; (4) worsening of myotonia. Data were transformed from the original 
studies by two authors (JT and CGF) with any disagreement being resolved by 
discussion. 
Analysis 
For statistical analysis of the primary outcome we dichotomised the variable scoring 
system:  
(1) no residual myotonia or an improvement; 
(2) no change or worsened. 
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Relative risks (RR) with 95% confidence intervals (CI) were calculated from the 
dichotomised data for each study if this was possible. Where possible the numbers 
needed to treat (NNT) and the numbers needed to harm (NNH) would also have been 
calculated. If all necessary data could be deduced from the published results, the 
primary outcome for crossover studies were analysed using the McNemar's test, 
calculating the odds ratios.60,61 If there had been continuous data in the secondary 
outcomes we would have calculated the weighted mean difference (WMD) with 95% 
CI or presented the original statistical analysis of the study. If there had been more 
than one trial with the same agent in the same disease group we would have 
calculated a weighted treatment effect across those trials using a fixed-effect model 
with the Cochrane statistical package, Review Manager (RevMan). We interpreted a p-
value less than or equal to 0.05 as statistically significant. If chi-squared analysis 
showed heterogeneity of the study results (p-value<0.1), sensitivity analyses would 
have been carried out to explore plausible causes. If heterogeneity could still not be 
explained, we would have reported the results using a random-effects model. We 
would have analysed the dystrophic myotonic syndromes and the non-dystrophic 
myotonic syndromes as subgroups if possible. We also discussed adverse events and 
cost benefits drawing upon non-randomised data.62 
Description of studies 
See Table 2.1 characteristics of included studies and Table 2.2 characteristics of 
excluded studies. 
 
Table 2.1 Characteristics of included studies 
Study Antonini 1990 63 
Methods Randomised, double blind crossover study. 
Method of randomisation not stated. 
Single centre Italy. 
Treatment period of 33 days, total duration 166 days. 
Results presented as combined data from both active treatment arms and both 
placebo arms. Two washout periods of 30 days. Results first arms stated. 
Participants 17 patients with 2 withdrawals. 
17 patients with myotonic dystrophy. 
8 patients were male, 9 female. 
Mean age 29 (SD not stated). 
Inclusion criteria: well-established criteria for myotonic dystrophy. 
Exclusion criteria: Subjects with cardiac, ophthalmologic, or urologic diseases. 
Interventions Clomipramine 75 mg/day. Comparison treatment placebo. 
Outcomes Grip myotonia by relaxation time in seconds; time necessary to completely open 
the fist after three seconds of maximum voluntary contraction performed by 
maintaining a constant pressure in a rolled sphygmomanometer cuff. 
Allocation concealment B 
Study Durelli 1983 64 
Methods Randomised, double-blind crossover study. 
Methods of randomisation not stated. 
Single centre Italy. 
Treatment periods of 6 months, total duration of 1 year. 
Results presented as combined data from both active treatment arms and both 
placebo arms. No washout period. Results first arms not stated. 
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Characteristics of included studies (Continued) 
Participants 9 patients without withdrawals. 
9 patients with myotonic dystrophy. 
Number of males and females not stated. 
Mean age not stated. 
Inclusion criteria: established clinical EMG-criteria 
Exclusion criteria: None stated 
Interventions Taurine 100-150 mg/kg. 
Comparison treatment placebo. 
Outcomes EMG relaxation time after maximum voluntary contraction, occurrence of 
percussion myotonia, occurrence of myotonic discharges by electrical 
stimulation of median nerve, KCl loading test in mmol/litre necessary for 
occurrence of myotonia. 
Allocation concealment B 
Study Finlay 1982 69 
Methods Randomised, double-blind crossover study. 
Method of randomisation not stated. 
Single centre United Kingdom. 
Treatment periods of 14 days, total duration 28 days. 
Results presented as descriptive, individually data for the four treatment arms.
No washout period. Descriptive data first arms stated. 
Participants 10 patients with 2 withdrawals. 
10 patients with myotonic dystrophy. 
7 patients were male, 3 female. 
Mean age not stated. Range from 31-59 years. 
Inclusion criteria: none stated. 
Exclusion criteria: none stated. 
Interventions Procainamide 250 mg 4x/day first week and 500 mg 4x/day second week versus 
disopyramide 100 mg 3x/day first week and 200 mg 3x/day second week.
Comparison between both treatments. 
Outcomes Grip myotonia by measuring relaxation time in seconds necessary to completely 
open the fist after three minutes of maximum voluntary contraction, grip 
strength by using RAF Gripometer, subjective comments. 
Notes Individually continuous data not stated, no statistical analysis, patients could be
recognise their original medicine by kind of adverse events. 
Allocation concealment B 
Study Gascon 1989 65 
Methods Randomised, double-blind crossover study. 
Methods of randomisation not stated. 
Treatment periods of 6 weeks, total duration of 12 weeks. 
Results presented as combined data from both active treatment arms and both 
placebo arms. No washout period. Results first arms not stated. 
Participants 12 patients out of a group of 23 patients with myotonic dystrophy (confirmed by
well-established criteria).  
1 drop-out because of normal relaxation time 
6 patients were male, 6 female. 
 Mean age not stated. Range from 18-55 years. 
Inclusion criteria: None stated. 
Exclusion criteria: None stated. 
Interventions Imipramine from 50-375 mg/day on the basis of plasma concentrations. 
Comparison with placebo. 
Outcomes Grip myotonia by measuring relaxation time after squeezing the examiner’s two 
fingers for 2-3 seconds. Three successive timings of grip and percussion 
myotonia were taken, and the mean of these three was used as the patient’s 
‘score’. 
Allocation concealment B 
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Characteristics of included studies (Continued) 
Study Grant 1987 66 
Methods Randomised, single-blind crossover study. 
Method of randomisation not stated. 
Single centre Glasgow, Scotland. 
Treatment periods of 2 weeks. Total duration unclear. 
Results presented as combined data from both active treatment arms and both
placebo arms. No washout period. Results first arms not stated. 
Participants 10 patients without withdrawals. 
10 patients with myotonic dystrophy. 
6 patients were male, 4 female. 
Mean age 40.4 (SD not stated). 
Inclusion criteria: accepted clinical criteria and electromyographic criteria. 
Exclusion criteria: None stated. 
Interventions Nifedipine 10 mg 3x/day and nifedipine 20 mg 3x/day. 
Comparison treatment placebo. 
Outcomes Finger extension time of both hands measured as relaxation time after maximal
voluntary contraction. The mean value of the first five extension times was
measured. 
Allocation concealment B 
Study 
Methods 
 
 
 
 
 
 
Participants 
 
 
Interventions 
Outcomes 
 
 
 
Allocation concealment 
Kratz 1986 68 
Randomised, double-blind crossover study.  
Methods of randomisation not stated. 
Single centre, Washington, D.C., USA. 
Treatment period not stated. 
Total duration not clear. 
Results presented as number of patients that improved. No insights in data. 
No washout period. 
6 patients without withdrawals. 
4 patients with myotonic dystrophy and 2 with myotonia congenita. 
Number of males, females, mean age and inclusion/exclusion criteria not stated. 
Mexiletine in doses up to 600 mg/day. 
Grip strength. 
Relaxation time after making a fist, at room temperature and after the hand in
icewater for 1 minute. 
Length of myotonic discharges. 
B 
Study Kwiecinski 1992 45 
Methods Randomised, single-blind study. At beginning a crossover trial of phenytoin and 
placebo. Afterwards randomisation for disopyramide, tocainide or mexiletine.  
Methods of randomisation not stated. 
Single centre Poland. 
Treatment period of 4 weeks. Total duration unclear. 
Results for the crossover part of the study presented as combined data from 
both active treatment arms and both placebo arms. No washout period. Results
first arms not stated. Overall results presented as outcome measures after 4
weeks of treatment. 
Participants 30 patients with 2 withdrawals. 
9 patients with myotonic dystrophy, 9 with dominant myotonia congenita and
12 with recessive myotonia congenita. 
22 patients were male, 8 female. 
Mean age 31.8 years old (SD not stated). 
Inclusion criteria: accepted clinical criteria and electromyographic characteristics 
for different diseases. 
Exclusion criteria: None stated. 
Interventions Phenytoin 400 mg/day for 2 weeks and 600 mg/day last 2 weeks. 
Disopyramide 300 mg/day for 2 weeks and 600 mg/day last 2 weeks. 
Mexiletine 400 mg/day for 2 weeks and 600 mg/day last 2 weeks. 
Tocainide 800 mg/day for 2 weeks and 1200 mg/day last 2 weeks. 
Comparison treatment placebo. 
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Characteristics of included studies (Continued) 
Outcomes Time needed to open eyes maximally after closure (Lid myotonia). 
Time needed to open hand after firm closure (Hand opening). Time needed to 
climb ten stairs (Stair-test). 
EMG relaxation time (Afterdischarge). 
Subjective responses. 
Each test was repeated three times at intervals of at least ten minutes. The
mean value from three such measurements was taken as the time value for each 
test. 
Notes It is conspicuous that the sum of the number of patients in the different
treatment groups of the randomisation part of the study exceeds the total
number of included patients. 
Outcome measures were not measured in all patients (No reasons given). 
Allocation concealment B 
Study Lewis 1966 67 
Methods Randomised, double-blind crossover study. 
Randomisation arbitrarily by secretary. 
Single centre United Kingdom. 
Treatment periods of 3 weeks, total duration of 6 weeks. 
Results presented as combined data from both active treatment arms and both
placebo arms. No washout period. Results first arm stated. 
Participants 20 patients and 13 controls. 
19 patients with myotonic dystrophy and 1 with myotonia congenita. 
Number of males and females not stated. 
Mean age not stated. 
Inclusion criteria: None stated. 
 Exclusion criteria: None stated. 
Interventions Diazepam 5 mg 2x/day – 4x/day. 
Comparison treatment placebo. 
Outcomes Relaxation time with EEG surface electrodes on right forearm after 5 seconds of 
maximum voluntary contraction. Value was the mean of three measurements.  
Accurate progress notes with specific on grasp myotonia, percussion myotonia
and toxic effects medication.  
Notes Great placebo effect; research into placebo pointed out that they contain 0.5 mg 
quinine sulphate per tablet. 
Allocation concealment B 
Study Leyburn 1960 46 
Methods Randomised, double-blind crossover study. 
Randomisation by statistician.  
Single centre United Kingdom. 
Treatment periods of three weeks, total duration twelve weeks. 
Results presented as individual data for different interventions and as combined
data for treatment arms and placebo arms. No washout period. Results first arm
not stated. 
Participants 23 patients with 4 withdrawals. 
16 patients with myotonic dystrophy and 4 with myotonia congenita. 
9 patients were male, 11 female. 
Mean age not stated. 
Inclusion criteria: None stated. 
Exclusion criteria: None stated. 
Interventions Quinine (5 grain sugar coated tablets): 5 grains 2x/day first week and 5 grains 
3x/day second and third week. Procainamide (0.25 g tablets): 0.5 g q.i.d. first
week, 0.75 g q.i.d. second week and 1.0 g q.i.d. third week.  
Prednisone (5 mg tablets): 10 mg b.i.d. first throughout the three week period.  
Comparison treatment placebo. 
Outcomes Objective myotonia by measuring 3 times the after discharge with EMG and by
measuring 3 times clinical relaxation time. The result is the average of all six
measurements. 
Subjective opinion. 
Allocation concealment A 
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Characteristics of included studies (Continued) 
Study Munsat 1967 47 
Methods Randomised, double-blind crossover study. 
 Method of randomisation not stated. 
Single centre Los Angeles, USA. 
Treatment periods of three weeks, total duration 9 weeks. 
Results presented as combined data from four active treatment arms and both
placebo arms. No washout period. Results first arm not stated.  
Participants 9 patients without withdrawals. 
7 patients with myotonic dystrophy and 2 with myotonia congenita. 
Number of males and females not stated. 
Mean age not stated. 
Inclusion criteria: Accepted clinical criteria, electromyography and muscle
biopsy. Selected on the basis of intelligence and capability of being examined
weekly and presented a spectrum of clinical involvement. 
Exclusion criteria: None stated. 
Interventions Diphenylhydantoin 100 mg 2x/day first week, 3x/day second week and q.i.d.
third week. Procainamide 1 g 2x/day first week, 3x/day second week and 4x/day
third week.  
Comparison treatment placebo. 
Outcomes Ergographic evaluation of hand grasp after five seconds of maximum voluntary
contraction. 
Subjective report regarding efficacy or toxicity or both. 
Repeated ECG utilising standard leads. 
Notes Researcher could recognise medicine of patients by kind of adverse events. 
Allocation concealment B 
 
 
Nine trials were found that compared active drug treatment with placebo for the 
treatment of myotonia, in a total of 103 patients with myotonic dystrophy type 1 and 
30 patients with myotonia congenita.45-47,63-68 One trial was found that compared two 
different drug treatments for the treatment of myotonia in 10 patients with myotonic 
dystrophy type 1.69 On the basis of the title or the abstract a further 34 studies initially 
appeared to be eligible. However, by reading the full text of all potentially relevant 
studies 17 were non-randomised studies 48,54,70-83,101, ten were case studies 84-93 and a 
further seven did not have measures of myotonia as outcome measures (Table 
2.2).94-100 
 
Another study102 is awaiting assessment because at the time of writing this review the 
trial results were not available in sufficient detail. We were informed about this study 
by contacting one of the disease experts in this field and read the abstract. This trial 
will be included in the next update of the review. 
Trial design 
Eight included trials were placebo-controlled, randomised, double-blind, crossover 
studies. The other two were placebo-controlled, randomised, single-blind, crossover 
studies.45,66 All included trials were performed in a single centre and a total of 143 
patients received treatment (active drug or placebo) over two weeks to six months. In 
one study the treatment period was separated by a 30-day period washout interval.63 
The other eight trials had no washout interval between the treatment periods. 
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The trial of Kwiecinski started as a crossover study.45 Afterwards randomisation for 
three different study drugs took place. Remarkably the sum of the number of patients 
in the different treatment groups in the randomised part of the study exceeded the 
total number of included participants. An attempt to clarify this with the author was 
unsuccessful. We assume the second part of the study was not randomised until we 
receive evidence to the contrary. 
 
Table 2.2 Characteristics of excluded studies 
Study Reason of exclusion 
Alfonsi 2007 84  
Backman 1990 70 
Benstead 1987 85  
Case study 
Non-randomised study 
Case study 
Birnberger 1975 71 Non-randomised study 
Brumback 1983 72 Non-randomised study 
Cook 1984 88 Case study 
Durelli 1982 73 Non-randomised study 
Garai 1954 89 Case study 
Geschwind 1955 90 Case study 
Griggs 1977 74 Non-randomised study 
Griggs 1978 54 Non-randomised study 
Griggs 1989 95 No myotonia as outcome measure 
Guilleminault 1978 75 Non-randomised study 
Hughes 1991 86 
Jackson 1994 87 
Karli 1974 91 
Case studies 
Case study 
Case study 
Matsumura 2004 101 
Mielke 1985 76 
Non-randomised study 
Non-randomised study 
Milner-Brown 1990 77 Non-randomised study 
Müller 1980  78 Non-randomised study 
Orndahl 1986 79 Non-randomised study 
Orndahl 1994 96 No myotonia as outcome measure 
Pendefunda 1974 92  Case study 
Pénisson-Besnier 2008 97  
Ricker 1980 80 
No myotonia as outcome measure 
Non-randomised study 
Rüdel 1980 48 Non-randomised study 
Samaha 1964 81  Non-randomised study 
Schneider 2003 98 No myotonia as outcome measure 
Sechi 1983 82 Non-randomised study 
Streib 1987 93 Case study 
Sugino 1998 83 
Tarnopolsky 2004 94 
Non-randomised study 
No myotonia as outcome measure 
Vlachopapadopoulou 1995 99 No myotonia as outcome measure 
Walter 2002 100 No myotonia as outcome measure 
Participants 
The trials did not provide baseline characteristics of the individual participants or of 
the two separated groups. Five trials did not give the baseline characteristics at 
all46,47,64,67,68, the other trials gave the characteristics of the entire study population. 
Five trials included people with myotonic dystrophy only and five trials45-47,67,68 
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included participants with myotonic dystrophy as well as participants with non-
dystrophic myotonic syndromes, in this case myotonia congenita. Five trials did not 
define explicit inclusion criteria.46,65,67-69 Only Antonini et al. defined explicit exclusion 
criteria.63 In this trial cardiac, ophthalmologic or urologic diseases were excluded. 
Since cardiac and ophthalmologic diseases are symptoms of myotonic dystrophy this 
trial probably included a selected group of patients. 
Interventions 
The regimens of treatment varied between studies (see characteristics of included 
studies). Most studies used drugs that block sodium channels (procainamide, 
disopyramide, phenytoin, quinine, tocainide and mexiletine) by which myotonia is 
diminished by reducing the level of depolarisation. Other drugs used were 
clomipramine, imipramine, taurine, nifedipine, diazepam and prednisone. It is 
hypothesised that the tricyclics (imipramine and clomipramine) act on the 
sympathetic nerve terminals to increase levels of norepinephrine, which exerts an 
inhibitory influence on skeletal muscle membranes by ß2-adrenoreceptor 
stimulation.65,103 Taurine, an amino-acid, may affect cellular hyperexcitability by 
increasing membrane conductance of potassium and chloride.64,73 All these types of 
drugs seem to act as membrane-stabilisers.  
Outcome measures 
The outcome measures used differed between trials. The most frequently used 
outcome measure was the clinical relaxation time in seconds. It was measured three 
seconds, two to three seconds, five seconds and three minutes after a maximum 
voluntary contraction (MVC).63,65,67,69 Others did not specify the length of maximum 
voluntary contraction.45,66,68  
 
The EMG relaxation time (after-discharge) in seconds after MVC was also used.45,64,68 
Additional ways of measuring relaxation time were used such as the use of EEG 
surface electrodes or an ergographic device.47,67 Two trials used a mean score of three 
relaxation times and one used a mean score of five relaxation times after MVC.65-67 
Another trial used a mean score of six measurements consisting of three clinical 
relaxation times and three EMG relaxation times.46  
 
Other outcome measurements were occurrence of percussion myotonia, percussion 
myotonia in seconds, eyelid myotonia in seconds after firm closure, occurrence of 
myotonic discharges induced by electrical stimulation of the median nerve, potassium 
chloride (KCl) loading test in mmol/litre for occurrence of myotonia, time to climb ten 
stairs (stair test) and subjective responses.45,64,65,69  
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Analysis 
All trials were analysed on a per protocol basis (withdrawals were not included in the 
analysis) instead of an intention-to-treat basis. 
Methodological quality of included studies 
See Table 2.3. 
 
Table 2.3 Methodological quality of included studies. 
Study Allocation 
concealment 
Patient 
blinding 
Observer 
blinding 
Inclusion 
criteria 
Exclusion 
criteria 
Outcome 
measures 
Antonini 1990 63    B B B A A A 
Durelli 1983 64 B A A A B A 
Finlay 1987 69 B C A B B A 
Gascon 1989 65 B B A B B A 
Grant 1987 66 
Kratz 1986 68 
B 
B 
B 
B 
B 
B 
A 
B 
B 
B 
A 
A 
Kwiecinski 1992 45 B A D A B A 
Lewis 1966 67 C B A B B A 
Leyburn 1960 46 A B B B B C 
Munsat 1967 47 
 
B A C A B A 
 
A: adequate, B: unclear, C: inadequate, D: not done 
 
 
The methodological quality assessment took into account allocation concealment, 
patient blinding, observer blinding, explicit inclusion and exclusion criteria and explicit 
outcome measures. We graded these items as: A: adequate, B: unclear, C: inadequate, 
D: not done. If the information was not available the item was graded as unclear. The 
scores of each trial are included in Table 2.3.  
 
In all ten trials participants were randomised for crossover studies to either active 
treatment or placebo (or another active drug treatment). The allocation concealment 
was considered adequate in the study of Leyburn; a statistician randomised trial 
participants.46 For the study of Lewis the allocation concealment was inadequate; the 
procedure was described as "arbitrary by secretary".67 The other allocation 
concealments were unclear, because the method of randomisation was not explained. 
 
Patient blinding was intended in at least nine trials. In only three trials the blinding 
was considered adequate.45,47,64 In six trials the blinding was unclear because it was 
not described and in Finlay et al. the patient blinding was inadequate because 
participants could recognise the side effects of the medication, since these medication 
was previously used in a clinical setting.46,63,65-69 Observer blinding was also intended 
in at least nine trials. Four trials were considered adequate for observer 
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blinding.64,65,67,69 In one trial the observer could recognise the origin of the medication 
by the kind of adverse events.47 Another single trial did not have observer blinding 
and the study of Grant et al. was designed as a randomised single-blind crossover 
study but it was unclear if the participants or the observers were blinded. 45,66 The 
other two studies were unclear. None of the trials recorded effectiveness of blinding. 
 
We also graded the inclusion and exclusion criteria. This item is discussed under 
participants in the Description of studies section. 
As expected there was no uniform outcome measurement. The explicit outcome 
measurements were considered adequate in eight trials. We considered the outcome 
measure of Leyburn et al. as inadequate, because it was the mean value of six 
measurements in which three were EMG relaxation times and three were clinical 
relaxation times.46 It is difficult to give an explanation of the meaning of these values. 
Moreover, some studies took the mean of three to five relaxation times. It is likely 
that these times are shortened by the warm-up phenomenon. 
Results 
A total of ten single centre trials were included, in which 143 patients with myotonia 
were randomised in a single-blind or double-blind crossover study with a treatment 
period ranging from two weeks to six months. Twelve different drugs were used in 
those ten trials. Participants could be divided into 113 patients with myotonic 
dystrophy type 1 and 30 patients with myotonia congenita. Three studies were 
performed in the 1960s, six in the 1980s and one in the 1990s. In general the trials 
were small, with the participant numbers ranging from nine to thirty, and the 
methodological quality was poor. All ten included randomised crossover trials were 
based on a per protocol analysis which could result in an attrition bias. The data for an 
intention-to-treat analysis were not available. 
 
The data analysis of Finlay et al. was inadequate.69 The study only presented 
descriptive results. The individual continuous data were not stated and no statistical 
analysis was performed. The data of Kratz et al. were incomplete because we only 
have the information of the abstract (descriptive results).68 Attempts to contact the 
author were unsuccessful. Lewis had a large placebo effect.67 Research into the 
placebo tablets identified that they contained 0.5 mg quinine sulphate per tablet. This 
substance could be an effective treatment for myotonia, resulting in performance 
bias. For these reasons we were unable to use the data from these three trials. 
 
Six studies were of crossover design without washout intervals.45-47,64-66 Data were 
inappropriately presented in the form of combined results of both active treatment 
arms and both placebo arms. Since a washout interval was not incorporated there is a 
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strong possibility of a carry-over effect. Data from the first arms were not presented 
and four studies did not present data individually.45-47,66 From these four studies three 
included both participants with myotonic dystrophy as well as myotonia congenita, 
without defining subgroups. For these reasons we were unable to use data from those 
four trials. We tried to contact the authors of the trials but have not yet been 
successful in obtaining the raw data. Two single studies gave data for some of our 
specified outcome measures and in spite of a carry over effect we will present these 
data.64,65 For one study we can provide the results for the treatment of myotonia 
without any restrictions.63 Because most trials included different diseases in the same 
trial without giving the individual data and used different drug treatments, meta-
analysis was not possible. 
 
Thus, it is only possible to present the data of three single studies for the treatment of 
myotonia in myotonic dystrophy.63-65 We could not present potentially valuable data 
for the treatment of myotonia in non-dystrophic myotonic syndromes. For the study 
of Durelli et al. with a treatment period of six months it is only possible to present the 
data for our secondary outcome measure, the EMG relaxation time.64 The EMG 
relaxation time after treatment with taurine was lower (average 0.58 seconds; SD 
0.24) than both the baseline (average 1.33 seconds; SD 0.71) and after placebo 
(average 1.02 seconds; SD 0.36) (p-value<0.01; Student's t test). Taurine had no side 
effects.  
 
Gascon et al. measured both left and right-hand relaxation times after imipramine and 
placebo.65 Our primary outcome with the McNemar's test was significant for the right 
hand with an infinity odds ratio (95% CIs from binomial distribution 0.92 to infinity,  
p-value=0.025) and also significant for the left hand with an infinity odds ratio (95% 
CIs from binomial distribution 0.66 to infinity, p-value=0.046). The relaxation time was 
measured as a secondary outcome. Repeated measures of analysis of variance 
(ANOVAs) of these data revealed significant improvement of myotonia as measured 
by right grip (F(2.20)=11.14, p-value<0.001) and left grip (F(2.20)=6.65, p-value<0.01). 
The most important side effects of imipramine were dry mouth (8 out of 12 
participants; 67%), dizziness (four out of 12; 33%), increased sweating (four out of 12; 
33%), constipation (four out of 12; 33%), tremor (three out of 12; 25%), blurred vision 
(three out of 12, 23%) and diarrhoea (three out of 12, 23%). 
 
The trial of Antonini et al. used clomipramine and had two washout intervals of thirty 
days, so the risk of carry-over effect was reduced.63 They stated that there were no 
differences between patients receiving clomipramine in the first or second treatment 
period. The primary outcome measure of improvement of myotonia with the 
McNemar's test was not significant and showed an odds ratio of 3.00 (95% CIs 0.25 to 
157.49) (p-value=0.32). The analysis of a secondary outcome measure with a paired t-
test (crossover study) demonstrated that the mean relaxation time after 
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clomipramine (average 15.85 seconds, SD 9.44) was significantly shorter (p-
value=0.02) than after placebo (average 22.54 seconds, SD 16.47). The study has no 
electromyographic relaxation time, stair test or presence of percussion myotonia as 
outcome measures. Minor side effects were drowsiness (six out of 15 participants; 
40%), dry mouth (two out of 15; 13%), tiredness (two out of 15; 13%), hyperhydrosis 
(one of 15; 7%) and dizziness (one of 15; 7%). 
 
In conclusion, it was only possible to calculate our primary outcome measure in this 
review for two studies.63,65 This outcome was only significant for treatment with 
imipramine for myotonia in myotonic dystrophy.65 Our secondary outcome measure 
of relaxation time could be calculated in the same two studies. Both imipramine and 
clomipramine showed a significant result in relieving myotonia in myotonic dystrophy. 
We could only provide data for the EMG relaxation time from the study with the 
treatment of taurine for myotonia in myotonic dystrophy.64 This result was also 
significant. Meta-analysis was not possible. 
 
The side effects of the other active drug treatments taken from the included trials 
were: 
Mexiletine: 8% (2 of 24) epigastric distress prevented by taking the drug with food. 
Tocainide: 6% (1 of 18) lymphadenopathy and 11% (2 of 18) dizziness, anxiety and 
tremor. Diphantoin: 10% (3 of 30) skin rash, somnolence and mild ataxia. 
Disopyramide: 32% (7 of 22) dry mouth and blurred vision while taking high doses. 
Nifedipine: 20% (2 of 10) headache and lethargy while taking 3 doses of 20 mg and 
10% (1 of 10) light T wave flattening or T wave inversion on the ECG. Procainamide: 
39% (15 of 39) gastro-intestinal complaints. Quinine: 45% (9 of 20) mild and tolerable 
tinnitus, 30% (6 of 20) some degree of deafness and 5% (1 of 20) dull head without 
tinnitus. Prednisone: no side effects in three weeks. This is of course of little value in 
judging safety of steroid therapy as a long-term measure. Diazepam: 64% (7 of 11) 
sedation and 27% (3 of 11) of dizziness. 
 
The tested drug treatments in this review varied in costs from EUR 2.29 per month 
(phenytoin) to EUR 23.67 per month (quinine).104 
Discussion 
Despite the fact that different drug treatments have been used to reduce symptoms 
of myotonia since 1936, very few good randomised crossover trials have been 
performed to study the effect of these treatments. Overall, the methodological 
quality of the studies considered was poor. Moreover, methods reported in original 
papers were not described in sufficient detail. Only one crossover trial had a washout 
interval and reported data from each treatment period. Clomipramine, studied in this 
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small trial, demonstrated a significant effect on the relaxation time in participants 
with myotonic dystrophy type 1. For more reliable results it is necessary to perform 
studies with a larger cohort. The other crossover trials did not have a washout interval 
and did not report data from each (or at least the first) treatment period separately. 
Four studies included participants with myotonic dystrophy type 1 as well as 
participants with myotonia congenita, without defining subgroups. For these reasons 
it was not possible to estimate the treatment effect of those four studies. Two other 
small studies indicated, despite a carry-over effect, a short-term effect of imipramine 
and a long-term effect of taurine on myotonia in myotonic dystrophy type 1.  
 
In spite of the evidence (admittedly limited) for these three drugs mentioned above, 
these medications are probably not used very often in medical practice. Expert 
opinion still favours mexiletine. This is despite the lack of randomised controlled trials 
with mexiletine, although one is awaiting assessment.102 In conclusion, better 
randomised crossover studies with a proper washout interval and clearly presented 
data from both arms and with clear separation of the different diseases associated 
with myotonia are necessary for further determination of an effective and safe 
treatment for myotonia.  
 
The adverse events from randomised data are given in the results. Non-randomised 
data suggest serious side effects for tocainide and procainamide such as 
agranulocytosis and pancytopenia.105-109 Other side effects of tocainide are diplopia, 
dizziness, nausea, tremor and anxiety.48,76,80 For procainamide more than 50% of the 
patients had gastro-intestinal side effects and 33% complained of insomnia.90 Three 
patients with myotonic dystrophy and treated with phenytoin or carbamazepine had 
cardiac side effects (ventricular tachycardia and atrioventricular block grade 1).110 
Reported side effects of acetazolamide were paraesthesias, anorexia, weight loss, 
renal failure, renal calculi, osteoporosis, and haematological and hepatic 
dysfunction.54,74 In a non-randomised study with amitriptyline for myotonia six from 
the eight patients complained of a dry mouth and two had drowsiness. One 
participant had supraventricular tachycardia due to an adrenergic effect.77 Verapamil 
for myotonia was tested in a non-randomised study in five people. One participant 
complained of dizziness with a first-degree heart block, another had transient 
nausea.88  
 
The lack of appropriate trials and data is not the only difficulty in determining the 
treatment effect in myotonia. Difficulty also exists in the clinical assessment of 
myotonia. Although many outcome measures have been developed, until now no 
validated scale has been used with unanimous consent. Sansone et al. wrote an 
experimental protocol but also reported some unsolved problems.56 Furthermore, 
myotonia can be dependent on temperature, physical effort, rest, food intake, 
pregnancy, and genotype. Therefore, it is difficult to standardise outcome measures 
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for myotonia. A technique to overcome some of the standardisation problems in 
measuring relaxation times, is the use of computerised protocols in which a computer 
program places cursors along the relaxation phase and calculates the relaxation times 
between these points.1,57 
 
Another problem in determining the treatment effect of myotonia is the intriguing 
warm-up phenomenon (diminishing of myotonia after repetitive contractions). In ClCh 
this is probably the result of an improvement of both myotonia and transient paresis 
and in myotonic dystrophy and NaCh it is only the improvement of myotonia.2 The 
exact pathophysiological mechanism of the warm-up phenomenon is unknown but 
the phenomenon could influence the degree of myotonia, especially when measuring 
relaxation times after repeated maximum voluntary contractions. The length and 
frequency of maximum voluntary contractions differed between studies which could 
influence the outcome measures. Furthermore, paramyotonia can occur, which is a 
worsening of myotonia after repetitive contractions (paradoxical myotonia). Myotonia 
is thus a symptom in different diseases. We excluded the diseases with no true 
myotonia (see background and type of participants) but when these are excluded 
there are still four groups left: (1) myotonic dystrophy type 1 (2) myotonic dystrophy 
type 2, (3) non-dystrophic ClCh, and (4) non-dystrophic NaCh. In general myotonia is a 
mild symptom in myotonic dystrophy and a much more serious symptom in non-
dystrophic myotonic syndromes. 
 
Paradoxically in our review only 30 patients with myotonia congenita were studied 
and the majority had myotonic dystrophy type 1, perhaps reflecting the higher 
prevalence of myotonic dystrophy. However, most patients with myotonic dystrophy 
do not seek treatment for their myotonia because it often is a relatively mild symptom 
compared to the other symptoms they suffer. They also may have an avoidant 
personality with ‘avoidance’ of medical treatment as part of their disease. Moreover, 
all studies including patients with a non-dystrophic myotonic syndrome, included 
patients with myotonic dystrophy as well. This causes a mixture of different diseases 
with different pathophysiologies, and the outcome measures were not analysed for 
the two disorders separately. For all the reasons mentioned above it would seem 
appropriate to perform different RCTs for the different kinds of myotonic syndromes. 
It is also unlikely that a single method of assessment is appropriate for each separate 
disease. 
 
Finally, there is the lack of functional outcome measures. The most used functional 
outcome measure is the stair test (see last part of background), but only one study 
used this test. We recommend this test as a secondary outcome measure in future 
RCTs. Another possible functional test for future studies could be the chair test (time 
needed to stand up from a chair, walk around the chair and sit down again). 
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In conclusion, the best evidence for the treatment of myotonia in myotonic dystrophy 
type 1 is from single small studies with clomipramine, imipramine and taurine. Taurine 
did not have any side effects in nine people for six months. Clomipramine and 
imipramine have some side effects but seem to be safe treatments. We could not 
present valuable separate data for the treatment of myotonia in non-dystrophic 
myotonic syndromes. Based on the three single small randomised trials above in 
combination with clinical observations (subjective responses of the patients and 
expert opinion), some drugs have a potential effect in decreasing myotonia. To prove 
this hypothesis double-blind randomised controlled (multi-centre) trials have to be 
properly designed and performed for the different types of myotonic disorders. In the 
case of crossover trials a washout interval is recommended. Moreover, intention-to-
treat analysis and appropriate analysis and presentation of the results are required. 
Reviewers' conclusions 
Implications for practice 
The beneficial effect of active drug treatment for myotonia cannot be excluded and its 
use in certain patients with severe myotonia might be appropriate (for example in 
those in whom there is a clear impact on daily activities), however, there is a lack of 
randomised evidence to determine whether any drug treatment is safe and effective 
in the treatment of myotonia. 
Implications for research 
The clinical efficacy of drug treatment for myotonia has not yet been properly 
evaluated. Larger, well designed RCTs are needed to assess the efficacy and 
tolerability of drug treatment for myotonia.  
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Outline of this thesis 
The main objective of this thesis is to describe the phenotypic charecteristics of non-
dystrophic myotonic syndromes (NDMs), including both chloride (ClCh) and sodium 
channelopathies (NaCh), on the basis of their genetics. Since the clinical features of 
NDMs were already described in the pre-genetic era, we will redefine these 
characteristics. The redefinition is evaluated in patients with a clinical, 
electrophysiological, and genetic diagnosis of NDM that were referred to our tertiary 
research centre during one full year.  
 
Part I comprises the introduction to the research reported in this thesis. Chapter 1 
provides a general introduction of NDMs in which their history, pathophysiology, 
reclassification, ancillary investigations, differential diagnoses and treatment options 
are described. Chapter 2 comprises a Cochrane review describing the results of the 
first systematic review of drug treatments for myotonia. Chapter 3, the current 
chapter, gives the outline of this thesis. 
 
In Part II, Chapter 4, the genetic analyses of all the referred 54 NDM probands are 
reported. Furthermore, the value of in tandem analysis of CLCN1 and SCN4A is 
evaluated. Based on earlier clinical criteria either CLCN1 or SCN4A is sequenced. If no 
valuable mutations were detected in the first gene, the second gene was 
subsequently analysed. Besides the relevance of analysing CLCN1 and SCN4A in 
tandem and mapping the responsible mutations in 54 probands, this study enabled us 
to compose genetically homogeneous groups of patients, thus facilitating closer 
scrutiny of the two NDM subtypes. 
 
Part III of this thesis focuses on the redefinition of the clinical phenotypes of NDMs. 
Chapter 5 describes three patients with a genotype-phenotype mismatch, 
underscoring the need for a redefinition of the clinical phenotypes of NDMs. 
Subsequently, in Chapter 6, the phenotypes of ClCh and NaCh are presented as based 
on classical standardised interviews and clinical bedside tests. The purpose of this 
study was to investigate the clinical pattern of myotonia in three different body 
regions (face, hands, legs) for the two channelopathies using widely practised 
neurological examination. The study also provides clinical rules of thumb for focussed 
genetic testing. In Chapter 7 the health status of NDM patients is addressed, to our 
knowledge the first study to do so. It delineates the impact of this group of diseases 
on the patients’ physical, psychological and social functioning. Chapter 8 reports the 
results of muscle ultrasound measurements in combination with functional muscle 
parameters in genetically confirmed NDM patients in order to establish whether the 
various syndromes manifest structural muscle changes with functional consequences. 
 
Thesis_Trip_v13.pdf
60⏐Chapter 3 
The final section, Part IV, Chapter 9, comprises the general discussion in which the 
findings as presented in this thesis are summarised and put into context. Moreover, 
remaining questions are addressed and future perspectives discussed. 
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Abstract 
Objective 
To optimise the genetic characterisation of NDMs in the Netherlands by analysing CLCN1 and SCN4A in 
tandem. 
 
Methods 
All Dutch consultant neurologists and the Dutch Patient Association for Neuromuscular Diseases (Vereniging 
Spierziekten Nederland) were requested to refer patients with an initial diagnosis of a NDM for clinical 
assessment and subsequent genetic analysis over a full year. Based on clinical criteria, sequencing of either 
CLCN1 or SCN4A was performed. When previously described mutations or novel mutations were identified 
in the first gene under study, the second gene was not sequenced. If no mutations were detected in the 
first gene, the second gene was subsequently also analysed. 
 
Results 
Underlying NDM mutations were explored in 54 families. Twenty percent (8/40) of our probands with 
suspected chloride channel myotonia showed no CLCN1 mutations but subsequent SCN4A screening 
revealed mutations in all of them. All 14 probands in whom SCN4A was primarily sequenced showed a 
mutation. In total, CLCN1 mutations were identified in 32 families (59%) and SCN4A in 22 (41%), resulting in 
a diagnostic yield of 100%. The yield of mutation detection was 93% with three recessive and three sporadic 
cases not yielding a second mutation. Among these mutations, 13 in CLCN1 and three in SCN4A were novel. 
 
Conclusion 
The current results show that in tandem analysis of CLCN1 and SCN4A affords a high-level of mutation 
ascertainment in families with a NDM. 
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Introduction 
Non-dystrophic myotonic syndromes (NDMs) are a group of skeletal muscle disorders 
that have myotonia as their common feature, in reference to an abnormal muscle 
relaxation after voluntary or evoked muscle contraction. Myotonic discharges can be 
recorded by needle-electromyography (needle-EMG) from the skeletal muscles of 
these patients. Clinically, the NDMs are classified as dominant or recessive myotonia 
congenita (DMC; M. Thomsen [OMIM 160800] and RMC; M. Becker [OMIM 255700]), 
paramyotonia congenita (PC [OMIM 168300]) or potassium-aggravated myotonias 
(PAMs [OMIM 608390]). As suggested by Rüdel et al., PAM diagnosed without a 
potassium-loading test is referred to as a sodium-channel myotonia (SCM).1 
 
In 1971 Bryant and Morales-Aguilera showed that the membrane resistance of 
myotonic goat muscle fibres was considerably elevated at rest, which was found to be 
due to a strongly diminished sarcolemmal chloride conductance.2 The voltage-gated 
chloride channel concerned, was also shown to be involved in DMC as well as in RMC 
in humans.3,4 Subsequent genetic studies demonstrated a linkage to the skeletal 
muscle chloride channel gene (CLCN1 [OMIM 118425]), mapped to chromosome 
7q35.5,6 About 80 different CLCN1 mutations have, so far, been associated with MC.7 
Meanwhile, in a second group of NDMs, impaired inactivation of voltage gated 
sodium channels was observed.8 Various researchers later independently linked PC 
and PAM to the skeletal muscle sodium channel gene (SCN4A [OMIM 603967]), 
genetically mapped to chromosome 17q23-25.9-11 To date, at least 30 different 
missense mutations have been identified in this gene.12 
 
Although many mutations have been identified in CLCN1, 25 to 60% of the MC 
patients who were examined lacked any identifiable CLCN1 mutation.13-15 Comparable 
studies in patients with PC or PAM have so far not been performed. Although 
sequencing of the entire CLCN1 increased the yield of putative myotonia-associated 
mutants, this was never able to account for all patients.16 Limitations in mutation 
detection methods, genetic heterogeneity and additional modifying factors were 
proposed to explain the discrepancy.13-16 Plassart-Schiess et al. postulated the 
incomplete dominance of some mutations with variable penetrance and expressivity 
as another compounding factor.17 Additionally, patients with suspected DMC may 
show SCN4A mutations. The purpose of the present study was, therefore, to optimise 
the genetic characterisation of patients with NDMs in the Netherlands by in tandem 
analysis of CLCN1 and SCN4A, as necessary. 
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Patients and methods 
Proband selection 
The current investigation comprised a cross-sectional, nationwide study. In March 
2005, consultant neurologists across the Netherlands as well as the Dutch Patient 
Association for Neuromuscular Diseases (Vereniging Spierziekten Nederland), were 
requested to report patients with a clinical diagnosis of a NDM to our research group 
over a full year. All patients were subsequently contacted and those who responded 
positively were invited to the neurology outpatient clinic of the Radboud University 
Nijmegen Medical Centre for the proposed clinical assessment, needle-EMG and 
collection of blood samples for genetic analysis. Inclusion criteria were age over 18 
years, a clinical diagnosis of a NDM according to established clinical criteria (Table 
4.1), and myotonic discharges upon needle-EMG examination.18 
 
Table 4.1 Clinical criteria for non-dystrophic myotonic syndromes.18 
CHLORIDE CHANNELOPATHIES 
 
Dominant myotonia congenita (DMC) 
• Autosomal dominant inheritance 
• Age at onset from birth to early childhood 
• Myotonia, particularly after rest 
• Muscle function improves with continuing exercise (warm-up) 
• Myotonia fluctuates only slightly during lifetime, without progression 
 
Recessive myotonia congenita (RMC) 
• Autosomal recessive inheritance 
• Onset usually in the first decade of life 
• Myotonia, particularly after rest 
• Muscle function improves with continuing exercise (warm-up) 
• Often transient weakness after rest, improving with continuing exercise (warm-up) 
• Several years of progression, after which the condition stabilises 
SODIUM CHANNELOPATHIES 
 
Paramyotonia congenita (PC) 
• Autosomal dominant inheritance 
• Onset from birth 
• Muscle function worsens with continuing exercise (paradoxical myotonia) 
• Paradoxical myotonia is especially common when muscles are exercised in low temperatures 
• Sometimes muscle weakness occurs when muscles are exercised in low temperatures 
 
Potassium-aggravated myotonia (PAM) 
• Autosomal dominant inheritance 
• Myotonia fluctuans: myotonia, which may fluctuate from day to day, is provoked by long periods of 
exercise (delayed-onset myotonia) 
• Myotonia permanens: persistent generalised myotonia, particularly in neck and shoulder muscles 
• Acetazolamide responsive myotonia congenita: myotonia fluctuates and, in addition, exercise 
induces muscle pain 
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Exclusion criteria included a clinical or genetic diagnosis of type 1 or type 2 myotonic 
dystrophy (dystrophic myotonic syndromes), a clinical or genetic diagnosis of primary 
periodic paralysis and unwillingness or inability to reduce or stop drug therapy for 
myotonia for the duration of the study. This latter criterion was added to optimise the 
clinical and electrophysiological evaluations of the myotonia. The study was approved 
by the Medical Ethics Committee of the Radboud University Nijmegen Medical Centre 
and all patients gave their written informed consent prior to their participation.  
Preliminaries and procedure 
CLCN1 and SCN4A were sequenced in tandem following our specially designed study 
strategy. The decision to sequence first CLCN1 or SCN4A was based on established 
clinical criteria, which were independently verified for each patient by two authors (JT 
and GD). Disagreement was resolved by discussion. When previously described 
mutations were identified in the analysis of the first gene, we did not proceed with 
sequencing the second gene. In case of a suspected RMC in which we detected one 
mutation, we did not proceed with sequencing SCN4A. In case of novel mutations, 
their status and inheritance patterns were determined by clinical evaluations of first-
degree relatives and by direct sequence analyses of their DNA. In addition, all novel 
missense mutations were screened in a control panel consisting of the DNA from 50 
healthy Dutch individuals (100 chromosomes). In case no mutations were found in the 
first gene or novel mutations were not confirmed in first-degree relatives, we 
subsequently sequenced the second gene. 
Mutation analysis 
For each patient two 10-ml blood samples were collected in EDTA tubes. Genomic 
DNA was isolated from peripheral blood by the method of Miller et al. at the Leiden 
University Medical Centre and subsequently screened for mutations by direct 
sequence analysis of CLCN1 and/or SCN4A. PCR analysis, purification of the PCR 
products (Millipore Multiscreen HTS PCR plates), sequencing (Big Dye Terminator 
Cycle Sequencer kit from Perkin-Elmer) and the final analysis (ABI3730) were 
performed as described previously with some minor modifications, indicated between 
brackets.19,20 The primer sets used for amplification of CLCN1 were made according to 
Lorenz et al. and primer sets designed for amplification of SCN4A can be found at 
http://www.lumc.nl/4080/DNA/SCN4A.html. 21 
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Results 
Study cohort 
The recruitment procedure yielded a total of 113 probands, 23 of whom did not 
respond to initial contacts while 10 eventually refused participation without specifying 
their reasons. Nine were unable to participate due to transportation problems and 
three were unable to visit the hospital because of serious co-morbidity. Another 14 
probands were excluded based on the following exclusion criteria: primary periodic 
paralysis (n=7), unwillingness/inability to reduce and stop drug therapy for myotonia 
(n=5), and no clinical diagnosis of a NDM with absence of myotonic discharges by 
needle-EMG (n=2). Accordingly, 54 probands with a clinically and electro-
physiologically supported diagnosis of a NDM took part in this study. We, moreover, 
clinically and genetically examined 18 (20%) affected and 74 (80%) unaffected first-
degree relatives of those probands for whom novel mutations or indistinct inheritance 
patterns were established. Table 4.2 shows the basic demographics for all 54 
probands, and their 92 first-degree relatives. 
 
Table 4.2 Basic characteristics of all eligible probands and their first-degree relatives (affected and 
unaffected) included in the CLCN1 and SCN4A sequencing procedure. 
 Probands 
(n=54) 
First degree 
affected family 
members (n=18) 
First degree 
unaffected family 
members (n=74) 
Sex, n (%) 
Female 
Male 
 
 25 (46%) 
 29 (54%) 
 
 7 (39%) 
 11 (61%) 
 
 40 (54%) 
 34 (46%) 
Mean age yrs (SD) 
Age yrs, range 
 43.1 (12.4) 
19-71 
 49.9 (13.3) 
26-76 
 54.8 (16.1) 
18-87 
 
Preliminaries and procedure data 
For an overview of the results, see the flowchart depicted in Figure 4.1. In short, 
CLCN1 was sequenced in 40 probands. For the remaining 14 probands, we first 
sequenced SCN4A. Mutations in CLCN1 were identified in 32 probands. Subsequently, 
the remaining eight showed a mutation in SCN4A. For all 14 probands in whom SCN4A 
was the first to be sequenced, a SCN4A mutation was found. DNA analysis thus 
identified 32 (59%) probands with CLCN1 mutations and 22 (41%) probands with 
SCN4A mutations, reflecting a 100% gene detection yield. However, the mutation 
detection yield, including homozygous recessives, was 93% (78 of 84) as in three 
recessive and three sporadic probands (worst case scenario) no second mutation was 
found. 
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Figure 4.1 Flowchart presenting the numbers of probands (n, %) in whom the direct sequence analysis of 
CLCN1 or SCN4A was performed. The flowchart also presents the results. Note that based on 
established clinical criteria in 40 probands CLCN1 was sequenced first and that in 8 of these 
probands no mutation was identified. Also note that in 22 probands SCN4A was sequenced, 14 
based on the mentioned clinical criteria and 8 based on the negative sequencing result of 
CLCN1. In total, CLCN1 mutations were identified in 32 families and SCN4A in 22. 
 
Mutation analysis data 
CLCN1 mutations  
In 32 probands, 21 different CLCN1 mutations were identified, encompassing nine 
missense, five splice-site, four nonsense and three frameshift mutations (Table 4.3a). 
More than half (55%) of the mutations were detected in three exons (exon 3, 8 and 
11). The remaining mutations were scattered across the entire chloride channel 
(Figure 4.2). Most of the 32 probands were compound heterozygote (n=17; Table 
54 probands
Established
clinical criteria
Sequencing CLCN1
n=40 (74%)
Sequencing SCN4A
n=14 (26%)
Sequencing SCN4A
n=8 (15%)
Mutations in
CLCN1
n=32 (59%)
No mutations in
CLCN1
n=8 (15%)
Mutations in
SCN4A
n=8 (15%)
Mutations in
SCN4A
n=14 (26%)
Total mutations
in CLCN1
n=32 (59%)
Total mutations
in SCN4A
n=22 (41%)
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4.3b) and seven probands were homozygote, of whom four are known to result from 
consanguineous marriages. In eight probands only one mutation was detected of 
whom two showed an autosomal dominant inheritance (families 37 and 51; Table 
4.3b), three were sporadic (families 10, 16 and 38; Table 4.3b) and for the other three, 
autosomal recessive inheritance seemed plausible (families 9, 27 and 41; Table 4.3b). 
Overall, the F413C missense mutation was the most frequently observed mutation 
(n=8; see Table 4.3a). 
 
Table 4.3a Spectrum of CLCN1 mutations identified in selected probands residing in the Netherlands. 
Exon Nucleotide  
change 
Amino acid  
change 
No of families 
with mutations 
References 
1 
3 
3 
3 
3 
4 
5 
7 
8 
8 
10 
11 
11 
11 
13 
13 
16 
17 
21 
21 
23 
180+3A>T 
302-1G>A 
302-2A>C 
385G>A 
411C>G 
501C>G 
585_589del 
789delC 
854G>A 
914G>A 
1065-2A>G 
1167-10T>C 
1238T>G 
1250A>G 
1437_1450del 
1439C>T 
1841A>T 
1938G>A 
2419C>T 
2457C>A 
2680C>T 
splice-site donor 
splice-site acceptor 
splice-site acceptor 
A129T 
Y137X 
F167L 
K195fsX 
S264fsX 
G285E 
G305E 
splice-site acceptor 
splice-site acceptor 
F413C 
E417G 
I479fsX 
P480L 
K614M 
M646I 
Q807X 
C819X 
R894X 
2 
4 
2 
2 
1 
3 
1 
4 
5 
1 
1 
3 
8 
1 
1 
1 
1 
3 
1 
1 
3 
34 
present study 
present study 
present study 
present study 
13, 35 
present study 
present study 
26 
present study 
present study 
present study 
13, 35 
present study 
13, 14, 34, 36 
13, 37 
present study 
present study 
7, 22 
present study 
13, 14, 17, 32, 35 
No: number. Novel mutations are printed in bold. 
 
In total, 13 of the 21 different mutations in CLCN1 were newly identified mutations 
(62%) and comprised two nonsense, four splice-site, two frameshift and five missense 
mutations. The novel mutations 302-1G>A (n=4), S264fsX (n=4), M646I (n=3), 1167-
10T>C (n=3), 3022A>C (n=2), and A129T (n=2) were detected more than once in our 
families and none of the novel missense mutations were detected in the 100 control 
chromosomes. 
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Figure 4.2 The sites of the mutations in the skeletal muscle chloride (ClC-1) channel as identified in the 
present study. Novel mutations are underlined, circles represent DMC  (M. Thomsen) and squares 
RMC (M. Becker). The membrane topology of the ClC-1 channel is adapted from Dutzler et al.  45
 
Novel CLCN1 mutations 
Y137X and C819X (recessive): Two novel nonsense mutations were identified. The 
Y137X mutation was detected in a recessive pedigree (family 26). The C819X was 
identified as the only mutation in two affected sibs of family 41. The healthy mother 
appeared to be the carrier of this mutation. 
 
K195fsX (recessive): This novel frameshift mutation was identified in two patients of 
family 1 alongside the I479fsX mutation. A healthy sister, son and daughter appeared 
to be carriers of the K195fsX mutation. 
 
S264fsX (recessive): This mutation was detected in two patients of family 6 alongside 
the novel missense mutation G305E. The father was carrier of the S264fsX mutation 
and the mother and an unaffected brother were heterozygous for the G305E 
mutation. Furthermore, the S264fsX mutation was the only recessive mutation in the 
sporadic probands of families 10 and 16. Two unaffected children and three 
unaffected siblings of family 10 and the mother of proband 16 were carriers of this 
mutation. Lastly, S264fsX was also identified in family 43 alongside the novel splice-
site mutation 1065-2A>C. 
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Table 4.3b The mutational combinations in CLCN1 as identified in the 32 probands with myotonia 
congenita. 
Family nos Consequences allele 1 / 2 Inheritance 
01 
02 
04 and 05 
06 
07 
08 and 22 
09 
10 and 16 
11 
14 
21 
25 and 44 
26 
27 
29 and 32 
37 and 38 
40 
41 
42 
43 
46 
47 
48 
51 
54 
56 
K195fsX  /  I479fsX 
302-1G>A  /  F413C 
302-1G>A  /  1167-10T>C 
S264fsX  /  G305E 
302-2A>C  /  302-2A>C 
F167L  /  F413C 
F413C  /  - 
S264fsX  /  - 
180+3A>T  /  302-1G>A 
F413C  /  1167-10T>C 
F413C  /  F413C 
G285E  /  G285E 
Y137X  /  F413C 
F167L  /  - 
R894X  /  R894X 
A129T  /  - 
G285E  /  E417G 
C819X  /  - 
180+3A>T  /  K614M 
S264fsX  /  1065-2A>G 
G285E  /  M646I 
E807X  /  E807X 
M646I  /  R894X 
P480L  /  - 
302-2A>C  /  M646I 
G285E  /  F413C 
recessive 
recessive 
recessive 
recessive 
recessive 
recessive 
probably recessive 
sporadic 
recessive 
recessive 
recessive 
recessive 
recessive 
probably recessive 
recessive 
dominant and sporadic 
recessive 
probably recessive 
recessive 
recessive 
recessive 
recessive 
probably recessive 
dominant 
recessive 
recessive 
Nos: numbers. Novel mutations are printed in bold. 
 
 
302-1G>A (recessive): This novel splice-site mutation was identified in a compound 
heterozygous state in all three affected sibs of families 2, 4 and 5 and in the recessive 
pedigree of family 11. 
 
302-2A>C (recessive): This second novel splice-site mutation was observed in two 
families: homozygous in the proband of family 7, issue of a consanguineous marriage 
and compound heterozygous in a sporadic patient with a recessive mode of 
inheritance (family 54) alongside the newly identified missense mutation M646I. 
 
1065-2A>C (recessive): The third novel splice-site mutation was identified in the 
proband of family 43 alongside the novel frameshift mutation S264fsX. The mother 
and an unaffected sister were carriers of the novel splice-site mutation and the father 
and two siblings were carriers of the novel frameshift mutation. 
 
1167-10C>T (recessive): All affected sibs (n=5) of the recessive pedigrees 4 and 5 
showed this novel splice-site mutation together with the novel 302-1G>A mutation. 
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Unaffected first-degree relatives in both families appeared to be carriers of one of the 
novel mutations. This mutation was also identified in a compound heterozygous state 
in a single patient of family 14. First-degree unaffected relatives carried one of the 
two mutations. 
 
A129T (dominant): This missense mutation emerged in two families (37 and 38), i.e. 
one sporadic and one with a presumably dominant inheritance pattern. This could not 
be confirmed by DNA analysis because the affected father was deceased and the 
proband did not have children. SCN4A was also analysed retrospectively in both 
families and showed no mutations.  
 
G305E (recessive): The second novel missense mutation was identified in family 6 and 
occurred in all affected family members alongside a novel recessive frame-shift 
mutation (S264fsX). The mutation was also identified in two unaffected siblings and 
the unaffected father. 
 
E417G (recessive): This mutation was detected in the proband (E417G/G285E) of 
family 40. The unaffected mother was heterozygous for the E417G mutation; the 
father was deceased.  
 
K614M (recessive): This fourth novel missense mutation was identified in family 42. 
The affected proband was compound heterozygous (K614M/180+3A>T). Both parents 
were deceased, while one brother was a carrier of the 180+3A>T and one sister was a 
carrier of the K614M mutation. 
 
M646I (recessive): The M646I mutation was identified in three different families (46, 
48 and 54). It was identified alongside the recessive missense mutation G285E, the 
nonsense mutation R894X and the novel splice-site mutation 302-2A>C, respectively. 
In family 48 the mutation was also detected in two affected sibs. In the recessive 
pedigree of family 54 the described mutations occurred in a single patient. In family 
46 the father was a carrier of G285E, and the mother was deceased.  
Clinical features of the probands with CLCN1 mutations 
All probands with CLCN1 mutations showed obvious clinical signs of myotonia and 
97% showed the warm-up phenomenon. About 15% of the probands showed 
transient paresis and muscle wasting, 48% only showed transient paresis and 37% 
showed neither transient muscle weakness nor muscle wasting. The probands with 
novel mutations did not show new clinical features compared with those having 
already known mutations. 
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SCN4A mutations 
In 22 probands, 11 different missense mutations were identified (Table 4.4). Three 
mutations were located in domain I, one in domain II and six in the domains III and IV 
of the voltage-gated sodium channel, NaV1.4 (Figure 4.3). In 59% of the probands a 
mutation was identified in exon 22, of which the G1306V mutation was the most 
common (n=8). In total, three of the 11 different missense mutations were novel 
(27%), comprising two mutations in codon 250: L250V and L250P, and one in codon 
689: L689F. Each of the three novel mutations was detected once and none of the 
novel missense mutations were detected in the 100 control chromosomes. All 
probands with novel mutations showed a phenotype mimicking Thomsen’s disease. 
Therefore, DNA of these three probands was first sequenced for CLCN1 mutations, but 
no mutations were identified. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 The sites of the mutations in the skeletal muscle sodium (NaV1.4) channel as identified in the 
present study. Novel mutations are underlined, circles represent paramyotonia congenita (PC) 
and squares sodium-channel myotonias (SCM). The membrane topology of the NaV1.4 
channel is adapted from Jurkat-Rott et al.33 
 
Table 4.4 Spectrum of SCN4A mutations identified in selected probands residing in the Netherlands. 
Family nos Exon Nucleotide 
substitution 
Amino acid  
substitution 
No. of families 
with mutation 
References 
 
12 
39 
3, 18 
36 
52 
49 
15, 24 
19, 28, 30, 33, 45, 50, 53, 55
13, 17, 23 
35 
20 
 
6 
6 
9 
13 
19 
19 
22 
22 
22 
24 
24 
 
748C>G 
749T>C 
1333G>A 
2065C>T 
3472C>T 
3555A>G 
3917G>C 
3917G>T 
3938C>T 
4343G>A 
4372G>T 
 
L250V 
L250P 
V445M 
L689F 
P1158S 
I1160V 
G1306A 
G1306V 
T1313M 
R1448H 
V1458F 
 
1 
1 
2 
1 
1 
1 
2 
8 
3 
1 
1 
 
present study 
present study 
38 
present study 
39 
40 
10, 11, 34 
10, 41 
41, 42 
43 
44 
Nos: numbers. Novel mutations are printed in bold 
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Novel SCN4A mutations  
L250V (dominant): This missense mutation in the proband of family 12 is most 
probably a de novo mutation. Presumably, both his parents (deceased) were 
unaffected while his daughter and granddaughter were both affected and showed the 
same L250V mutation. 
 
L250P (dominant): This mutation was identified in the proband of family 39. The 
affected father and brother in this family also showed this mutation. It was not 
detected in an unaffected brother and sister.  
 
L689F (dominant): This mutation was detected as a de novo mutation in family 36. 
Both parents of the proband were unaffected and did not carry the mutation. The 
mutation was identified in both the proband and her affected daughter.  
Clinical features of the probands with SCN4A mutations 
All probands with SCN4A mutations showed obvious clinical signs of myotonia, 
especially in the eyelid muscles. Furthermore, probands with SCM, including the three 
probands with novel mutations, showed the warm-up phenomenon. The 
phenomenon was detected in the eyelid muscles (80%) as well as in the hand flexor 
muscles (80%). In contrast, probands with paramyotonia congenita showed 
paramyotonia in the eyelid muscles (40%) as well as in the hand-flexor muscles (75%). 
Finally, almost all probands with paramyotonia congenita showed an increase of 
paramyotonia or a flaccid paresis after cooling. Probands with SCM did not react to 
cooling. 
Discussion 
By sequencing CLCN1 and SCN4A in tandem, we detected mutations in all our 
probands. The yield of mutation detection was 93%, with six cases (7%) not yielding a 
second mutation. This is a high percentage, especially compared to previous studies 
that identified CLCN1 mutations in 40 to 75% of their MC patients, whereas analysis of 
SCN4A was not included.13-15 Although the yield of our mutation detection was high, 
we failed to detect a second mutation in six probands. Possibly, deletions or other 
type of mutations deep in the intron or the promoter region of CLCN1 may underlie 
the disease in these cases.16 
 
Our strategy yielded 13 novel mutations in CLCN1 and three in SCN4A. Although we 
did not perform in vitro studies, there are four lines of evidence affirming the 
suggestion that these mutations are pathogenic. First, eight of the 13 novel mutations 
in CLCN1 were splice-site, frameshift or nonsense mutations, which are predicted to 
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eliminate channel function.22 Second, none of the novel missense mutations occurred 
in the 100 control chromosomes. Thirdly, all original wild type amino acids at the sites 
of the missense mutations were well conserved across chloride or sodium channels of 
different species and/or among human chloride or sodium channels, and fourth, all 
but one (A129T) of the novel mutations were segregating with the disease. 
 
Since the pathogenic status of missense mutations is less clear than the status of the 
other mutations, these mutations will individually be discussed by their location and 
conservation. First, the A129T mutation is located in transmembrane segment B of the 
human ClC-1 channel. A129 is a highly conserved amino acid across ClC channels of 
different species and is well conserved among the human plasma membrane ClC 
isoforms ClC-1, -2, -Ka and –Kb. Furthermore, A129T is in the vicinity of the already 
established M128V and S132C mutations. Both mutations segregated with the 
Thomsen phenotype.23,24 M128V and S132C were both electrophysiologically 
characterised and showed a rightward shift in the current-voltage relationship, 
explaining their pathogenicity.23-25 Second, the G305E mutation is located in 
transmembrane segment I of ClC-1. G305 is a highly conserved amino acid across ClC 
channels of different species and is well conserved among the human ClC isoforms 
ClC-1, ClC-2, ClC-Ka and ClC-Kb. G305E is in the vicinity of F307S, which was reported 
to drastically shift the voltage dependence of ClC-1 to positive potentials, preventing 
these channels from repolarising muscle action potentials efficiently.26 Third, the 
E417G mutation is situated in the last codon of exon 11 and is therefore predicted to 
affect the splicing of this exon. However, further RNA studies are needed to explore 
this. Furthermore, E417, located in the linker between helix K and L of ClC-1, is highly 
conserved among ClC channels of different species. Fourth, the K614M mutation, 
conserved across ClC channels of different species but not among human ClC 
isoforms, and the L646I mutation, conserved across ClC channels of different species 
and among the human isoforms ClC-1 and ClC-2, are located in the β1 and β2-3 linker 
of the cystathionine β-synthase (CBS1) domain, respectively. Although the precise role 
of the CBS-domains is unknown, Estévez et al. suggested that mutations in this 
domain will influence the voltage-gated dependence of gating through the common 
gate.27 
 
The L250P/V mutations in SCN4A are located in the membrane-spanning segment 5 of 
domain I of Nav1.4. Although in the vicinity of a benign polymorphism (S246L), L250 is 
highly conserved across NaV1.4 channels of different species and among the α-
subunits of human sodium channels NaV1.1 to NaV1.8.
28 Furthermore, the mutations 
were retrospectively absent in 200 control chromosomes. Finally, both probands with 
these mutations showed a definite phenotype of a NDM in the absence of other 
mutations in CLCN1 or SCN4A, and both mutations were segregating with the disease. 
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The third novel SCN4A missense mutation (L689F), located in the linker between 
segment 4 and 5 of domain 2 in Nav1.4, is located at the same codon as the already 
established mutation L689I. This mutation was shown to cause in vitro effects of a 
hyperpolarising shift in the voltage dependence of activation causing hyperkalemic 
periodic paralysis.29 The proband with the L689F mutation in our population showed a 
Thomsen-like phenotype without symptoms of weakness. 
 
To exclude benign polymorphisms we tested 100 control chromosomes in accordance 
with the current best practice guidelines. Furthermore, the Leiden University Medical 
Centre analysed approximately 500 patients with suspected NDMs worldwide during 
the last five years and none of the detected variants were identified. Others mainly 
performed in vitro studies for the confirmation of novel mutations in one of these 
genes.23,30,31 In the future such studies should also be done for the eight novel 
missense mutations we detected in our study. 
 
In this study, we identified 21 different CLCN1 and 11 different SCN4A mutations. 
Meyer-Kleine et al. also found a high number of different mutations in their German-
based cohort.13 In Scandinavian studies, three and eight different CLCN1 mutations 
were detected, respectively.16,32 In one of these studies the A513V, F413C and R894X 
mutations clearly predominated.16 Thus, our study yielded a broad spectrum of 
mutations underlying NDMs in the Netherlands. We hypothesise that these findings 
may be attributable to the high population density in the Netherlands, especially 
when compared to the low population densities in Sweden, Norway and Finland. 
 
Our analyses revealed DMC to be scarce in the Netherlands, which is in sharp contrast 
with the initial clinical diagnoses. In 20% of the patients, the initial referral diagnosis 
was DMC. However, only two of these patients were finally classified as DMC while 
the others proved to have SCM. All the probands with a SCM mutation showed a 
clinical picture of a generalised myotonia in combination with the warm-up 
phenomenon, mimicking Thomsen’s disease.33 
 
In conclusion, we have shown that in tandem analysis of CLCN1 and SCN4A affords a 
high level of mutation ascertainment in families with a NDM. With this strategy we 
were able to identify 13 novel CLCN1 and three novel SCN4A mutations. Moreover, it 
enabled us to confirm earlier suggestions that the prevalence of SCN4A mutations is 
higher than previously assumed.18 Based on the results presented here, we feel safe in 
suggesting that our approach shows a great diagnostic potential and may offer 
optimal conditions for future genotype-phenotype studies. 
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Sirs: Myotonia is a clinical phenomenon consisting of uncontrolled temporary muscle 
stiffness after voluntary or evoked muscle contractions.1 It is a cardinal symptom in 
non-dystrophic myotonic syndromes, including chloride (ClCh) and sodium 
channelopathies (NaCh). Myotonia typically occurs after a period of rest and 
decreases with continuing exercise, commonly referred to as the warm-up 
phenomenon. This is in contrast with what occurs in paradoxical myotonia, where 
muscle stiffness increases as a result of continuing exercise. 
 
The warm-up phenomenon is an established clinical feature in ClCh, both in recessive 
myotonia congenita (RMC; M. Becker) as well as in dominant myotonia congenita 
(DMC; M. Thomsen). It has also been shown in limb muscles of patients with a 
NaCh.1,2 By contrast, paradoxical myotonia has been established as a characteristic 
feature of NaCh.3 
 
Thus, unlike the phenotypic homogeneity of ClCh, sodium-channel mutations are 
associated with a broad spectrum of clinical phenotypes.4 Here we report three 
patients with a predominant and generalised warm-up phenomenon associated with 
the V445M missense mutation of the SCN4A gene encoding the alpha-subunit of the 
voltage gated sodium channel.  
 
Three patients, from two families, with an autosomal dominant non-dystrophic 
myotonic syndrome and a predominant warm-up phenomenon were referred to our 
clinic. All patients had complaints of generalised muscle stiffness since birth and had 
earlier been diagnosed as Thomsen’s disease, but recent chloride channel gene 
(CLCN1) mutation screening was negative. Clinically myotonia was generalised, severe 
and painful. All patients noticed aggravation of myotonia at cold temperatures and 
only one patient reported aggravation after eating potassium rich food. They all used 
sodium channel blockers (mexiletine 200 mg three times a day, procainamide 1000 
mg three times a day and quinine 200 mg three times a day, respectively) with a good 
subjective effect. Needle EMG of all patients revealed myotonic discharges in all 
muscles investigated (left biceps muscle, right first interosseus muscle, right rectus 
femoris muscle, left tibialis anterior muscle and left orbicularis oculi muscle). We 
measured the warm-up phenomenon in three different muscle groups during a drug 
free period. The warm-up phenomenon of eyelid muscles and right hand flexor 
muscles was quantified by measuring the difference between two relaxation times - 
timed with a stopwatch -, i.e. after maximum voluntary contraction of three seconds 
following ten minutes of rest and after ten successive contractions. For leg muscles 
we compared the first and tenth trial on a ‘chair test’ in which the time required to 
rise from a standardised chair, to circumvent it and to sit down again was measured. 
DNA extracted from 20 ml of blood was screened for mutations in SCN4A by direct 
nucleotide sequence analysis.  
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All patients showed a marked generalised warm-up phenomenon (Table 5.1). Direct 
nucleotide sequence analysis of all three patients showed the same missense 
mutation (c.1333G>A; p.V445M) in SCN4A.  
 
Table 5.1 Clinical relaxation times (in seconds) of three patients after the first (1st) and tenth (10th) 
maximum voluntary contraction of eyelid muscles (eyes), right hand flexor muscles (hand) and 
leg muscles (legs). 
 Patient A Patient B Patient C 
Age (years)/Sex 29/M 52/F 68/M 
 
Eyes (1st) 
Eyes (10th) 
 
Hand (1st) 
Hand (10th) 
 
Legs (1st) 
Legs (10th) 
 
3.77 
1.37 
 
7.97 
< 1.00 * 
 
15.47 
  6.16 
 
25.00 
  6.57 
 
13.93 
  1.11 
 
  6.45 
  5.09 
 
17.46 
  1.35 
 
< 1.00 * 
< 1.00 * 
 
  9.70 
  5.67 
* no detection of clinical myotonia 
 
The V445M sodium channel mutation was first reported by Rosenfeld et al. causing a 
painful myotonia congenita.2 The warm-up phenomenon was mentioned in one 
patient. Here we report three patients with a predominant and generalised (eyelid 
muscles, right hand flexor muscles and leg muscles) warm-up phenomenon in 
association with the same V445M sodium-channel mutation. Although quantitative 
computer analysis for the warm-up phenomenon of a single muscle group has already 
been developed, we used clinical bedside tests in order to be able to measure this 
phenomenon in three various muscle groups.5 
 
For a definite molecular diagnosis clinicians should be aware that a predominant and 
generalised warm-up phenomenon may be found in ClCh, but also in NaCh. A definite 
diagnosis is important for informing patients about their disease, orienting therapy 
and genetic counselling.4 Thus, in cases with severe, painful myotonia in combination 
with a clear warm-up phenomenon, we recommend screening of SCN4A with 
particular attention for the V445M mutation. 
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Abstract 
Objective 
To redefine phenotypical characteristics for both chloride (ClCh) and sodium channelopathies (NaCh) in 
non-dystrophic myotonic syndromes (NDMs). 
 
Methods 
In a cross-sectional, nationwide study, standardised interviews and clinical bedside tests were performed in 
62 genetically confirmed NDM patients, 32 ClCh and 30 NaCh. 
 
Results 
Standardised interviews revealed that ClCh reported a higher frequency of muscle weakness (75 versus 
36.7%; p<0.01), the warm-up phenomenon (100 versus 46.7%; p<0.001), and difficulties in standing up 
quickly (90.6 versus 50%; p<0.001), running (90.6% versus 66.7; p<0.05), and climbing stairs (90.6 versus 
63.3%; p=0.01). Patients with NaCh reported an earlier onset (4.4 versus 9.6 years; p<0.001), and higher 
frequencies of paradoxical (50.0 versus 0%; p<0.001), and painful myotonia (56.7 versus 28.1%; p<0.05). 
Standardised clinical bedside tests showed a higher incidence and longer relaxation times of myotonia in 
the leg muscles for ClCh (100 vs. 60%; mean duration of chair tests 12.5 vs. 6.3 seconds; p<0.001), and in 
eyelid muscles for NaCh (96.7 vs. 46.9%; mean relaxation time of 19.2 vs. 4.3 seconds; p<0.001). Transient 
paresis was only observed in ClCh (62.5%) and paradoxical myotonia only in NaCh (30.0%). Multivariate 
logistic regression analyses allowed us to propose clinical guidelines for genetic testing.  
 
Conclusion 
This study redefined the phenotypical characteristics of NDMs in both ClCh and NaCh. The clinical guidelines 
that we proposed may help clinicians to perform focussed genetic analysis of either CLCN1 or SCN4A. 
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Introduction 
Non-dystrophic myotonic syndromes (NDMs) are a heterogeneous group of skeletal 
muscle disorders caused by mutations in genes encoding the skeletal muscle chloride 
(CLCN1) or sodium channel (SCN4A). Mutations in CLCN1 are responsible for recessive 
and dominant myotonia congenita (RMC and DMC), and mutations in SCN4A for 
paramyotonia congenita (PC), potassium-aggravated myotonias (PAM), and 
hyperkalemic periodic paralyses with myotonia (HYPP).1 As suggested by Rüdel et al., 
PAM diagnosed without a potassium-loading test is referred to as a sodium-channel 
myotonia (SCM).2  
 
Diagnosis of the various types of NDMs was originally based on clinical characteristics 
only. Thomsen was the first to describe DMC, distinguishing the stiffness (myotonia), 
reduction of stiffness through repetitive muscle contractions (warm-up phenomenon), 
and the dominant inheritance of the disease.3 In 1957 Becker described a recessive 
form with a more generalised myotonia in combination with transient paresis.4 Both 
symptoms also improved with sustained exercise (warm-up phenomenon).5 In 
contrast, myotonia in PC worsens with sustained exercise (paradoxical myotonia). 
Furthermore, in PC a flaccid paresis may be elicited by cold or long periods of 
exercise.6 PAM is clinically characterised by potassium sensitivity of myotonia and by 
unusual features as fluctuations in myotonia (myotonia fluctuans), permanent 
myotonia (myotonia permanens) or acetazolamide-responsive MC.7,8 HYPP shows 
attacks of generalised muscle weakness with myotonia.9  
 
Since genetic testing became available, several authors have reported genotype-
phenotype mismatches.10-12 For example, the warm-up phenomenon was assumed to 
be a specific symptom for chloride channelopathies. However, instead of the expected 
chloride channel defect, a mutation in the skeletal muscle sodium channel was found 
in some families with the warm-up phenomenon.10-12 The present study aims to 
redefine clinical phenotypes of NDMs segregated by chloride (ClCh) and sodium 
channelopathies (NaCh). To this end, we conducted standardised interviews and 
clinical bedside tests in a group of genetically confirmed patients with NDMs. 
Patients and methods 
Patients 
All neurologists across the Netherlands as well as the Dutch Patient Association for 
Neuromuscular Diseases (Vereniging Spierziekten Nederland) were requested to 
report all patients with NDMs to our research group for a full year. All reported 
patients aged 18 years and over were invited to the neurology outpatient clinic of the 
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Radboud University Nijmegen Medical Centre and seen once for clinical assessment, 
needle-EMG, and collection of blood samples for genetic analysis. Inclusion criteria 
were a clinical diagnosis of a NDM according to established clinical criteria and 
myotonic discharges upon needle-EMG examination.13 Exclusion criteria were a 
clinical or genetic diagnosis of myotonic dystrophy type 1 or type 2, a clinical or 
genetic diagnosis of primary periodic paralysis without clinical signs of myotonia, 
serious co-morbidity, absence of mutations by direct sequence analysis in CLCN1 or 
SCN4A, and unwillingness or inability to temporarily stop drug therapy for myotonia. 
The study was approved by the medical ethics committee of the Radboud University 
Nijmegen Medical Centre, and all participating patients gave their written informed 
consent prior to the study. 
Genetic analysis  
Genomic DNA was isolated from peripheral blood at the Leiden University Medical 
Centre and subsequently screened for mutations by direct sequence analysis of CLCN1 
and SCN4A.14 Primer sets designed for amplification of CLCN1 or SCN4A can be found 
at http://www.lumc.nl/4080/DNA/CLCN1.html or SCN4A.html, respectively. 
Phenotype characterisation  
All clinical evaluations were conducted by the same examiner (JT) who had been 
amply trained in the standardised examination of patients with NDMs.  
Standardised interview 
A standardised interview was conducted to establish demographic and general clinical 
aspects (age, sex, age of onset, duration of symptoms, duration prior to diagnosis, use 
and duration of drug therapy and anesthesia-related adverse events), specific clinical 
features such as myotonic features (presence, provoking factors, pattern, frequency 
and severity (Numerical Rating Scale (NRS), range 1-10), presence of painful myotonia, 
severity of the pain (NRS, range 1-10), course of the disease, other neuromuscular 
features (presence of muscle weakness), disabilities (disability interfering with 
household and employment), and finally, the patient’s ability to walk, climbing stairs, 
stand-up quickly, run, and play sports.  
Standardised neuromuscular examination (clinical bedside tests) 
A standardised neuromuscular examination was performed to determine the 
presence of myotonia in eyelid, hand flexor, and leg muscles. Furthermore, presence 
or absence of the warm-up phenomenon, paradoxical myotonia, and transient paresis 
was tested. All tests were performed in predefined, standardised positions and 
environments (20 °C) at the same time of the day. Before the study, a trained clinical 
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team pilot tested the draft standardised neuromuscular examination and also 
repeated this is in several patients. 
Myotonia assessment 
Clinical tests for myotonia were performed after ten minutes of rest. Action myotonia 
in eyelid muscles and right-hand flexor muscles was determined after a maximum 
voluntary contraction of three seconds, which was initiated and the maximum 
possible contraction maintained on instruction from the examiner, after which the 
patients were asked to open their eyes or fist as quickly as possible. Action myotonia 
in leg muscles was evaluated during a modified ‘chair-test’, in which the time required 
to rise from a standardised chair, to walk around it and to sit down again was 
measured.15 Percussion myotonia in the hands and legs was determined with a blow 
of the percussion hammer on the right thenar and right quadriceps muscle, 
respectively. Finally, myotonia of each muscle group was scored as positive if either 
action myotonia or percussion myotonia or both were present.  
Assessment of the warm-up phenomenon and paradoxical myotonia 
Relaxation times of the eyelid muscles and right-hand flexor muscles as well as 
performance of the chair tests were timed by stopwatch. The tests were conducted 
after ten minutes of rest and after ten successive contractions or, for the chair test, 
ten consecutive cycles. The warm-up phenomenon was defined as a reduction of the 
relaxation interval following the contractions or chair-test cycles with at least one 
second. Conversely, paradoxical myotonia was defined as an increase of the relaxation 
interval with at least one second. 
Assessment of transient paresis 
Presence of transient paresis was evaluated by manually testing the left biceps during 
isometric muscle force maintained during five seconds. If during this 5-sec interval the 
Medical Research Council (MRC) score fell below 5, the patient was encouraged to do 
warm-up exercises (i.e. 10 strong, successive 10 second contractions with the 
examiner exerting counterforce).16 If following the warm-up exercises the MRC-score 
had increased by minimally one point, transient paresis was recorded as positive and, 
if it had not, as negative. 
Statistical analysis 
The clinical and genetic data were recorded as independent variables in an SPSS 
database. All data analyses were performed using SPSS version 15.0 for windows 
(SPSS Inc, Chicago, IL, USA). To compare ClCh with NaCh, DMC with RMC, and 
PC/HYPP with SCM, we applied the Mann-Witney-U test for independent groups for 
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continuous variables and the chi-squares test for categorical variables. For the 
distinction between ClCh and NaCh we used multivariate logistic regression analysis. 
We regarded age, gender, and all variables obtained by the standardised 
neuromuscular examination as possible predictors. To find the best-fitting predictive 
model we used backward elimination and log-likelihood chi-squares. Subsequently, 
we searched for a reduced regression model including only predictors with a log-
likelihood chi-squares p-value lower than 0.10. Next, first-order interactions between 
all pairs of predictors remaining within the reduced model were tested by forward 
selection with log-likelihood chi-squares. Finally, we tried to construct a practical 
instrument for the distinction between ClCh and NaCh in daily clinical practice. A  
p-value of less than 0.05 was considered to be statistically significant.  
Results 
Patient demographics and genetic data  
The 1-year recruitment period yielded a total of 158 patients of whom 110 had been 
reported by neurologists and 48 by the Dutch Patient Association for Neuromuscular 
Diseases. Of the former contingent, 38 ultimately refused participation without 
specifying their reasons, and 23 patients of the latter group were non-responders. 
Nine patients were unable to participate due to transportation problems and 26 
patients were excluded because of periodic paralysis without clinical myotonia (n=7), 
unwillingness or inability to temporarily stop drug therapy for myotonia (n=5), 
misdiagnosis (n=2), or serious co-morbidity (n=12). Finally, we included 62 patients 
with a clinical, electromyographical and genetically confirmed diagnosis of a NDM, 
originating from 48 unrelated families. Thirty-three were men (53.2%) and 29 women 
(46.8%) and their mean age was 42.3 years (± 11.9 years, range 19-68). Direct 
sequence analysis showed CLCN1 mutations in 32 and SCN4A mutations in 30 
patients.14  
Phenotype characterisation 
Standardised Interview  
Differences between ClCh and NaCh 
Table 6.1 shows the prevalence of clinical aspects that were statistically significantly 
different between ClCh and NaCh. 
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Table 6.1 Prevalence of clinical aspects derived from the standardised interview that were statistically 
significantly different between chloride (ClCh) and those with sodium channelopathies (NaCh). 
 ClCh NaCh p-value 
Mean age in yrs (SD), range 45.7 (10.6), 23-60 38.7 (12.3), 19-68   0.02 
Mean age of onset in yrs (SD), range   9.6 (7.3), 0-31   4.4 (7.0), 0-36 <0.001 
Mean duration to diagnosis in yrs (SD), range 12.0 (10.4), 0-33 7.7 (11.9), 0-51   0.04 
Sleep deprivation, provoking factor of 
myotonia, n (%) 
11 (34.4) 19 (63.3)   0.02 
Decrease myotonia after repetitive 
contractions, n (%) 
32 (100) 15 (50.0) <0.001 
Increase myotonia after repetitive  
contractions, n (%) 
  0 (0) 15 (50.0) <0.001 
Presence of muscle weakness, n (%) 24 (75) 11 (36.7)   0.002 
Presence of painful myotonia, n (%)   9 (28.1) 17 (56.7)   0.02 
Difficulty in climbing stairs, n (%) 29 (90.6) 19 (63.3)   0.01 
Difficulty in standing-up quickly, n (%) 29 (90.6) 15 (50.0) <0.001 
Difficulty in running, n (%) 29 (90.6) 20 (66.7)   0.02 
Differences within ClCh and NaCh 
Within the ClCh there were no statistically significant differences between RMC and 
DMC. Within the NaCh group only muscle weakness showed a significant difference 
between PC and SCM (PC 85.7% versus SCM 21.7%; p=0.002). 
Similarities between ClCh and NaCh 
In addition to the discriminating variables, most patients mentioned daily complaints 
(ClCh: 96.9% and NaCh 83.3%) and myotonia was reported as severe (ClCh: 71.9% ≥5 
versus NaCh: 67.7% ≥5) with symptoms having increased during their lives. 
Furthermore, patients with painful myotonia rated their pain as severe (ClCh: 77.8% 
≥5 versus NaCh: 76.5% ≥ 5). Muscle contractions (95.2%), low temperatures (88.7%), 
and stress and emotions (61.3%) were the main provoking factors for myotonia. In the 
female patients both menstruation and pregnancy tended to aggravate the symptoms 
(menstruation: ClCh: 25% and NaCh: 41%; pregnancy: ClCh: 40% and NaCh: 80%). 
About 30% of the patients (ClCh: 31.3% and NaCh: 26.7%) had been taking drugs to 
combat myotonia for a prolonged time (mean duration of drug therapy 10.1 vs. 15.3 
years). Fifty percent used mexiletine, the other half carbamazepine, fenytoine, 
tocainide, procainamide, or flecainide. In each group about one third of the patients 
was fully or partially disabled (ClCh: 34.4 and NaCh: 33.3%). Finally, complications 
during anesthesia were reported in 21.7% in ClCh and in 23.3% in NaCh: two patients 
with a NaCh showed myotonia in tongue and throat muscles, which hampered their 
intubation. One patient with a NaCh showed abundant myotonia in his abdominal 
muscles, which made it necessary to cancel surgery. Two patients with a ClCh were 
excessively fatigued for a prolonged time, and eight patients, four ClCh and four NaCh, 
experienced an excessive increase of their myotonia after surgery. 
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Standardised neuromuscular examination 
Differences between ClCh and NaCh 
Table 6.2 shows the results of the standardised neuromuscular examinations. Eleven 
of the 16 variables differed statistically significantly between the two NDM groups. 
Most noticeable were the higher occurrence and longer relaxation times of myotonia 
in the leg muscles for ClCh and in the eyelid muscles for NaCh. Furthermore, 
paradoxical myotonia was exclusively present in the NaCh and transient paresis in 
ClCh.  
 
Table 6.2 Clinical features obtained from the standardised neuromuscular examinations in patients with 
chloride (ClCh; n=32) and sodium channelopathies (NaCh; n=30). 
 ClCh NaCh p-value 
Action myotonia right-hand flexor muscles, n (%) 29 (90.6) 27 (90.0)   0.93 
Action myotonia leg muscles, n (%) 29 (90.6)   7 (23.3) <0.001 * 
Percussion myotonia right abd. poll. brevis, n (%) 28 (87.5) 26 (86.7)   0.92 
Percussion myotonia right quadriceps, n (%) 27 (84.4) 17 (56.7)   0.02 * 
Myotonia in eyelid muscles, n (%) 15 (46.9) 29 (96.7) <0.001 * 
Myotonia in right-hand flexor muscles, n (%) 29 (90.6) 29 (96.7)   0.32 
Myotonia in leg muscles, n (%) 32 (100) 18 (60.0) <0.001* 
Mean relaxation time of patients with myotonia in 
eyelid muscles after 1 contraction in sec (SD), range
  4.3 (3.7), 0.7-13.1 19.2 (14.1), 1.0-54.5 <0.001 * 
Mean relaxation time of patients with myotonia in 
eyelid muscles after ten contractions in sec (SD), 
range 
  0.7 (0.8), 0-2.9 14.1 (18.0), 0-79.9 <0.001 * 
Mean relaxation time of patients with myotonia in 
hand muscles after 1 contraction in sec (SD), range 
  4.7 (3.9), 1.1-17.5   5.6 (6.5), 0.7-30.7   0.90 
Mean relaxation time of patients with myotonia in 
hand muscles after 10 contractions in sec (SD), 
range 
  1.1 (1.2), 0-5.9   7.9 (19.3), 0-99.0   0.01 * 
Mean duration of the chair test after rest in sec 
(SD), range 
12.5 (5.7), 5.2-29.9   6.3 (2.2), 4.0-15.5 <0.001 * 
Mean duration of the chair test after 10 cycli in sec 
(SD), range 
  7.0 (2.1), 4.3-15.3   5.7 (1.0), 4.0-8.9 <0.01 * 
Warm-up phenomenon, n (%) 30 (93.8) 23 (76.7)   0.05 
Paradoxical myotonia, n (%)   0 (0)   9 (30.0) <0.001 * 
Transient paresis, n (%) 20 (62.5)   0 (0) <0.001 * 
* p<0.05 
Differences within ClCh and NaCh 
In ClCh transient paresis showed no differentiation between RMC (66.7%) and DMC 
(0%) (p= 0.13). Furthermore, there were no other differentiating variables between 
the two MC types. In NaCh the presence of myotonia in the leg muscles (p=0.05), 
action myotonia (p=0.10), and percussion myotonia of the right quadriceps muscle 
(p=0.09) showed a trend for differentiation between SCM and PC (Table 6.3). 
However, only the warm-up phenomenon contributed statistically significantly to the 
differentiation between SCM and PC (Table 6.3).  
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Table 6.3 Clinical features as obtained from the standardised neuromuscular examinations in the patients 
with paramyotonia congentia (PC; n=7) and sodium-channel myotonias (SCM; n=23). 
 PC SCM p-value 
Myotonia in leg muscles, n (%)  2 (28.6)  16 (69.6)  0.05 
Action myotonia leg muscles, n (%)  0 (0%)  7 (30.4)  0.10 
Percussion myotonia right quadriceps, n (%)  2 (28.6)  15 (65.2)  0.09 
Warm-up phenomenon, n (%)  2 (28.6)  21 (91.3)  0.001 * 
* p<0.05 
Similarities between ClCh and NaCh 
Both groups exhibited a high incidence and similar severity of myotonia in the hand-
flexor muscles, and both displayed the warm-up phenomenon. 
Practical instrument of parameters for the distinction between ClCh and NaCh 
Tables 6.4a and 6.4b show the results of the final logistic regression model.  
 
Table 6.4a Results of the final logistic regression model with type of channelopathy as the dependent 
outcome measure (n=62). 
 B S.E. Wald df Sig. Oddsratio 95% C.I. for OR 
Lower - Upper 
Predictors        
   Myotonia in eyelid muscles  4.47  1.22  13.49 1  <0.001 87.00      8.02 -943.35 
   Transient paresis  -22.69  7812.13  0.00 1  0.998   0.00      0.00 - 
   Constant  -2.20  1.05  4.35 1     0.037          0.01  
 
 
Table 6.4b Test results of myotonia in eyelid muscles and transient paresis in the final model. 
 Model Log 
Likelihood 
Change in -2Log 
Likelihood 
df Sig. of 
Change 
Predictor     
   Myotonia in eyelid muscles -25.13 23.84 1 <0.001 
   Transient paresis -32.09 37.77 1 <0.001 
 
 
The resultant model only comprises myotonia in eyelid muscles and transient paresis. 
The log-likelihood chi-squares of this model are 59.47 by 2 df (p<0.001), and the ROC 
area-under-the-curve parameter is 0.947 (asymptotic 95% CI: 0.884-1.000). Based on 
these results quite simple rules for an effective and practical instrument to distinguish 
ClCh from NaCh can be described: if both eyelid myotonia and transient paresis are 
absent OR if transient paresis is present (regardless of the absence or presence of 
eyelid myotonia) a ClCh is most likely (See Table 6.5). Conversely, if eyelid myotonia is 
present and transient paresis is absent a NaCh is the most likely conclusion (Table 
6.5). 
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Table 6.5 Cross table showing the relationship between the clinical bedside tests (transient paresis and 
myotonia in eyelid muscles) and type of channelopathy (chloride channelopathies (ClCh) and 
sodium channelpathies (NaCh); n=62). 
 ClCh NaCh 
TESTS   
Myotonia in eyelid muscles absent  
AND Transient paresis absent 
 
OR 
 
Transient paresis present 
29 1 
Myotonia in eyelid muscles present  
AND 
Transient paresis absent 
3 29 
 
Sensitivity and specificity of this test for ClCh are 90.6% and 96.7%, respectively. Thus, 
the combination of the individual results and their multivariate regression analyses 
showed that the presence or absence of paramyotonia, transient paresis, and eyelid 
myotonia discriminate between ClCh and NaCh (Figure 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Clinical guideline for genetic testing based on the standardised clinical bedside tests. 
Discussion 
In this systematic cross-sectional study with a thorough standardised clinical protocol 
and a robust methodology we were able to redefine the clinical phenotypes of NDMs. 
Using one of the largest genetically confirmed NDM cohorts of both ClCh and NaCh, 
we showed novel genotype-phenotype correlations and confirmed earlier ones. 
Before, Becker and colleagues had thoroughly studied the clinical picture of NDMs in 
the pre-genetic era.17,18 Fialho et al. recently reported a large cohort of ClCh, while 
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Matthews et al. described a large cohort of NaCh.19,20 This study included both ClCh 
and NaCh, allowing a direct comparison of the two phenotypes.  
 
The main result of our study is the high frequency and severity of myotonia in the 
eyelid muscles in NaCh and in the leg muscles in ClCh. Furthermore, we confirmed 
that transient paresis is a unique clinical feature for ClCh and paradoxical myotonia for 
NaCh. Interestingly, the warm-up phenomenon was demonstrated in both NDM 
groups. Another remarkable finding is that 28.1% of the ClCh patients and 56.7% of 
those with NaCh experienced painful myotonia, whereas myotonia is usually 
considered painless.1 
 
The distribution pattern of myotonia in our study differs between ClCh and NaCh. 
Original reports described the distribution patterns of MC as generalised with leg 
muscles often severely affected.17 Eulenburg, Streib and Rüdel et al. reported a 
predilection of myotonia in PC for facial, tongue, throat, and hand muscles.2,6,21 In 
Matthews’ genetically confirmed PC population 26 of the 32 patients reported 
myotonia in the face and the upper limbs.20 Although we, as yet, have to do without 
an established explanation for the different distribution patterns of myotonia in ClCh 
and NaCh, we hypothesise that they may partly be explained by the fact that in most 
ClCh patients the eyelid muscles are already ‘warmed-up’ as a result of blinking, while 
a subgroup of NaCh patients still show myotonia. Alternatively or concurrently, the 
distribution patterns of voltage-gated chloride and sodium channels may differ for the 
various muscles. For example, human facial muscles probably contain more sodium 
channels than human skeletal muscles.22,23 
 
The high incidence of the warm-up phenomenon (76.7%) in our NaCh group is 
remarkable. Initially, the warm-up phenomenon was predominantly reported for ClCh 
and was only rarely observed in NaCh.10 However, in about 20% of our patients with 
the initial suspicion of a “DMC” phenotype, we detected a mutation in SCN4A 
(NaCh).14 All these patients were sodium-channel myotonias (SCM).14 Hence, the 
warm-up phenomenon is a clinical feature in RMC, DMC as well as in SCM. Although 
the warm-up phenomenon has now been established as a clinical feature in both 
types of NDMs, its pathophysiological mechanism is still unclear.24  
 
Transient paresis is a unique clinical feature in ClCh. The prevalence (62.5%) of this 
phenomenon in our patients with CLCN1 mutations is comparable with earlier reports 
of RMC.25,26 This is congruent with the fact that only two of our patients were 
diagnosed with DMC. Due to the patient distribution in the Netherlands, this 
phenomenon cannot distinguish RMC from DMC. However, Fialho et al. showed that 
generalised muscle hypertrophy, transient paresis, and depressed tendon reflexes 
occurred more frequently in RMC than in DMC.19  
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In parallel with the transient paresis in ClCh, our study confirmed that paradoxical 
myotonia is unique for NaCh. However, the symptom was only observed in 30.0% of 
our NaCh patients, but it should be noted that we saw no patients with HYPP, only 
seven patients with PC and a relatively large number of patients with SCM. 
Furthermore, we only tested at room temperature. Future studies should also test 
patients at lower temperatures, although in these conditions some patients with PC 
will show paradoxical myotonia while others will exhibit a flaccid (periodic) paralysis.21  
 
A crucial point in the literature of NDMs is the quantification of myotonia.27 For this 
reason dedicated equipment and computerised protocols to quantify myotonia in 
hand muscles have been employed.28,29 However, the purpose of our study was not to 
quantify myotonia in the hand muscles, but to investigate using daily practice 
neurological examination, the clinical pattern of myotonia in three different body 
regions (face, hands, legs) for ClCh as well as for NaCh. Moreover, the employed 
devices are not freely available and neither useful for facial nor for leg muscles. 
Therefore, we developed standardised clinical bedside tests, which are easily 
applicable in every outpatient clinic.10 We were the first who developed such a 
standardised, robust and detailed methodology for clinical bedside tests of myotonia 
in three different body regions. Actually, all patients showed clear myotonia in at least 
one body region. It is the ultimate goal to quantify these phenomena with special 
devices, as the resultant parameters will be important to set clinical endpoints in 
future randomised controlled trials. As we were aware of the crucial points about the 
quantification of myotonia, we only used the presence or absence of the different 
clinical phenomena for our multivariate logistic regression analysis.  
 
A formal test-retest assessment is the ultimate guarantee for the quality of our study. 
However, myotonia especially fluctuates under different conditions. We standardised 
these conditions. Furthermore, a trained clinical team pilot tested the draft 
standardised neuromuscular examination and also repeated this in several patients. 
We detected robust and reliable data. Subsequently, the clinical team amply trained 
one examiner who performed all clinical bedside tests. At last, we have unpublished 
data of the same patient population for high density surface-EMG. Hereby we also 
observed force profiles. Actually, all patients with a transient paresis in our study 
(n=20) showed a decline in their force of the left biceps shortly after contraction (data 
not shown). Subsequently, all 20 patients showed an increase of their force after 
repetitive contractions. Since none of the other patients showed such force profiles, 
the presence of transient paresis was confirmed by a retest. Of course we are aware 
that such a good test-retest result is probably not the case for the warm-up 
phenomenon and paradoxical myotonia. However, the standardised interviews 
support our data. 
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The aim of our study was to redefine the clinical phenotypes of ClCh and NaCh. The 
results allowed us to propose clinical guidelines for genetic testing (Figure 6.1). In 
2006 Fournier et al. proposed electrophysiological guidelines to focus genetic 
testing.30 They distinguished three different repetitive nerve stimulation patterns.30 
Since a repetitive nerve stimulation test detects hypo-excitability of the skeletal 
muscle membrane, clinically observed as muscle weakness, the clinical features 
observed in the different subgroups of NDMs may explain the different patterns 
detected by Fournier. For instance, most patients with ClCh experience transient 
paresis followed by the warm-up phenomenon. This short period of muscle weakness 
corresponds with the initial hypo-excitability, followed by a progressive increase of 
CMAP amplitude after the short exercise test by Fournier (EMG pattern II). This effect 
is not shown in sodium-channel myotonias (SCM). These patients do not show any 
kind of muscle weakness and also show a very stable repetitive nerve stimulation 
pattern (pattern III). The frequent warm-up phenomenon detected in these patients 
could be puzzling. However, the warm-up phenomenon in ClCh reduces transient 
paresis (muscle weakness) as well as myotonia. Since there is no muscle weakness in 
SCM, the warm-up phenomenon in SCM probably only reduces myotonia. It would be 
interesting to correlate clinical and neurophysiological tests in the SCM in more detail. 
At last, paramyotonia congenita (PC) patients may show either paradoxical myotonia 
and/or weakness after successive short exercises. We only tested paradoxical 
myotonia and have no clinical correlate with the progressive hypo-excitability 
detected by Fournier (pattern I). Most probably successive short exercises of the same 
muscle group may clinically induce such a weakness in this group of patients. Finally, 
Fournier detected a hypo- or in-excitability of the muscle membrane after cold 
exposure in PC patients. We detected a paralysis of the hand muscles in two of the 
seven PC patients after cold exposure (data not shown). However, since it was too 
difficult to define a standardised clinical outcome measurement after cold exposure 
for PC patients (PC patients after cold exposure may show muscle weakness, 
paradoxical myotonia or paralysis), we removed this item from our protocol. 
Moreover, the clinical features in PC highly depend on the type of mutation.30 
Nevertheless, standardised clinical tests after cold exposure should also be developed. 
Conclusions 
We systematically investigated 62 patients with a genetically confirmed diagnosis of 
non-dystrophic myotonic syndromes and redefined the clinical phenotypes of chloride 
and sodium channelopathies. The results allowed us to propose clinical guidelines for 
genetic testing. These may help clinicians to perform focussed genetic analysis of 
either CLCN1 or SCN4A. However, if this test is negative, the other gene should 
subsequently be analysed, too. 
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Abstract 
Objective 
To determine self-reported health status in non-dystrophic myotonic syndromes (NDMs) and its 
relationship to painful myotonia and fatigue. 
 
Methods 
In a cross-sectional study 32 NDM patients with chloride (ClCh) and 30 with sodium channelopathies 
(NaCh), all off treatment, completed a standardised interview, the fatigue assessment scale (FAS), and the 
36-Item Short-Form Health Survey (SF-36). Beside formal assessment of pain, assessment of painful or 
painless myotonia was determined. The domain scores of the SF-36 were compared with Dutch community 
scores. Apart from the relationship among SF-36 scores and (1) painful myotonia and (2) fatigue, regression 
analyses in both NDM groups were conducted to determine the strongest determinants of the SF-36 
domains general-health perception, physical component (PCS) and mental component summary (MCS). 
 
Results 
All physically oriented SF-36 domains in both NDM groups (p≤0.01) and social functioning in the patients 
with NaCh (p=0.048) were substantially lower relative to the Dutch community scores. The patients with 
painful myotonia (41.9%) scored substantially (p<0.05) lower on most SF-36 domains than the patients 
without painful myotonia (58.1%). Fatigued patients (53.2%) scored substantially lower (p≤0.01) on all SF-36 
domains than their non-fatigued counterparts (46.8%). The regression analysis showed that fatigue was the 
strongest predictor for the general-health perception and painful myotonia for the physical component 
summary. None of the patients showed below-norm scores on the domain mental component summary.  
 
Conclusion 
The impact of NDMs on the physical domains of patients’ health status is substantial, and particularly 
painful myotonia and fatigue tend to impede their physical functioning. 
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Introduction 
Non-dystrophic myotonic syndromes (NDMs) are caused by mutations in genes 
encoding the skeletal muscle chloride (CLCN1) or sodium channel (SCN4A). Mutations 
in CLCN1 are responsible for recessive and dominant myotonia congenita (recessive 
MC [MIM 160800] and dominant MC [255700]), and mutations in SCN4A for 
paramyotonia congenita (PC [MIM 168300]) and potassium-aggravated myotonias 
(PAM [MIM 608390]).1 
 
The key symptom of MC is myotonia, and especially patients with recessive MC show 
a combination with transient paresis.2 Both symptoms improve with continuing 
exercise, which is referred to as the warm-up phenomenon.3,4 Conversely, in PC 
myotonia worsens with continuing exercise. Muscle weakness is also observed in PC 
and is mostly elicited by cold or prolonged exercise.5 Myotonia in PAM is clinically 
characterised by unusual features such as temporal fluctuation (myotonia fluctuans), 
permanent myotonia (myotonia permanens) or acetazolamide-responsive myotonia 
(acetazolamide-responsive myotonia congenita).6-8 
 
Myotonia in NDMs is often described as painless muscle stiffness.9 However, Becker 
found 15% of his patients with recessive MC to report pain complaints.2 Also, a 
fluctuating form of dominant MC, acetazolamide-responsive myotonia congenita and 
the V445M sodium channel mutation were associated with painful myotonia; thus, 
pain appears to be a recurrent symptom in NDMs.2,8,10,11 
 
Another symptom in neuromuscular diseases is fatigue. Although initially under-
reported in neuromuscular disorders, fatigue has now been established in post-polio 
syndrome, immune-mediated polyneuropathies, myasthenia gravis, facioscapulo-
humeral muscular dystrophy, myotonic dystrophy, and type-I hereditary motor and 
sensory neuropathy.12-16 Our clinical experience has taught us that also patients with 
NDMs may complain of fatigue. 
 
Despite their symptoms and signs, NDMs are considered to be a group of ‘benign 
diseases’ with possible influences on the patients’ ability to perform activities of daily 
living, affecting their social participation.17 This explains why to date no clinical reports 
are available that have systematically examined the effects NDMs have on the 
patients’ health status, where health status is defined as the impact of the disease on 
a patient’s physical, psychological and social functioning.18 The presence of painful 
myotonia and fatigue in patients with NDMs and their impact on the patients’ health 
status has likewise not been systematically investigated. Therefore, we investigated 
the impact of NDMs on health status. We additionally examined the presence and 
effects of painful myotonia and fatigue and, finally, performed regression analyses to 
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investigate the contribution of various determinants assumed to impair the patients’ 
physical, psychological and social functioning.  
Patients and methods 
Patients 
In March 2005 neurologists across The Netherlands as well as the Dutch Patient 
Association for Neuromuscular Diseases (Vereniging Spierziekten Nederland) were 
requested to report all patients with a clinical suspicion of NDMs to our research 
group for a full year. Inclusion criteria were age (≥18 years), a diagnosis of NDM 
according to established clinical criteria and needle-EMG evidence of myotonic 
discharges.19 Exclusion criteria were a clinical or genetic diagnosis of myotonic 
dystrophy type 1 or 2, primary periodic paralysis, serious co-morbidity, unwillingness 
or inability to reduce or stop drug therapy for myotonia during the study and no 
detectable mutations in CLCN1 or SCN4A.  
 
The 1-year recruitment period yielded a total of 97 potentially eligible patients. Nine 
patients were unable to participate due to transportation problems. Based on the 
selection criteria, another 26 patients were excluded: 7 had a primary periodic 
paralysis, 12 serious co-morbidity, 5 were unwilling to reduce and stop myotonia-
related drug therapy, and 2 did not present clinical signs of myotonia and lacked 
myotonic discharges (needle-EMG). All remaining 62 patients demonstrated DNA 
mutations in either CLCN1 (n=32) or SCN4A (n=30).20,21 The study was approved by the 
Medical Ethics Committee of the Radboud University Nijmegen Medical Centre, and 
all patients gave their written informed consent prior to their participation. 
Examination procedures 
Standardised interview 
With the standardised interview the following characteristics of all NDM patients were 
established: age, gender, duration of symptoms, frequency, pattern (reduction or 
augmentation of myotonia after repetitive movements) and severity of the myotonia 
[Numerical Rating Scale (NRS), range 1-10; 1 means almost no myotonia and 10 means 
very serious myotonia], changes in severity, presence of muscle weakness, presence 
of painful or painless myotonia and eventually the severity of the painful myotonia 
(NRS, range 1-10; 1 means almost no painful myotonia and 10 means very serious 
painful myotonia).  
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Painful myotonia 
We used the outcome of the standardised interview to dichotomise patients with 
painless and those with painful myotonia. Patients with painful myotonia were also 
asked about the severity of their pain (NRS, range 1-10). 
Fatigue assessment scale 
Fatigue was assessed with the ten-item self-reported fatigue assessment scale (FAS).22 
Five items probe physical and five mental fatigue. Each item is scored on a 5-point 
Likert scale with the total score ranging from 10 to 50. Higher scores indicate higher 
fatigue levels. The scale’s validity and reliability of the FAS were good.22-24 We took 
FAS scores equal to or higher than 22 to be indicative of fatigue and used this as the 
cut-off score to dichotomise fatigued and non-fatigued NDM patients.24 
Short-Form 36-Item Health Survey 
Patients completed the Short-form 36-Item Health Status Survey (SF-36, Dutch 
version), a generic questionnaire to establish patients’ self-reported health status.25,26 
It appraises the following domains: physical functioning (10 items), role functioning 
physical (4), role functioning emotional (3), social functioning (2), body pain (2), 
mental health (5), vitality (4), general-health perception (5), and change in health, 
which is scored separately.26 The number of response categories per item ranges from 
two to six. Each domain has a scoring range of 0-100 with higher scores indicating 
better health or functioning and less body pain. The scale’s physical component 
summary (PCS) and mental component summary (MCS) scores were also calculated 
using the reported means, standard deviations and factor-score coefficients derived 
from the general Dutch population.25-28 The PCS captures the individual’s overall 
physical functioning by considering reported limitations in care, physical, social and 
role activities, amount of pain, and level of energy. The MCS reflects the respondent’s 
overall mental functioning by considering the frequency of psychological distress and 
limitations in usual social and role activities due to emotional problems.27 A linear T 
score transformation method was used so that the PCS had a mean of 49.7 (SD 9.3) 
and the MCS had a mean of 52.1 (SD 9.6), as reported for the general Dutch 
population.25-28 The SF-36 has been shown to have a good validity and reliability.25-28 
For our comparative analyses, we used the reported mean (SD) SF-36 domain scores 
of a random, Dutch nationwide sample of 1,742 healthy individuals consisting of 976 
men and 766 women with a mean age of 47.6 years (18.0 years; range 16-94 
years).25,28  
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Statistical analysis 
Validity and reliability 
Prior to the health status analyses, we tested the validity and reliability of the scales 
used. Validity was determined by means of Spearman’s rank correlation tests among 
(1) the various SF-36 dimensions, (2) the SF-36 dimension vitality and FAS and (3) the 
SF-36 domain body pain and painful myotonia. The reliability of the SF-36 and FAS was 
estimated by calculating the internal consistency (Cronbach’s α). A Cronbach’s α≥0.7 
is considered as having a good reliability.29 
SF-36 values 
The mean SF-36 domain and summary (PCS and MCS) values for (1) chloride (ClCh) 
and sodium channelopathies (NaCh), (2) the fatigued and the non-fatigued group and 
(3) the painful and painless myotonia group were compared with Dutch community 
scores (Student’s t test for independent groups).25,28 In addition, the SF-36 domain 
scores of the patients with a ClCh were compared with those with a NaCh, the 
fatigued patients were compared with non-fatigued patients, and those patients with 
painful myotonia were compared with their painless counterparts (Student’s t test for 
independent groups). 25, 28 
Regression analysis 
In both NDM groups linear regression analyses were performed to determine which 
variable had the greatest impact on the patients’ general-health perception, PCS and 
MCS (dependent variables). Age, gender, duration of symptoms, frequency of 
myotonia, its pattern after repetitive contractions, myotonia severity and changes in 
severity, presence of muscle weakness, presence of painful myotonia, severity of the 
pain and the FAS were considered as explanatory variables. Prior to the regression 
analyses, the distribution pattern of the dependent variables were examined and, if 
necessary, a transformation of the values was carried out to obtain a normal 
distribution pattern. Univariate regression analyses were conducted to reveal those 
independent variables that were related to dependent variables, separately. This was 
achieved through a systematic evaluation of constructed graphs with linear regression 
studies that included a restricted cubic spline function on the independent variable.30 
Subsequently, separate multivariate linear regression analyses were performed for 
each dependent variable, using the stepwise method including only the independent 
variables that had shown p≤0.2 in the univariate analyses. The strength of the 
association between the dependent variable and the independent variables was 
presented as R2: the fraction of variance explained by the independent variables from 
the regression model. All analyses were performed using Stata 7.0 for Windows 2000 
(Stata Corp., College Station, TX). A value of p<0.05 was considered statistically 
significant. 
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Results 
Interview outcomes 
Table 7.1 shows the basic characteristics of all NDM patients obtained during the 
standardised interview. All patients complained of myotonia, and the majority (96.9% 
in ClCh and 83.3% in NaCh) reported daily complaints. All the patients with ClCh 
reported a decrease in myotonia after repetitive contractions, which was 50% for the 
patients with a NaCh, while the other half indicated an increase (paradoxical 
myotonia). Although ten patients in the chloride group and eight patients in the 
sodium group used drugs to relieve myotonia before the study, both groups claimed 
the severity of their myotonia had increased since the onset of symptoms. Over half of 
all patients with NaCh (56.7%) and about 30% (28.1%) of the patients with ClCh 
characterised their myotonia as painful (χ2=5.18, p=0.02). Finally, 75% of the ClCh 
versus 37% in the NaCh experienced muscle weakness (χ2=9.26, p=0.002). 
 
Table 7.1 Basic characteristics of all patients with a non-dystrophic myotonic syndrome (NDM), for each 
subtype separately. 
 ClCh 
(n=32) 
NaCh 
(n=30) 
p-value 
Gender, n (%) 
   Men 
   Women 
 
20 (62.5) 
12 (37.5) 
 
13 (43.3) 
17 (56.7) 
  0.131  
Mean age in years (SD), range 
Mean duration of symptoms (SD), range 
45.7 (10.6), 23-60 
36.1 (12.8),   9-57 
38.7 (12.3), 19-68 
34.3 (13.5),   6-68 
  0.019 * 
  0.599 
Frequency of myotonic symptoms, n (%) 
   On a daily basis 
   Several times a week 
   Several times a year 
 
31 (96.9)    
  1 (  3.1) 
  0 (  0) 
 
25 (83.3) 
  4 (13.3) 
  1 (  3.3) 
  0.184 
Myotonia after repetitive movements, n (%) 
   Reduced (warm-up phenomenon) 
   Increased (paramyotonia) 
 
32 (100) 
  0 (    0) 
 
15 (50.0) 
15 (50.0) 
<0.001 * 
Severity of myotonia 
(1 = very mild - 10 = most severe), n (%) 
   1-5 
   6-10 
 
 
13 (40.6) 
19 (59.4) 
 
 
15 (50.0) 
15 (50.0) 
  0.459 
Changes in severity of myotonia, n (%) 
   Increasing 
   Stable 
   Decreasing 
 
19 (59.4) 
12 (37.7) 
  1 (  3.1) 
 
17 (56.7) 
10 (33.3) 
  3 (10.0) 
  0.541 
Muscle weakness, n (%) 
   Yes 
   No 
 
24 (75.0) 
  8 (25.0) 
 
11 (36.7) 
19 (63.3) 
  0.002 * 
Painful versus painless myotonia, n (%) 
   Painful myotonia 
   Painless myotonia 
 
  9 (28.1) 
23 (71.9) 
 
17 (56.7) 
13 (43.3) 
  0.023 * 
Severity of painful myotonia 
(1 = very mild - 10 = most severe, n (%) 
   0 
   1-5 
   6-10 
 
 
23 (71.9) 
  4 (12.5) 
  5 (15.6) 
 
 
13 (43.3) 
  5 (16.7) 
12 (40.0) 
  0.443 
* p<0.05 
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Incidence painful myotonia 
Twenty-six (41.9%) patients reported painful myotonia with a mean NRS score of 6.1; 
36 patients (58.1%) reported painless myotonia. There was neither a relationship 
between the presence of painful myotonia and gender (χ2=0.287, p=0.670), nor 
between the presence of painful myotonia and age (r=- 0.07, p=0.60). 
Fatigue rates by FAS 
Based on their FAS scores, 33 (53.2%) patients were classified as fatigued (FAS 
27.2±4.3) and 29 (46.8%) as non-fatigued (FAS 16.2±3.5). In ClCh 15 patients were 
fatigued (46%) and in NaCh 18 patients were fatigued (60%), (χ2=1.07, p=0.30). The 
FAS scores showed neither a relationship with gender (r=0.10, p=0.440), nor with age 
(r=- 0.05, p=0.70).  
FAS and SF-36 validity and reliability scores 
The matrix in Table 7.2 shows correlations among (1) the various SF-36 domains, (2) 
the SF-36 domain vitality and the FAS and (3) the SF-36 domain body pain and painful 
myotonia for the two NDM groups separately. For most SF-36 dimensions significant 
correlations were obtained. In both groups the SF-36 scores for vitality (higher scores 
mean better vitality) correlated inversely with the FAS scores (higher scores mean 
more fatigued), and the SF-36 scores for body pain (higher scores mean less pain) 
correlated inversely with painful myotonia (higher scores mean more pain). Table 7.2 
also shows the internal consistencies for the SF-36. For all SF-36 dimensions, good 
reliability scores (Cronbach’s alpha ≥0.7) were obtained. Cronbach’s alpha for the FAS 
was also good: 0.81 for ClCh and 0.90 for NaCh. 
SF-36 outcomes 
Chloride and sodium channelopathies 
Compared with the Dutch community scores, the means for the physically oriented 
SF-36 domains (physical functioning, role functioning physical, vitality and general-
health perception) and the corresponding PCS means were notably lower (p≤0.01) in 
both NDM groups, indicative of an inferior health status in the patients (Figure 7.1a). 
The means for the more mentally oriented SF-36 domains (role functioning emotional, 
social functioning, mental health and body pain) and MCS were comparable with 
Dutch community scores, with social functioning in the patients with NaCh (p=0.048) 
as the only exception. The body pain scores in the chloride group were even 
significantly higher (indicating less pain) than in the Dutch community (p=0.014). The 
SF-36 domain scores and the component scores did not differ between the two NDM 
groups, with the exception of the body pain scores, which were significantly lower 
(indicating more pain) in the sodium group (p=0.032). 
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Painful and painless myotonia 
Painful myotonia was associated with a significant decrease (p≤0.0001) of all SF-36 
domain scores relative to the Dutch community scores, except for the domains role 
functioning emotional, mental health and MCS (Figure 7.1b). The values for role 
functioning emotional, social functioning, body pain and mental health for the 
patients that not report painful myotonia were equal to or higher than the Dutch 
community scores, whereas their means for physical functioning, general-health 
perception and PCS were significantly (p≤0.048) lower. The pain group showed 
significantly lower (p≤0.034) mean scores than the non-pain group for role functioning 
physical, social functioning, body pain, vitality, general-health perception and PCS. 
Fatigued and non-fatigued patients 
All SF-36 domain scores of the fatigued patients were significantly lower (p≤0.01) than 
the Dutch community scores, except for the domains role functioning emotional, 
mental health and body pain (Figure 7.1c). The means for the non-fatigued patients 
were equal or higher than the Dutch community scores, apart from the mean for 
physical functioning (p=0.02). All SF-36 domain and summary scores of the fatigued 
patients were substantially lower (p≤0.01) than those found than their non-fatigued 
counterparts (Figure 7.1c). 
Regression analysis 
As the MCS scores (reflecting overall mental functioning) for our NDM patients closely 
resembled the Dutch community scores, we restricted our regression analyses to 
general-health perception and PCS (see Figure 7.1a). The results of the analyses are 
shown in Figure 7.2. In the chloride group, 46% of the general-health perception 
scores and 46% of the PCS scores were explained by the explanatory variables. The 
variance proportions obtained in the sodium group were higher: 77% for general-
health perception and 71% for PCS. Fatigue proved the strongest predictor of the 
general-health perception (p≤0.01 for ClCh and p≤0.0001 for NaCh). In the sodium 
group the pattern of myotonia (p=0.001), gender (p=0.002), painful myotonia 
(p=0.009), and duration of symptoms (p=0.019) also significantly contributed to the 
model. Painful myotonia was the strongest contributor to the PCS score in the ClCh 
(p=0.001), in whom fatigue was also a significant (p=0.045) contributor. In NaCh, 
painful myotonia (p=0.018), fatigue (p=0.018), and pattern of myotonia (p=0.023) 
were also significant contributors to the PCS score.  
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Figure 7.2 Overview of the outcomes of the multivariate regression analyses conducted to establish the 
variance and strongest predictor of the general-health perceptions and the physical 
component summary in patients with NDMs. 
Discussion 
Despite the general notion that NDMs are benign diseases, the current cross-sectional 
study demonstrates that the symptoms of these patients do greatly impact their self-
reported health status. To our knowledge, ours is the first study to investigate health 
status in a large group of genetically confirmed NDM patients. The scores of the NDM 
patients on the scale’s physically oriented domains were substantially lower than the 
scores reported for the Dutch community (Figure 7.1a), reflecting a poorer clinical 
condition for the patients.25-28 In addition, 42% of the patients characterised their 
myotonia as painful and, based on their FAS scores, 53% could be classified as being 
fatigued. Furthermore, both painful myotonia and fatigue were associated with a 
significant decrease in almost all SF-36 domain scores (Figure 7.1b and 7.1c). Finally, 
our regression analyses revealed that in our sample fatigue was the strongest 
predictor of low general-health perceptions, while painful myotonia best predicted 
low overall physical functioning (Figure 7.2). 
 
The relatively low scores we found in our NDM patients for the physical domains of 
the SF-36 closely resemble the scores of other chronic diseases like type-II diabetes 
mellitus, myocardial infarction and angina pectoris with hypertension, as reported in 
the USA population by the constructors of the SF-36.39 In contrast, most of the NDM 
Chloride channelopathies Sodium channelopathies
General-health perception General-health perception
Explanatory variables
Gender and age
Duration of symptoms
Frequence of myptonia
Pattern of myotonia after repetitive contractions
Severity and change in severity of myotonia
Muscle weakness
Painful myotonia and severity of pain
Fatigue
Physical component summary
Pain > Fatigue
strongest predictors
Physical component summary
Pain and fatigue > Pattern of myotonia
strongest predictors
Fatigue > Painful myotonia
gender and pattern of
myotonia strongest predictors
Fatigue
strongest predictor
R2 = 0.46
R2 = 0.46 R2 = 0.71
R2 = 0.77
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patients’ scores on the scale’s mental domains and its mental component score were 
quite similar to the Dutch community scores.25-28 Studies of elderly patients with 
chronic conditions, including various peripheral neuropathies and eight chronic 
medical disorders, also found lower scores on the SF-36 physical dimensions and an 
unaltered mental state.14,31,32 Presumably, these patients are preoccupied by changes 
in their physical status, making them more focused on physical disabling symptoms. 
Since NDMs are chronic and presumably indolent, progressive diseases, it is possible 
that patients might learn to cope with their limitations. Indirect support for this 
hypothesis is found in studies of more pronounced progressive chronic illness, such as 
myotonic dystrophy, ALS, Parkinson disease and multiple sclerosis. Here, the SF-36 
showed the patients’ emotional and mental state to be more affected, although 
involvement of the central nervous system could not be excluded.33-37 
 
The physical domains of the SF-36 from NDM patients with painful myotonia were 
substantially more affected than those from patients with painless myotonia. Pain had 
earlier been observed to correlate with lower scores on physical domains of the SF-36 
in other slowly progressive neuromuscular diseases.38 Fatigue resulted in our study 
even in a substantial decrease of all SF-36 domains. A negative impact of fatigue on 
health status was also reported earlier in some chronic neurological diseases and 
various muscular dystrophies.13,39,40 On the other hand, NDM patients without pain or 
fatigue often had similar or even higher SF-36 scores (better health condition) than 
the normal Dutch population. This confirms earlier assumptions that there indeed is a 
group of NDM patients with only a minor or no impact on their health status.  
 
Since Aaronson et al.25 studied the SF-36 domain scores in different age classes of the 
Dutch population and detected lower scores with increasing age, age differences 
among the Dutch population, the NDM population and the NDM subgroups should be 
discussed in the evaluation of the results. However, since our data showed no 
correlation between age and the domains of the SF-36 (data not shown), including the 
physical component summary and the general-health perception, age differences do 
not appear to play a role. Furthermore, the mean age of the total NDM population 
(42.3±11.9 years) is even lower than the mean age of the Dutch population studied by 
Aaronson (47.6±18.0 years).25 Therefore, the lower SF-36 scores of our NDM 
population are most probably not caused by age differences. Also, the mean age of 
the two patient subgroups (painful myotonia versus painless myotonia and fatigued 
versus non-fatigued) showed no significant differences. Only the NDM subgroup ClCh 
versus NaCh showed a significant difference in age: ClCh were significantly older 
(Table 7.1). This is the only group in which we could not pertinently rule out a 
influence of age differences. 
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As explained in the introduction, NDMs are not a single disease. However, in this 
manuscript we only compared ClCh with NaCh. Of course, for more thorough 
genotype-phenotype correlation studies, a further subdivision should be made. Since 
the goal of this manuscript was not to describe the different diseases as such but the 
burden of the total NDM group in daily life and the fact that we have only seen small 
groups for the different diseases, which makes the groups possibly too small for 
statistical analysis, we did not analyse more detailed genotype-phenotype 
correlations. 
 
Some permanent muscle weakness may be a feature of NDMs, especially in recessive 
myotonia congenita and some NaCh. This could be a confounder. However, since 
most patients with recessive myotonia congenita experience transient paresis, chronic 
muscle weakness is very difficult to measure in this group. In the NaCh all patients 
showed a maximum MRC sum score (data not presented). Furthermore, none of the 
patients showed such severe myotonia that muscles became functionally weak. We 
therefore only used standardised interview parameters in the regression analyses. We 
used different variables, including frequency of myotonia, severity of myotonia, and 
muscle weakness, as explanatory variables. None of these, in contrast to fatigue and 
pain, were a significant variable for the variance of the general-health perception or 
the physical component summary. 
 
Prior to this study, no valid and reliable health status measures had been obtained in 
patients with NDMs. We opted for the SF-36 because of its brevity, its extensive use in 
clinical studies and its good psychometric properties.25-28 We selected the FAS to 
measure fatigue because of its one-dimensionality, ease of use and proven validity 
and relability.22-24 The scales’ good content validity and reliability make them 
potentially useful endpoints for future randomised clinical trials that evaluate the 
efficacy of and responsiveness to drug treatments such as mexiletine. 
 
Despite the solidity of our nationwide findings, it needs to be noted that we did not 
evaluate the test-retest reliability for the SF-36 and FAS, a psychometric omission 
future research projects in this field should correct. Furthermore, five patients were 
unwilling to reduce and stop their drug therapy, and nine patients had transportation 
problems, including one patient who was severely handicapped. This means that 
there is a potential bias in this study. Possibly some patients with more severe 
myotonia have not been assessed. However, these patients may even have a worse 
health status than the rest. 
 
In summary, the current study shows that NDMs substantially affect the patients’ 
physical health status, with painful myotonia and fatigue being the strongest 
predictors of the deficits. Beside direct measurements of myotonia, it is 
recommended that future intervention studies in patients with NDMs should also use 
the SF-36 and FAS to establish the efficacy of the therapeutic regimes under study.  
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Abstract 
Background 
Patients with  non‐dystrophic myotonic  syndromes,  including  chloride  (myotonia  congenita)  and  sodium 
channelopathies  (paramyotonia  congenita  and  potassium  aggravated  myotonias),  may  show  muscular 
hypertrophy  in  combination with  some  histopathological  abnormalities.  However,  the  extent  of muscle 
changes has never been objectified in a large group genetically confirmed patients. 
 
Objective 
To  determine  echo  intensities,  echo  thickness,  ranges  of  motion  and  force  of  four  skeletal  muscles  in 
genetically confirmed patients with NDM. 
 
Methods 
In 63 genetically confirmed patients with NDM we examined four skeletal muscles in the transverse plain by 
ultrasound:  left  biceps  brachii,  right  forearm  flexors,  right  quadriceps  femoris,  and  left  tibialis  anterior 
muscle. Mean muscle echo  intensity was quantified using a computer‐assisted grey‐scale analysis.  In each 
muscle a predefined region of interest in the ultrasound image was selected and the mean grey value was 
calculated. Muscle thickness was measured with electronic callipers at predefined standardised locations in 
the ultrasound image.  
Active ranges of motion of the  left elbow, right wrist, right knee and  left ankle were measured  in degrees 
using a transparent goniometer with standardised positions for patients, examiner and goniometer. Using 
the ‘make’ technique, the maximum isometric contraction values of the left elbow flexion, right three‐point 
grip,  right  knee  extension  and  left  ankle  dorsiflexion  were  measured  with  a  calibrated  hand‐held 
dynamometer.  
 
Results 
The main findings revealed elevated echo intensities in all muscles except the rectus femoris (+ 1.3‐2.2 SD, 
p<0.0001), and hypertrophy of the arm muscles (+ 0.5‐0.9 SD, p<0.01). The echo intensities of the dominant 
biceps  brachii muscle  and  the  dominant  forearm  flexor muscles were  significantly  higher  (p=0.002  and 
p=0.038, respectively) than the levels observed for the non‐dominant side.  
Muscle echo  intensities were  inversely correlated  to  the corresponding  ranges of motion  (biceps brachii: 
r=‐0.43; p<0.001,  forearm  flexors:  r=‐0.47; p<0.001,  rectus  femoris:  r=‐0.40; p=0.001, and  tibial anterior: 
r=‐0.27; p=0.04) and positively correlated to age (r=0.22; p=0.05). The echo intensity of the forearm flexors 
was inversely correlated to their muscles’ force (r=‐0.30; p=0.02).  
 
Conclusion 
These data suggest  that non‐dystrophic myotonic syndromes may  lead  to structural muscle changes  that 
increase with age and muscle use. 
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Introduction 
Non-dystrophic myotonic syndromes (NDMs) form a group of rare hereditary 
diseases, existing of either chloride (recessive and dominant myotonia congenita) or 
sodium channelopaties (paramyotonia congenita/potassium aggravated myotonias), 
that exclusively affect skeletal muscles.1-3 The key symptom of NDMs is myotonia, i.e. 
a delayed muscle relaxation after a voluntary or evoked contraction. Needle-
electromyography of patients with NDMs show myotonic discharges in almost all 
skeletal muscles, even at rest.4,5 Both myotonia and myotonic discharges are the 
consequence of a hyperexcitable sarcolemma caused by a disturbed chloride or 
sodium conductance. Recently, the molecular basis of NDMs was discovered allowing 
the diagnosis to be confirmed by genetic testing.6,7 
The term NDMs by definition implies that, in contrast to  the dystrophic myotonic 
syndromes (myotonic dystrophy type 1 and type 2), they neither show dystrophy, nor 
structural muscle changes. Indeed, muscle biopsies of NDMs were initially described 
as normal or showing mild, non-specific abnormalities.8 Subsequent investigations 
reported an absence of type 2B fibres in chloride channelopathies (ClCh), while 
patients with paramyotonia congenita, a sodium channelopathy (NaCh), were found 
to show intracellular large vacuoles and tubular aggregates.9-11 However, the presence 
of muscle changes has never been systematically investigated in a large group of 
genetically confirmed patients.  
Clinically, muscle hypertrophy may be prominent in patients with NDMs and is 
thought to be caused by repetitive and prolonged muscle contractions. Becker 
reported muscular hypertrophy in 71% of his patients with recessive myotonia 
congenita and in 25% of the patients with dominant myotonia congenita (both ClCh).8 
In paramyotonia congenita muscular hypertrophy is reported to be rare (NaCh).1 Even 
so, these findings stem from the pre-genetic era and were all solely based on 
subjective, visual examinations.  
Muscular ultrasound has been shown to be accurate in detecting the presence and 
extent of muscle changes and muscle thickness.12-16 Fibrosis and fatty infiltration as 
for example detected in abundance in muscular dystrophies are thought to account 
for an increased echo signal detected by muscle ultrasound.12,14,17,18 Although muscle 
ultrasound cannot determine the exact nature of changes, this technique is non-
invasive and allows easy examination of multiple muscles, yielding a clear overview of 
the extent and distribution of the pathology within the patient’s body.19  
In order to determine whether and where in NDMs muscle changes and muscular 
hypertrophy occur, we quantitatively measured the echo intensities and thicknesses 
of two proximal and two distal skeletal limb muscles in a large group of genetically 
confirmed NDM patients. We, moreover, compared the outcomes for the ClCh and 
NaCh and those of the male and female patients and, lastly, investigated whether the 
echo data were correlated to the corresponding ranges of motion, muscle force and 
age. 
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Patients and methods 
Subjects 
Between April 2005 and March 2006 a large cohort of NDM patients residing in the 
Netherlands participated in our comprehensive non-dystrophic myotonic syndrome 
study, 63 of whom took part in the present investigation. Inclusion criteria were a 
minimum age of 18 years, a clinically and genetically confirmed diagnosis of NDM 
according to established clinical criteria, and needle electromyographic evidence of 
myotonic discharges.20 We distinguished ClCh from NaCh and paramyotonia from 
other NaCh (potassium aggravated myotonias or sodium-channel myotonias) by 
clinical criteria and DNA-analysis.20,21 The study was approved by the local medical 
ethics committee and all patients gave their written informed consent prior to their 
participation. 
Ultrasound measurements 
The method of ultrasound scanning is described in detail in earlier reports.22,23 In 
short, we examined four muscles in the transverse plane: left biceps brachii, right 
forearm flexors, right quadriceps femoris, and left tibialis anterior muscle. The 
apparatus used was a phased-array real-time scanner (Sonos 2000 Phased Array 
Imaging System; Hewlett-Packard Company, Andover, Massachusetts, USA), with a 
7.5 MHz transducer. To enable us to use previously established normal values, all 
system parameters were equivalent to the ones we used in our previous study.22 
Mean muscle echo intensity was quantified using a computer-assisted grey-scale 
analysis. In each muscle a region of interest was selected according to our previous 
protocol and the mean grey value was calculated: 8-bit scale; black = 0; white = 255.22 
These values are related to the amount of decibels that return to the transducer, 
which is incorporated in the hard- and software of the ultrasound device. A 
predefined look-up-table in the ultrasound machine converts the decibels to 
corresponding grey values. In our study (as in all studies on muscle ultrasound) this 
look-up-table was the same in every measurement, as a fixed preset (gain and 
compression) was used.22 As in severe neuromuscular disorders the outline of the 
vastus intermedius muscle may be difficult to delineate, we opted to use the rectus 
femoris in the quadriceps femoris muscle for our echo-intensity analysis.24 Muscle 
thickness was measured with electronic callipers at predefined standardised locations 
in the ultrasound image.22 To gauge differences in the dominant and non-dominant 
arm muscles we performed bilateral measurements in 38 patients (18 chloride 
channelopathies and 20 sodium channelopathies), with dominance having been 
established during the intake interview. All images were also independently evaluated 
visually by two investigators (JT and SP) to investigate if specific patterns of 
distribution or increased echo intensities were present either among different 
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muscles or within the muscle, as has previously been described  in certain congenital 
myopathies or anterior horn cell disorders.25  
Range of motion and muscle‐force measurements 
Active ranges of motion of the  left elbow, right wrist, right knee and  left ankle were 
measured  in degrees using a  transparent goniometer while adhering  to Norkin and 
White’s system with standardised positions for patients, examiner and goniometer.26 
The maximum isometric contraction values of the left elbow flexion, right three‐point 
grip, right knee extension and left ankle dorsiflexion were measured with a calibrated 
hand‐held dynamometer  (type CT 2001, C.I.T. Technics, Haren, the Netherlands).27,28 
We used the ‘make technique’: the patients were instructed to take 1 or 2 seconds to 
reach maximum effort  levels and subsequently contract their muscle as forcefully as 
possible. All measurements were conducted using standardised positions for patients, 
examiner and dynamometer.28 All patients were  tested  in a  temperature‐controlled 
room  (20°C)  at  the  same  time  of  day  and  by  the  same  investigator  (JT)  to  reduce 
variations in testing. 
Data analysis 
The  patients’  ultrasound  results  were  compared  to  previously  established  normal 
values and transformed into z‐scores (corrected for age and gender), i.e. the number 
of  standard  deviations  above  or  below  normal.22,23,29  In  general,  z‐scores  are 
constructed  in  such  a  way  that  in  a  healthy  or  reference  population  they  lead  to 
z‐scores with an average of 0 and a standard deviation of 1. This ‘normalisation’ helps 
to interpret the outcome of a variable in a population that may otherwise be difficult 
to interpret (or changes with age). When the z‐score in a diseased population is 0, the 
outcome  is  ‘normal’, while values above 2 and under  ‐2 are  ‘abnormal’  in the sense 
that they occur in less than 5% of the healthy population.  
Statistical analyses were performed using the SPSS package for Windows, version 11.0 
(SPSS  Inc,  Chicago,  IL,  USA).  A  one‐sample  t‐test  was  used  to  assess  whether  the 
patients  showed  a  significant  increase  in  their  echo‐intensity  and muscle‐thickness 
z‐scores and an independent‐sample t‐test to compare the respective z‐scores for the 
ClCh  and  NaCh  and  male  and  female  patients.  We  ran  a  paired‐sample  t‐test  to 
compare the absolute values of the echo intensities and thicknesses of the dominant 
and  non‐dominant  arm muscles.  Correlations  between muscle  echo  intensities  and 
the  corresponding  ranges  of  motion  and  muscle  forces  were  calculated  using 
Pearson’s correlation coefficients, as were the correlations between muscle thickness 
and muscle  force. Echo  intensities and  thicknesses were  correlated  to age  for each 
muscle  separately  as well  as  for  their  sum  scores. A  p‐value  of  less  than  0.05 was 
considered to be significant. 
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Results 
Table 8.1 shows the primary diseases and antropometric data of all 63 participating 
patients. In three patients the measurements for one muscle were excluded from 
further analysis: the left biceps muscle in one recessive chloride channelopathy 
because of weakness due to a mechanical accident; the left tibialis anterior muscle in 
a sodium channelopathy because of chronic muscle weakness due to a previous 
lumbar disc hernia; the right rectus femoris muscle in a chloride channelopathy 
because the echo intensity could not be measured reliably as the rectus femoris was 
located at a depth of more than 3.5 cm and thus outside the maximum setting 
stipulated in the ultrasound protocol. Furthermore, knee extension appeared to 
exceed the investigator’s force in a majority of patients and could therefore not be 
measured reliably. 
 
Table 8.1 The primary genetically confirmed diseases and antropometric data of the 63 participating 
patients with a non-dystrophic myotonic syndrome. 
Primary disease No of 
patients 
Sex 
M/F 
Age (yr) 
median 
(range) 
Weight (kg) 
median 
(range) 
Length (m) 
median 
(range) 
Chloride channelopathies 
Recessive myotonia congenita 
Dominant myotonia congenita 
 
Sodium channelopathies 
Paramyotonia congenita 
Sodium-channel myotonias 
 
31 
  3 
 
 
10 
19 
 
21/10 
  2/  1 
 
 
  6/  4 
  8/11 
 
45 (23-61) 
60 (32-61) 
 
 
42 (23-72) 
40 (20-68) 
 
75 (59-136) 
89 (57-  92) 
 
 
77 (45-115) 
75 (51-  93) 
 
1.72 (1.56-1.87) 
1.83 (1.57-1.89) 
 
 
1.80 (1.65-1.96) 
1.72 (1.60-1.96) 
Total 63 37/26 43 (20-72) 75 (45-136) 1.74 (1.56-1.96) 
No: number; M: male; F: female; yr: year; kg: kilogram; m: meter 
 
Muscle echo intensities 
Except for the rectus femoris muscle, echo intensity was significantly increased in all 
other muscles with the forearm flexors reaching the highest levels (Table 8.2). 
Moreover, if abnormal, the forearm flexors sometimes showed a typical pattern with 
predominant involvement of the flexor carpi ulnaris and flexor digitorum profundus 
while the flexor digitorum superficialis and flexor carpi radialis were largely spared 
(Figure 8.1). This distinct pattern was present in both ClCh and NaCh and visible in 
15% of all patients. 
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Figure 8.1 Transverse ultrasound image from the forearm flexors of a 56-year-old healthy woman (left-
hand panel) and a same aged female patient with recessive myotonia congenita (right-hand 
panel). Comparison of the two images reveals a typical pattern within the forearm flexors of 
the patient, with predominantly higher echo intensities for the flexor carpi ulnaris (†) and 
flexor digitorum profundus (‡), and relatively spared flexor digitorum superficialis (*) and 
flexor carpi radialis (#). U: ulna; R: radius.  
 
Table 8.2 The mean standardised muscle thickness and echo intensity readings (standard deviation) of 
the four muscles under investigation for all non-dystrophic myotonic syndromes together, for 
the two types of channelopathies separately, and for male and female patients separately. 
 
Number of patients 
NDMs 
(n=63) 
ClCh 
(n=34) 
NaCh 
(n=29) 
Men 
(n=37) 
Women 
(n=26) 
Echo intensities 
   Left biceps brachii 
   Right forearm flexors 
   Right rectus femoris 
   Left tibial anterior 
 
-1.33 (1.6)*1 
-2.17 (1.7)*1 
-0.27 (1.2) 
-1.74 (1.1)*1 
 
-1.36 (1.5)*1 
-2.77 (1.8)*1 
-0.32 (1.2) 
-1.85 (1.1)*1 
 
-1.31 (1.6)*1 
-1.47 (1.2)*1 $1 
-0.22 (1.5) 
-1.60 (1.0)*1 
 
-1.97 (1.6)*1 
-2.55 (1.7)*1 
-0.83 (0.9)*1 
-1.77 (1.0)*1 
 
-0.45 (1.0)*2  $2 
-1.63 (1.6)*1  $3 
-0.50 (1.0)*1$2 
-1.68 (1.2)*1 
Muscle thickness 
   Left biceps brachii 
   Right forearm flexors 
   Right rectus femoris 
   Left tibial anterior 
 
-0.52 (1.2)*2 
-0.85 (1.7)*1 
-0.01 (1.3) 
-0.13 (0.7) 
 
-0.69 (1.1)*2 
-0.53 (1.6) 
-0.26 (1.1) 
-0.21 (0.7) 
 
-0.32 (1.3) 
-1.23 (1.6)*1 
-0.32 (1.5) 
-0.03 (0.7) 
 
-0.55 (1.3)*2 
-0.55 (1.9) 
-0.01 (1.5) 
-0.13 (0.8) 
 
-0.47 (1.1)*2 
-1.28 (1.2)*1 
-0.04 (1.0) 
-0.12 (0.7) 
NDMs: non-dystrophic myotonic syndromes; ClCh: chloride channelopathies; NaCh: sodium 
channelopathies; *1 Significantly elevated (p<0.0001) relative to norm scores; *2 Significantly elevated 
(p<0.05) relative to norm scores; $1 Significant difference (p=0.002) between chloride and sodium 
channelopathies; $2 Significant difference (p<0.0001) between male and female patients; $3 Significant 
difference (p<0.05) between male and female patients 
Subgroup analysis  
The echo intensities of the forearm flexors were significantly higher in the ClCh than 
they were in the NaCh (Table 8.2). Except for the tibialis anterior muscle, all echo 
intensities were also significant higher in the male patients (Table 8.2). The intensities 
of the dominant biceps brachii muscle and the dominant forearm flexor muscles were 
significantly higher (44.7±9.2 versus 39.9±9.5 /256 grey levels; p=0.002 and 40.1±8.6 
versus 38.2±7.9/256 grey levels; p=0.038, respectively) than the levels observed for 
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the non-dominant side. In the healthy controls the reverse was true: the intensities 
for the dominant muscles were significantly lower (difference -2.8; p<0.001 and -1.3; 
p=0.018, respectively) than they were in the non-dominant ones. 
Muscle thickness  
The arm muscles were significantly more pronounced than the values observed in 
normal, healthy individuals (Table 8.2), whereas the results for the leg muscles fell in 
the normal range.  
Subgroup analysis 
In patients with a non-dystrophic myotonic syndrome there were no significant 
differences in muscle thickness between the ClCh and NaCh nor between men and 
women (Table 8.2). However, the dominant forearm flexors in non-dystrophic 
myotonic syndrome patients were significantly thicker (difference 0.17 cm; p<0.001) 
than the non-dominant forearm flexors. In our previously established data of healthy 
controls we recorded no such significant difference (only 0.1 cm). In contrast, the 
biceps brachii muscle normally is significant thicker at the dominant side (0.2 cm), 
whereas in non-dystrophic myotonic syndrome patients we did not detect a 
significant difference between the dominant and non-dominant thickness of the 
biceps brachii muscle.  
Muscle forces and ranges of motion 
Table 8.3 shows the mean muscle force values in Newton (standard deviation) and the 
ranges of motion in degrees (standard deviation) for all non-dystrophic myotonic 
syndromes together and for the ClCh and NaCh separately. 
 
Table 8.3 The mean muscle force readings in Newton (standard deviation) and mean ranges of motion 
in degrees (standard deviation) for all non-dystrophic myotonic syndromes together and for 
the two types of channelopathies separately. 
 
Number of patients 
NDMs 
(n=63) 
ClCh 
(n=34) 
NaCh 
(n=29) 
Muscle force 
Elbow flexion 
Three-point grip 
Knee-extension 
Foot dorsoflexion 
 
 89 (41) 
 155 (58) 
ND 
 125 (46) 
 
 84 (38) 
 140 (53) 
ND 
 118 (49) 
 
 95 (44) 
 172 (60) $1 
ND 
 134 (42) 
Range of motion 
Elbow 
Wrist 
Knee 
Ankle 
 
 113 (27) 
 139 (15) 
 126 (12) 
 61 (14) 
 
 106 (24) 
 134 (16) 
 123 (12) 
 57 (13) 
 
 121 (28) $1 
 145 (13) $1 
 131 (11) $1 
 66 (14)$1 
NDMs: non-dystrophic myotonic syndromes; ClCh: chloride channelopathies; NaCh: sodium 
channelopathies; ND: Not done. $1 Significant difference (p<0.05) between chloride and sodium 
channelopathies. 
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Correlations 
Table 8.4 shows the correlations between the muscle echo intensity and range of 
motion, muscle force exerted and age for each muscle separately. The echo intensity 
levels of all muscles showed significant negative correlations with the corresponding 
ranges of motion and the intensity of the forearm flexors showed a significant 
negative correlation with muscle force as measured by the three-point grip. The echo 
intensities for the rectus femoris muscle were significantly positively related to age, as 
were the intensities for the sum score. Muscle thickness of the right forearm flexors 
showed a significant positive correlation with muscle force (r=0.44; p<0.001) and was 
negatively correlated with age (r=-0.33; p=0.009). The muscle thickness sum score was 
also negatively correlated to age (r=-0.23; p=0.035).  
 
Table 8.4 Correlations between the echo intensities and corresponding ranges of motion, muscle force 
and age for the four muscles and rank sum z-scores. Correlation coefficients are given in r-
values (p-value). 
Echo intensity ROM Muscle force Age 
Biceps brachii muscle 
Forearm flexors 
Rectus femoris 
Anterior tibial muscle 
Sum z-score 
 -0.43 (<0.001)* 
 -0.47 (<0.001)* 
 -0.40 (0.001)* 
 -0.27 (0.04)* 
- 
 0.10 (0.46) 
 -0.30 (0.02)* 
ND 
 -0.13 (0.32) 
- 
 0.13 (0.31) 
 0.23 (0.07) 
 0.31 (0.02)* 
 -0.01 (0.93) 
 0.22 (0.05)* 
ROM: range of motion; ND: not done; * Significant correlation. 
Discussion 
To our knowledge, ours is the first study to systematically investigate muscle changes 
and muscle thickness in a large cohort of genetically confirmed patients with non-
dystrophic myotonic syndromes and to correlate the obtained data to functional 
parameters. The results revealed that the patients showed high echo intensities in all 
muscles (except the rectus femoris), indicating muscle changes.12,14,17,18 Furthermore, 
the arm muscles showed hypertrophy. The muscle echo intensities were negatively 
correlated to the patients’ ranges of motion and to the muscle force in their forearm 
flexors. The changes were, moreover, positively correlated to age and more 
pronounced in the dominant arm muscles. Together, these data suggest structural 
muscle changes in non-dystrophic myotonic syndromes. Although the correlations 
were not very strong, muscle changes seem to increase with age and degree of muscle 
use. 
The muscle echo intensities were negatively correlated with the corresponding ranges 
of motion. Since high echo intensities are caused by muscle changes such as fat and 
fibrosis, these processes may subsequently lead to muscle shortening, which will limit 
the range of motion.1 The muscle changes we observed are thus more than likely 
responsible for a limited range of motion (contracture) in non-dystrophic myotonic 
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syndromes. This pathophysiological mechanism has also been described in other 
skeletal muscle diseases like Duchenne’s and Emery-Dreifuss muscular dystrophy and 
Ullrich’s syndrome.30-33 The echo-intensity did not differ between ClCh and NaCh, 
except for the forearm flexors. The range of motion, however, was significantly lower 
in ClCh than in NaCh. If the decreased range of motion would be due to fibrosis, range 
of motion measurements might be more sensitive than ultrasound measurements as 
a measure of fibrosis. Future research projects should investigate this hypothesis. 
The highest muscle echo intensities were found in the dominant forearm flexors of 
our male patients. Since myotonia is most common in the forearm flexors and more 
pronounced in men than in women, it can be hypothesised that the muscle changes in 
non-dystrophic myotonic syndromes are exacerbated by the duration of the exposure 
to the symptom.34,35 The long-term increase of sodium influx or a prolonged high 
intracellular sodium concentration may induce muscle fibre damage with as 
consequence muscle changes, which may subsequently lead to functional changes in 
terms of weakness and contractures.36,37  
The positive correlation we found between the muscle echo intensity sum score and 
age is another argument supporting the hypothesis that the muscle changes are 
stepped up in proportion to the length of exposure to myotonia. Obviously muscle 
echo intensity increases with age, possibly due to an age-related replacement of 
muscle tissue by fat and fibrous tissue.12,38 By using z-scores we already corrected for 
the influence of age in our healthy control group. As we still detected a correlation in 
non-dystrophic myotonic syndrome patients between z-scores and age, it means that 
myotonia at older age is more associated with higher echo-intensities. Thus, it is likely 
that structural muscle changes are especially found in older patients with a NDM, 
which is supported by the literature where myopathies are mainly reported in 
patients over 65 years.39,40  
Unexpectedly, our muscular ultrasonography readings showed hypertrophy of the 
arm muscles only. Except in a few patients, we did not detect any significant 
hypertrophy in the quadriceps and anterior tibial muscles. With a test-retest 
correlation of 0.98-0.99 and a 0.99 correlation with MRI, muscle ultrasound is a 
reliable method to measure muscle thickness.15, 41,42 In the literature, dominant 
myotonia congenita is reported with generalised muscular hypertrophy, whereas in 
recessive myotonia congenita especially the thighs, gluteal, shoulder girdle and calf 
muscles were hypertrophied.8 When the condition is severe, the neck and (upper) arm 
muscles may also be involved.8 In our study hypertrophy was most pronounced in the 
biceps brachii muscles of the patients with ClCh, whereas in the patients with NaCh 
the forearm flexors were hypertrophied. However, ClCh yielded higher echo 
intensities in the forearm flexors than NaCh. As yet, we have no sound 
pathophysiological explanation for the differences between these groups. 
The greatest ultrasound abnormalities were detected in the forearm flexors of ClCh 
and men. Since both these groups also have relatively the smallest forearm size, one 
could hypothesise that the increased echo intensity may result from atrophy. 
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However, previous studies have shown that atrophy, for example caused by disuse, 
does not significantly increase muscle echo intensity.16,19 Furthermore, in ALS the 
increased echo intensity is more pronounced than the atrophy, indicating that the 
structural changes are responsible for the increased echo intensity and not the 
atrophy.43 
Muscle imaging in non-dystrophic myotonic syndromes has, to date, only been 
applied in a few patients with paramyotonia congenita but the few available results 
do support our ultrasound findings indicating that muscle changes occur in non-
dystrophic myotonic syndromes: the MRI’s of the gastrocnemius muscle showed a 
bilateral symmetrically elevated signal intensity on T1- as well as on T2-weighted 
images, which were interpreted as fatty infiltration.44 Future research in NDMs should 
compare muscle ultrasound with MRI, preferable together with muscle histology as 
the golden standard. 
Previous ultrasound studies showed that increased echo intensity is strongly related 
to structural muscle changes.12,14,17,18,25 However, we emphasise that muscle 
ultrasound hyperechogenicity is an aspecific feature, that might reflect both fatty 
infiltration and fibrosis as well. As stated before, muscle biopsies are necessary to 
establish the exact nature of the muscle pathology in non-dystrophic myotonic 
syndromes. Biopsies performed in previous studies revealed only minor 
histopathological abnormalities.9-11,45 However, most of these biopsies were obtained 
from proximal muscles, especially the quadriceps muscle.9-11,45 In our study, the 
quadriceps muscle was the least affected muscle. In future studies muscle biopsies in 
non-dystrophic myotonic syndromes should be obtained from other affected muscles 
or guided by skeletal muscle ultrasound.46,47 
In conclusion and in contrast to previous assumptions, quantitative muscle features in 
NDMs suggest structural muscle changes that increase with age and degree of muscle 
use. Forearm flexors are most affected. Future research should focus on muscle 
biopsies of the muscles that are most affected to further delineate the extent and 
nature of these structural changes. If these studies will also demonstrate some degree 
of muscle dystrophy, the name non-dystrophic myotonic syndromes could be open to 
debate.  
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General discussion 
Clinical features of non-dystrophic myotonic syndromes (NDMs) were already 
described exhaustively in the pre-genetic era. However, after DNA analysis had 
become available, important genotype-phenotype mismatches were reported and a 
new subtype of NDMs, called Potassium Aggravated Myotonias (PAM) or Sodium-
Channel Myotonias (SCM), was defined. It became clear that there was a need for an 
overall redefinition of NDMs that would be based on their distinct genotypes. In the 
present thesis the results of a nationwide study with the aim to redefine the clinical 
phenotypes of genetically confirmed NDMs are reported. Besides describing the 
phenotypes of NDMs on the basis of their genetics, it was our aim to provide clinicians 
with rules of thumb for focused genetic testing and to devise a better strategy to 
detect genetic mutations. Moreover, we looked for ways to facilitate better 
circumstances for the development of double blind randomised clinical trials for the 
treatment of myotonia. We evaluated the existing literature on the subject, and 
subsequently studied the genotypes, clinical features, health status and muscle 
ultrasound readings of a group adults with clinical and electrophysiological evidence 
of NDMs. Our systematic cross-sectional study about various clinical aspects of NDMs 
was conducted using a standardised protocol in one of the largest genetically 
confirmed NDM cohorts including both ClCh and NaCh. In this final chapter the results 
of our investigations are summarised and put into context, ending with future 
perspectives.  
 
Chapter 1 gave a general introduction to NDMs, describing the clinical features of 
NDMs as defined in the pre-genetic era, the pathophysiology with respect to chloride 
and sodium conductance disturbances of the sarcolemma, the implicated genes, 
ancillary investigations, differential diagnoses and the current treatment options.  
 
Chapter 2 comprised a systematic review of the available drug treatments for 
myotonia, the first in its kind. The literature search yielded ten randomised controlled 
trials in patients with myotonia comparing active drug treatment to placebo or 
comparing active drug treatment to any other active drug treatment. The trials either 
involved double-blind or single-blind crossover studies and included a total of 143 
patients of which 113 had myotonic dystrophy type 1 and 30 had myotonia congenita. 
The majority of the trials were of poor quality, with some studies examining both 
patients with a dystrophic myotonic syndrome (i.e., myotonic dystrophy type 1) and 
patients with a non-dystrophic myotonic syndrome (i.e., myotonia congenita). This 
precluded a reliable analysis of the results reported. Three small-scale crossover 
studies evaluating myotonia in myotonic dystrophy type 1 were of good quality and 
demonstrated significant effects of imipramine, clomipramine and taurine, 
respectively. Unfortunately, for the treatment of myotonia in NDMs we were unable 
to find valid, separate data. Due to the scarcity and poor quality of the trials, we 
Thesis_Trip_v13.pdf
138⏐Chapter 9 
hence could not establish whether the tested drug therapies for myotonia were safe 
or effective. Our review prompted the conclusion that well-designed double-blind 
randomised controlled (multi-centre) clinical trials, testing the drug effects for the 
different dystrophic and non-dystrophic types of myotonia separately, are needed. In 
the case of crossover trials, a washout interval is recommended, while intention-to-
treat analyses and appropriate presentation of the results are indispensable.  
 
Given that no randomised controlled clinical trials for myotonia in NDMs is available, 
past and current treatment strategies have been based on selective case reports, 
results from myotonic dystrophy type 1 trials, clinical experience, and theoretical 
benefits.1-3 But what explains this lack of sound Randomised Controlled Trials (RCTs) in 
NDMs? Firstly, randomised, placebo-controlled trials in NDMs are difficult to set up 
because they are likely to be underpowered because of the rarity of NDMs.2,3 
Secondly, phenotypic and genotypic heterogeneity, with the possibility of different 
treatment responses, necessitates the definition of subgroups in such trials, which in 
turn, limits the number of patients even further. Lastly, it is difficult to define clinical 
endpoints for RCTs in NDMs since, to date, widely accepted outcome measures for 
such trials are lacking.2 
 
Evidently, there is a pressing need for soundly designed and adequately supported 
multicentre trials. In the US the Food and Drug Administration (FDA) last year pledged 
to fund – within the framework of the orphan products grand programme- a placebo-
controlled trial of mexiletine for the treatment of NDMs, which was started in 
December 2008.3 However, in rare diseases with subsequent low numbers of eligible 
patients like NDMs, a controlled, multiple crossover trial, implemented in a single 
form (the ‘n-of-1 design’) is a viable, attractive alternative.3 In such trials the patient 
acts as his or her own control, with the periods in which the agent under study and its 
placebo are used being randomly switched to determine the compound’s therapeutic 
effect.3,4 Studies based on the ‘n-of-1 design’ are hence especially recommended 
when individual treatment responses in rare diseases like NDMs are being 
investigated.  
 
But which outcome measures are most suitable for RCTs or multiple crossover 
studies? For the evaluation of myotonia, standardised clinical bedside tests (Chapter 
6) provide adequate parameters. To identify, confirm and quantify myotonia, several 
dedicated techniques are already available. Recently developed devices to assess the 
hand muscles are, however, not commercially available yet.5,6 To test leg muscles, we 
propose the trunk sway analysis method.7 The technique consist two angular-velocity 
transducers mounted on the lower back of the patient that allow his/her gait and 
postural stability to be objectively assessed. The results obtained in ten patients with 
DNA-proven RMC showed that postural instability can be accurately determined 
during naturalistic gait and balance tasks. 7 The authors also found it a useful tool to 
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detect and quantify myotonia in leg muscles and to detect and quantify the warm-up 
phenomenon in leg muscles. It proved to be especially sensitive and responsive when 
applied during tandem walking (eight successive toe-to-heel steps).7 However, the 
trunk sway analysis does not distinguish between the effects caused by the myotonia 
and those originating from transient paresis. At last, it will be a major challenge to 
design devices to detect and quantify myotonia and the warm-up phenomenon in the 
eyelid muscles.  
 
For the evaluation of clinical weakness, repetitive nerve stimulation (RNS) studies as 
described by Fournier et al. and high-density surface EMGs as described by Drost et al. 
are useful techniques.8,9 However, both methods first require correlation studies with 
relevant clinical parameters. As clinical endpoints health status, functional disability 
and social participation are also vital parameters. Based on the results of our study 
presented in Chapter 7 we propose the SF-36 and FAS for the assessment of these 
aspects. We will discuss the desired standardisation of clinically relevant outcome 
measures and methods to test the clinimetric soundness of these outcomes measures 
later on in this chapter. 
 
Chapter 3 was dedicated to the outline of the thesis. 
 
As a redefinition of the clinical phenotypes of NDMs requires genetically 
homogeneous groups of patients we performed a genetic study in all the 54 probands 
we managed to recruit within one year. In Chapter 4 their genetic profiles were 
determined by analysing CLCN1 and SCN4A in tandem. With our study protocol we 
first sought to evaluate the relevance of in tandem analysis of the two 
channelopathies. Our second aim was to identify the mutations implicated in these 
probands and to compose homogeneous cohorts segregated by ClCh and NaCh. We 
established CLCN1 mutations in 32 families (59%) and SCN4A mutations in 22 families 
(41%), reflecting a high-level of mutation ascertainment. However, the yield of our 
mutation detection was 93%, with six cases not yielding a second mutation. The 
genetic tests of all six were negative for myotonic dystrophy type 2. As suggested by 
Deymeer et al, these six cases could theoretically be carriers of NDMs.10  
 
Our approach yielded 13 novel CLCN1 and three novel SCN4A mutations, 
demonstrating the relative heterogeneity of the disease in the Netherlands. The 
clinical evaluations and DNA analyses of all first-degree relatives with a novel 
mutation revealed that all but one of these novel mutations segregated with the 
disease. Finally, our investigations enabled us to select homogeneous groups of 
patients segregated by the two channelopathies. In conclusion, in tandem analyses of 
CLCN1 and SCN4A afford a high level of mutation ascertainment and allow 
homogeneous groups of patients with either ClCh or NaCh to be composed. 
Compared to previous studies, the yield of our mutation detection was high.11-13 Based 
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on these results, we suggest that analysing CLCN1 and SCN4A in tandem has a great 
diagnostic potential, offering optimal conditions for genotype-phenotype studies.14  
 
In Chapter 5 we discovered three NDM patients with a genotype-phenotype 
mismatch. In the pre-genetic era the warm-up phenomenon was assumed to be a 
specific symptom of ClCh. The three patients we examined, however, had a 
generalised warm-up phenomenon in combination with the V445M sodium-channel 
mutation. These three cases hence illustrate that the warm-up phenomenon is not 
typical for ClCh but may also occur in NaCh. It also underscores the urgency of a 
redefinition of the clinical phenotypes of NDMs for both ClCh and NaCh. 
 
In Chapter 6, we reported the results of a descriptive cross-sectional study using 
standardised interviews and clinical bedside tests in 62 genetically confirmed NDM 
patients (32 ClCh and 30 NaCh) with the aim to redefine the clinical phenotypes of 
NDMs in the Netherlands and to formulate rules of thumb for focused genetic testing 
of either CLCN1 or SCN4A. Based on widely used neurological examination 
procedures, we determined the presence and nature of myotonia (action myotonia 
and/or percussion myotonia), the relaxation times, and the presence of the warm-up 
phenomenon, paramyotonia, and transient paresis in three different body regions (i.e. 
the eyes and the upper and lower extremities). In the standardised interviews, 
patients with ClCh reported a higher frequency of muscle weakness, the warm-up 
phenomenon, and problems with standing up quickly, running, and climbing stairs. 
The patients with NaCh more often reported an earlier onset, and higher frequencies 
of paradoxical, and painful myotonia. The bedside tests revealed a higher incidence 
and longer relaxation times of myotonia in the leg muscles for the ClCh group and in 
eyelid muscles for the NaCh cohort.15 The incidence and duration of relaxation times 
in the hand muscles were similar in both channelopathy groups. Furthermore, 
transient paresis was observed in ClCh only and paradoxical myotonia in NaCh only 
(Figure 9.1). Multivariate logistic regression analyses subsequently allowed us to 
develop the following clinical guidelines for genetic testing in NDMs: if both eyelid 
myotonia and transient paresis are absent OR if transient paresis is present 
(regardless of the absence or presence of eyelid myotonia), a ClCh is most likely. 
Conversely, if eyelid myotonia is present and transient paresis absent, a NaCh is the 
most likely diagnosis (see Chapter 6, Table 6.5).  
Looking at ClCh in more detail, we did not find any variables differentiating between 
RMC and DMC, although it needs to be noted that our sample comprises only two 
DMC patients, indicating an apparent but unexpected scarcity of DMC in the 
Netherlands. This uneven distribution rendered a comparison of our clinical data on 
DMC and RMC unreliable. However, during our studies Fialho et al. were also 
comparing RMC and DMC in the UK.16 In contrast to our study, theirs included an 
unexpectedly high proportion of DMC patients (37%), which was probably due to a 
founder effect. This did enable their team to contrast the two congenital myotonias 
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reliably: generalised muscle hypertrophy, transient paresis, and depressed upper limb 
reflexes were strongly associated with RMC but rare in DMC. Severe myotonia or 
muscle weakness were also typical seen in RMC.16  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 General clinical features in chloride (ClCh) and sodium channelopathies (NaCh). Patients with a 
ClCh especially show myotonia in the hand- and leg-muscles (ovals) and only a minority of these 
patients show myotonia in the eyelid-muscles. Patients with a ClCh never show paramyotonia. 
Patients with a NaCh especially show myotonia in eyelid- and hand-muscles (ovals) and a 
minority of these patients show myotonia in the leg-muscles. Patients with a NaCh never show 
transient paresis. Both forms of channelopathies may show the warm-up phenomenon (WU). 
 
 
In our patients with a NaCh, the presence of myotonia in the leg muscles, and action 
myotonia and percussion myotonia in the right quadriceps muscle showed a trend 
towards the differentiation between SCM and PC, but it was only the warm-up 
phenomenon (SCM) that contributed statistically significantly to this differentiation.15  
 
During our study two other research teams were also evaluating the clinical 
phenotypes of genetically confirmed NDM patients.17,18 In the UK Matthews and 
colleagues studied clinical and genetic features in 32 patients with PC and in Canada 
Dupré et al. studied the clinical profiles of 50 genetically confirmed Canadian NDM 
patients.17,18 In Matthews study, most PC patients mentioned cold, exercise or rest 
after exertion as exacerbating factors for their myotonia. The disease had first 
manifested itself in their early teens and especially affected the muscles of the face 
and upper limbs. The patients sometimes showed muscle weakness, especially in cold 
conditions or following exercise.17 These findings accordingly confirmed von 
Eulenburg’s original descriptions of PC. We observed the same symptoms in our Dutch 
group of PC patients.15,19 Dupré et al. evaluated the clinical characteristics of 36 
patients with CLCN1 and 14 patients with SCN4A mutations.18 In harmony with our 
study, they identified clinical features that were more likely to be associated with 
NEVER
PARAMAYOTONIA
NEVER
TRANSIENT PARESIS
wu wu
Chloride-channelopathies Sodium-channelopathies
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particular genotypes. Their patients with CLCN1 mutations, for example, typically 
showed myotonia in their lower extremities, and also suffered from myotonia of the 
tongue and from transient paresis. For their patients with SCN4A mutations, Dupré 
described eyelid myotonia and exacerbations of myotonia by cold temperatures as 
the leading symptoms. In accordance with our findings, they also found pain to be 
more frequent in this group of patients. They further noted that the warm-up 
phenomenon, hand- grip myotonia and percussion myotonia, the eyelid lag and 
hormonal effects did not differ between the two channelopathies.18 
 
Besides the clinical features of NDMs, we were also interested in the impact on the 
patients’ physical, psychological, and social functioning. These effects are evaluated in 
Chapter 7. Because NDMs are typically considered to be ‘benign’ diseases, little 
attention has been paid to its effects on the patients’ ability to perform activities of 
daily living or their social participation.20 Ours thus was the first study to determine 
the self-reported health status in patients with NDMs. In a cross-sectional design 32 
patients with confirmed ClCh and 30 patients with confirmed NaCh, all off treatment, 
completed a standardised interview, the Fatigue Assessment Scale (FAS), and the 36-
item Short-Form health survey (SF-36). We opted for the SF-36 because of its brevity, 
its extensive use in clinical studies, and its good psychometric properties.21-24 The 
patients’ SF-36 domain scores were compared with general community domain scores 
obtained in the Netherlands. We also conducted regression analyses to determine the 
strongest determinants of the SF-36 domains regarding general-health perception, 
and the physical component (PCS) and mental component summaries (MCS). All 
physically oriented SF-36 domains were substantially lower in both channelopathy 
groups compared to the Dutch community scores, reflecting a poorer clinical 
condition for the patients. In addition, 42% of the patients characterised their 
myotonia as painful and 53% could be classified as being fatigued. Fatigue proved to 
be the strongest predictor of low general-health perceptions, while painful myotonia 
best predicted low overall physical functioning. The level of social participation was 
also substantially lower in the NaCh patients compared to Dutch community scores, 
probably because of pain. None of the patients showed below-norm scores on the 
MCS domain. By showing that the impact of NDMs on the patient’s health status is 
substantial and that particularly painful myotonia and fatigue tend to impede their 
physical functioning substantially, we disproved previous contentions that, given the 
condition’s assumed mild nature, health-related aspects do not warrant particular 
attention. Because we were the first to use self-report questionnaires in this domain 
we also tested the validity and reliability of the scales used. Both the SF-36 and the 
FAS showed good content validity and reliability in our NDM cohort, making them 
potentially useful endpoints for future, randomised clinical trials.  
 
In Chapter 8 we systematically charted the changes in and thickness of four limb 
muscles from a large cohort of genetically confirmed NDM patients by means of 
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ultrasound and correlated the obtained data to functional parameters. The results 
showed elevated echo intensities in all muscles except the rectus femoris, and 
surprisingly, we only detected hypertrophy in the arm muscles. The elevated muscle 
echo intensities were significantly negatively correlated to the patients’ ranges of 
motion and to the muscle force in their forearm flexors. The changes were positively 
related to age and more pronounced in the dominant arm muscles. Together, our 
readings suggest structural muscle changes in NDMs that increase with age and 
degree of muscle use. To establish the exact nature of the muscle pathology, muscle 
biopsies are required. In the past, such biopsies revealed only minor histopathological 
abnormalities,25-27 but most were obtained from proximal muscles, especially the 
rectus femoris muscle.25-27 However, this was the least affected muscle in our study. 
We propose that in future NDM studies muscle biopsies are obtained from the most 
affected muscles or guided by skeletal muscle ultrasound. However, the most affected 
muscles were the dominant forearm muscles and these are difficult to puncture, 
which implies that the procedure is not without risk, thus complicating further in-
depth studies. If relevant muscle biopsies will be obtained in the future and if they will 
show structural (dystrophic) changes, the designation non-dystrophic myotonic 
syndromes would be open to debate.  
 
As to the muscle hypertrophy we detected, it needs to be noted that the increased 
volume was restricted to the upper limb muscles whereas in the literature a definite 
generalised muscle hypertrophy is reported, particularly for RMC.28,29 Also some of 
our patients showed clear generalised muscle hypertrophy, but others demonstrated 
a relative muscle atrophy. Using objective measures we thus established that in our 
NDM sample the mean muscle thickness of the patients’ leg muscles was not 
enlarged.  
What have we learned?  
The Cochrane review in which we evaluated drug treatments for myotonia underlined 
that, to date, no double-blind randomised clinical trials have been conducted in NDM 
patients. In our genetic study we tested a new, approach to screen mutations in 
NDMs, i.e., in tandem analysis of CLCN1 and SCN4A, which resulted in a 100% 
diagnostic yield. The technique, moreover, helped to uncover 13 novel CLCN1 and 
three novel SCN4A mutations, expanding our knowledge of NDM subtypes. It also 
enabled us to compose genetically homogenous NDM groups on the basis of the two 
channelopathies, allowing us to describe their distinct clinical features and redefine 
the NDM phenotypes. Our investigations accordingly allowed us to develop new 
clinical guidelines for focused genetic testing. Moreover, it was possible to compare 
PC with SCM in NaCh, showing that only the warm-up phenomenon contributed 
statistically significantly to the differentiation between the two syndromes. Besides 
delineating the clinical features of NDMs in more detail, we were the first to study the 
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effects on the patients’ physical, psychological and social functioning and found them 
to have a serious impact on the physical parameters. Furthermore, about 42% of our 
NDM patients reported painful myotonia and about 53% was fatigued. Using the SF-
36 in combination with our standardised interviews and the FAS, painful myotonia 
proved the strongest predictor of the physical component summary and fatigue the 
strongest predictor of general-health perception. This new knowledge about the 
impact the various clinical features have on the patients’ health status can be 
exploited to select outcome measures for future double-blind RCTs. Lastly, our muscle 
ultrasound measurements suggested structural muscle changes in NDMs, with 
hypertrophy being negligible and restricted to the upper limbs. The structural muscle 
changes preferably need to be confirmed by muscle biopsies. 
What do we still need to know? 
Numerous vital questions regarding genotype-phenotype relationships still remain 
unanswered, of course. For instance, how do different mutations relate to the specific 
phenotypic manifestations within and between kindred’s with the same mutation?1 
And why do some individuals within an affected kindred manifest only mild or minimal 
symptoms while other members are severely affected?1 Theoretically, these 
phenomena could possibly be explained by metabolic, hormonal or environmental 
influences or a combination of these factors. Myotonia, for instance, tends to intensify 
during pregnancy and menstrual periods,15,22,30 while men with myotonia congenita 
have more severe symptoms than women.15,31 However, the basis of these differences 
are, as yet, unknown and warrant further investigation. Recently, Fialho showed that 
both testosterone and progesterone may rapidly and reversibly inhibit wild-type ClC-1 
channels expressed in Xenopus oocytes,32 which may hence serve as an explanatory 
mechanism for the observed modulations in the severity of symptoms in myotonia 
congenita. Furthermore, ClC-1 channels in vitro can be inhibited via a rapid, non-
genomic metabolic signalling pathway,32 which phenomenon may potentially help 
provide a mechanistic explanation for the variable clinical observations in NDMs, 
meriting further scrutiny in humans. If confirmed, epigenetic factors may provide 
additional prospects for novel targeted therapies.  
Future perspectives 
Since clinical phenotypes can be misinterpreted, it is important to mention that 
phenotypic descriptions in the literature without proper genetic information should 
be considered with caution. For instance, a recently published paper in the journal of 
AAPOS (the American Association for Pediatric Ophthalmology and Strabismus) 
reported two cases with DMC in which orbital magnetic resonance imaging (MRI) 
showed extraocular muscle hypertrophy with pronounced delayed orbicularis 
relaxation after forceful blinking.33 The authors first suggested these phenomena to 
be phenotypical characteristics of DMC, but subsequent genetic testing revealed no 
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disease-causing mutations in the 23 exons of the CLCN1 gene.33 This, of course, does 
not rule out DMC, but in the light of the findings we obtained in our study, we should 
strongly recommend to analyse SCN4A.15,34 The authors did and actually they detect 
the V445M sodium-channel mutation in both patients.35 
 
Before our approach can be used in diagnostic protocols, some of the results we 
obtained need to be confirmed in patient cohorts from other countries. During the 
2008 annual meeting of the American Academy of Neurology (AAN) in Chicago, we 
were informed that such studies are currently underway in the US.36 Furthermore, 
during the 2009 AAN meeting in Seattle, Meola et al. presented an Italian study which 
confirmed our results.37 The American-based multicentre study will include very 
sizeable patient cohorts, which, besides the obvious advantages, probably also implies 
that the selected standardised clinical bedside tests for the various muscle groups will 
not be performed under the same conditions and almost certainly not by the same 
investigator, as was the case in the studies reported in this thesis. In such large-scale 
investigations, test-retests are highly recommended, which corroboration was 
logistically impossible in our studies, as well as inter-observer studies. 
 
As stated, based on our phenotype redefinitions we were able to devise rules of 
thumb for focused genetic testing of either CLCN1 or SCN4A. Although it was not our 
aim to define the clinical phenotypes of individual mutations in CLCN1 or SCN4A, we 
were able to define a typical phenotype for the V445M sodium-channel mutation 
(Chapter 5). The definition of clinical guidelines for other individual mutations requires 
a far larger number of patients. Probably a combination of clinical bedside tests and 
ancillary investigations are more practicable. Fournier, for instance, recommends RNS 
studies to focus genetic testing.8,38 Additionally, needle EMGs may detect differences 
in amplitude and frequency in the various mutations.39 Although Fournier was not 
able to pinpoint apparent differences in the abundance of myotonic discharges 
between ClCh and NaCh8,38, we did manage to identify different types of myotonic 
discharges for the two channelopathies in our patient cohorts (unpublished data). We 
hope future results will facilitate the development of needle EMG criteria for focussed 
genetic testing. It is even plausible that the combined data obtained by means of 
clinical bedside tests, nerve stimulation studies, and needle EMG will be superior in 
defining guidelines for targeted genetic testing. 
 
Another interesting issue is the quantification of myotonia, a crucial element in 
improving our understanding of the natural history of the syndromes involved as well 
as for the evaluation of medication studies. Several techniques to quantify myotonia 
in the hand muscles have already been developed and tested.5,40 The purpose of our 
study was not to quantify myotonia, but to describe its clinical pattern in three 
different body regions using true-to-life neurological tasks, to which end we 
developed standardised clinical bedside tests, all easily applicable in any outpatient 
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clinic. The tests indeed allowed us to discern a differentiating myotonic pattern for 
ClCh and NaCh. Ideally, for future double-blind RCTs, we should also be able to 
objectively quantify myotonia in the leg and eyelid muscles. For leg-muscle 
measurements we propose the trunk sway analysis elucidated earlier in this 
discussion.7 Regrettably, techniques to detect and quantify myotonia in eyelid muscles 
are as yet lacking.  
 
Maybe even more important for NDM research is the definition of sound clinical 
endpoints and outcome measures to facilitate double-blind RCTs. A first prerequisite 
is standardisation of the assessment of symptoms and signs. Moreover, the 
translation of these standardised, quantified symptoms and signs to the limitations 
the patients experience in their health status, should likewise be standardised. This is 
essential given earlier experiences with inflammatory neuropathies, where an 
overwhelming assortment of scales have been applied, thereby hampering any 
reliable comparison of the various trials.41 Subsequently, the selected outcome 
measures need to be clinimetrically tested and need to be simple, communicable, 
valid, reliable, and responsive.42-44 Moreover, all outcome measures should be 
unambiguously constructed and hence represent only one of the outcome levels as 
specified in the international classification of functioning, disability, and health (ICF) 
drafted by the World Health Organisation (WHO) and the WHO health status 
concept.45-47 According to the ICF and the concept of health status, when designing an 
RCT, researchers should determine a priori outcome measures, i.e., which domains 
and outcome levels they intend to assess.46,47 They should also incorporate the 
minimal clinically important difference (MCID), which has been defined as “the 
smallest difference in score in the domain of interest which patients perceive as 
beneficial and which would mandate [..] a change in the patient’s management”.48 
The MCID is not equivalent to statistical significance. In fact, results may show a 
statistical significance, as is generally seen in large samples, without providing an 
indication of clinical significance.49 Sloan et al. have recently published a pragmatic 
review of existing practical guidelines for the assessment of the MCID.50 In summary, 
one of the major challenges for future scientific research in NDMs will be defining 
accurate and viable outcome measures. 
 
As a last recommendation, we would suggest scheduling a new ENMC (European 
Neuromuscular Centre) International workshop dedicated to NDMs. The last such 
workshop was in 1995 and concerned the topics of paramyotonia, potassium-
aggravated myotonias, and periodic paralyses.51 We think it is time that NDM experts 
from across the world exchange newly acquired insights and the latest developments 
in patient management practices. The possibility of setting up a large-scale, European, 
multicentre RCT with mexiletine should also be discussed, with priority being given to 
the inclusion/exclusion criteria and the required and potential sample sizes. Finally, a 
toolkit for future fundamental studies and double-blind RCTs should be developed to 
Thesis_Trip_v13.pdf
 General discussion⏐147 
help define patients, outcome measures, trial medications, and symptomatic 
treatment regimens for all NDM subtypes. Of course, the ultimate goal of future 
investigations will be to find effective, evidence-based treatments for the various 
NDM syndromes. 
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Samenvatting 
In dit proefschrift worden de resultaten van een nationale studie beschreven waarin 
we de genetica, de klinische kenmerken, de gezondheidsstatus en spierecho-waarden 
van een groep volwassen patiënten met een bewezen niet-dystrofische myotonie 
hebben bestudeerd. Het hoofddoel was om het fenotype van de niet-dystrofische 
myotonieën op basis van homogene genetische groepen (CLCN1 en SCN4A, 
respectievelijk chloor- en natrium-kanalopathieën) te herdefiniëren. Daarnaast was 
het doel om een betere strategie voor het vinden van de verantwoordelijke mutaties 
te ontwikkelen en om optimale omstandigheden voor toekomstig dubbelblind 
gerandomiseerde studies naar myotonie te creëren.  
 
In Hoofdstuk 1 wordt een introductie en een historisch perspectief betreffende de 
niet-dystrofische myotonieën gegeven. Als eerste worden de klinische kenmerken van 
de niet-dystrofische myotonieën in het pre-genetische tijdperk beschreven. Daarna 
worden de pathofysiologie, de ontdekking van de verantwoordelijke genen, de 
mogelijkheden voor aanvullend onderzoek, de differentiaal diagnose en de 
behandelingsmogelijkheden van de niet-dystrofische myotonieën besproken. 
Vervolgens worden de argumenten voor het schrijven van dit proefschrift beschreven.  
 
Hoofdstuk 2 behandelt de resultaten van het door ons verrichtte systematische 
review betreffende de medicamenteuze behandeling van myotonie. Er werden in dit 
review tien gerandomiseerde gecontroleerde trials geïncludeerd waarbij het effect 
van een medicamenteuze behandeling versus placebo of versus een andere 
medicamenteuze behandeling werd onderzocht. De geïncludeerde trials waren allen 
dubbel- of enkelgeblindeerde cross-over studies waarbij in totaal 143 patiënten 
werden geïncludeerd. Bij 113 patiënten was de diagnose myotone dystrofie type 1 en 
bij 30 patiënten was de diagnose myotonia congenita vastgesteld. Over het algemeen 
waren de geïncludeerde studies van slechte kwaliteit. Daarnaast werd in een aantal 
studies zowel patiënten met myotone dystrofie als patiënten met myotonia congenita 
geïncludeerd. Hierdoor was het niet mogelijk om van alle gevonden studies de 
resultaten betrouwbaar te analyseren. Samengevat zijn er uiteindelijk drie kleine 
cross-over studies bij patiënten met myotone dystrofie type 1 geselecteerd die van 
goede kwaliteit zijn. Deze studies waarin respectievelijk de middelen imipramine, 
clomipramine en taurine werden onderzocht toonden allen een significante 
vermindering van de myotonie aan. Helaas kunnen we geen betrouwbare data voor 
de behandeling van myotonie ten aanzien van de niet-dystrofische myotonieën 
presenteren. Concluderend is het vanwege te weinig onderzoek en insufficiënte data 
onmogelijk om te bepalen of medicamenteuze therapie voor myotonie veilig en 
effectief is. Wij concludeerden dat nieuwe dubbel-blind gerandomiseerd 
gecontroleerde onderzoeken nodig zijn waarbij de studies goed opgezet dienen te 
worden en waarbij de verschillende myotone aandoeningen afzonderlijk onderzocht 
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dienen te worden. Aangezien in de meest gevonden cross-over studies geen washout 
interval werd gebruikt, raden wij in de toekomst bij dergelijke studies wel een 
washout interval aan. Bovendien zijn een intention-to-treat analyse en een goede 
presentatie van de resultaten noodzakelijk. 
 
Hoofdstuk 3 betreft een uiteenzetting van de opzet van dit proefschrift. 
 
In Hoofdstuk 4 worden de resultaten van de genetische analyse van achtereenvolgens 
CLCN1 en SCN4A bij 54 index patiënten (probands) besproken. Het doel van deze 
studie was ten eerste om de genetische karakterisering van de niet-dystrofische 
myotonieën in Nederland te optimaliseren en ten tweede om homogene groepen 
patiënten, gesplitst in chloor- en natrium-kanalopathieën, te selecteren. Als resultaat 
van deze studie werden bij 32 families (59%) CLCN1 mutaties en bij 22 families (41%) 
SCN4A mutaties gevonden. Deze studie heeft dan ook geresulteerd in een 
diagnostische opbrengst van 100%. Aangezien er echter bij drie recessieve en bij drie 
sporadische patiënten geen tweede mutatie werd gevonden was de opbrengst van 
individuele mutatie detectie 93% (worst case scenario). Onder alle gevonden mutaties 
ontdekten we 13 nieuwe CLCN1 en drie nieuwe SCN4A mutaties. Klinische evaluatie 
en DNA-analyses van alle eerstegraads familieleden van patiënten met een nieuwe 
mutatie wees uit dat behoudens één mutatie alle andere mutaties met de ziekte 
segregeerden. Wij concludeerden dat de genetische analyse van achtereenvolgens 
CLCN1 en SCN4A een zeer hoge mutatie detectie oplevert en dat het eveneens 
resulteert in de mogelijkheid om relatief homogene groepen patiënten, gesplitst in 
chloor- en natrium-kanalopathieën, te selecteren. Dit laatste gaf ons de mogelijkheid 
om de klinische kenmerken van de niet-dystrofische myotonieën in Nederland te 
herdefiniëren. 
 
Hoofdstuk 5 beschrijft drie patiënten met een genotype-phenotype mismatch. In het 
pre-genetisch tijdperk werd namelijk verondersteld dat het warm-up fenomeen een 
specifiek symptoom was voor chloor-kanalopathieën. Wij beschrijven hier echter drie 
patiënten met een evident gegeneraliseerd warm-up fenomeen op basis van een 
V445M natriumkanaal mutatie. Wij concludeerden dat deze case-reports laten zien 
dat er een noodzaak is om de klinische kenmerken van de niet-dystrofische 
myotonieën te herdefiniëren. 
 
In Hoofdstuk 6 presenteren wij de resultaten van een descriptieve cross-sectionele 
studie waarin bij 62 genetisch bewezen patiënten met een niet-dystrofische 
myotonie, 32 chloor- en 30 natrium-kanalopathieën, gestandaardiseerde interviews 
en gestandaardiseerde klinische bedside tests werden afgenomen. De resultaten van 
de gestandaardiseerde interviews tonen dat patiënten met een chloor-kanalopathie 
vaker spierzwakte, het warm-up fenomeen en problemen bij snel opstaan, rennen en 
traplopen rapporteren. Patiënten met een natrium-kanalopathie rapporteren vaker 
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een vroeger begin van de klachten en gaven eveneens aan dat ze vaker last hadden 
van paradoxe en pijnlijke myotonie. De gestandaardiseerde klinische bedside tests 
tonen bij patiënten met een chloor-kanalopathie een hogere incidentie en langere 
relaxatie tijden van myotonie in de beenspieren en bij patiënten met een natrium-
kanalopathie een hogere incidentie en langere relaxatie tijden van myotonie in de 
ooglidspieren aan. Een transiënte parese komt alleen voor bij chloor-kanalopathieën 
en paradoxe myotonie komt alleen voor bij natrium-kanalopathieën. Multivariate 
logistische regressie analyse gaf ons de mogelijkheid om klinische vuistregels voor het 
gerichter aanvragen van genetisch onderzoek op te stellen. Het komt er op neer dat 
op basis van klinische uitkomstmaten geadviseerd kan worden om eerst het CLCN1 of 
eerst het SCN4A gen te analyseren. De in dit hoofdstuk beschreven klinische 
uitkomstmaten voorspellen met een sensitiviteit van 91% en een specificiteit van 97% 
of de patiënt een chloor-kanalopathie heeft. Vice versa voorspellen de klinische 
uitkomstmaten met een sensitiviteit van 97% en een sensitiviteit van 91% of de 
patiënt een natrium-kanalopathie heeft. Concluderend hebben we de klinische 
kenmerken van de niet-dystrofische myotonieën in Nederland geherdefinieerd. 
Daarnaast kunnen de aan- of afwezigheid van enkele eenvoudig te testen klinische 
kenmerken clinici helpen bij het gerichter aanvragen van genetisch onderzoek. Echter, 
indien er bij het eerste geanalyseerde gen geen afwijkingen gevonden worden, dient 
ook het tweede gen onderzocht te worden. 
 
Gezondheidsstatus onderzoek binnen de niet-dystrofische myotonieën was voor de 
verschijning van dit proefschrift nooit onderzocht. Een dergelijk door ons uitgevoerde 
studie wordt in Hoofdstuk 7 beschreven. Het hoofddoel van deze studie was om te 
bepalen wat de zelf-gerapporteerde gezondheidsstatus van patiënten met niet-
dystrofische myotonieën is, zodat de impact van het ziektebeeld op het gebied van 
fysiek, psychologisch en sociaal functioneren beschreven kan worden. In een cross-
sectionele studie werden bij 32 bewezen patiënten met een chloor- en 30 patiënten 
met een natrium-kanalopathie, waarbij overigens geen van de patiënten medicatie 
voor de myotonie gebruikte, gestandaardiseerde interviews afgenomen en vulden alle 
patiënten de Fatigue Assessment Scale (FAS) en de 36-item Short-Form health survey 
(SF-36) in. De domeinscores van de SF-36 ten aanzien van patiënten met een niet-
dystrofische myotonie werden vergeleken met beschikbare SF-36 domeinscores van 
de Nederlandse bevolking. Bovendien werden regressie analyses uitgevoerd om zo de 
sterkste determinant van de SF-36 domeinen general-health perception, physical 
component summary (PCS) en mental component summary (MCS) te bepalen. De 
belangrijkste resultaten toonden dat de scores van alle fysiek georiënteerde SF-36 
domeinen in zowel chloor- als natrium-kanalopathieën en sociaal functioneren in 
natrium-kanalopathieën significant lager (slechtere health-status) zijn in vergelijking 
met de overeenkomstige domeinscores van de Nederlandse bevolking. Regressie 
analyse toonde aan dat vermoeidheid de sterkste voorspeller was voor een lagere 
general-health perception en dat pijnlijke myotonie de sterkste voorspeller was voor 
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een lagere physical component summary. Geen van de patiënten toonde overigens 
verlaagde scores op de mental component summary. Wij concludeerden dat de 
impact van niet-dystrofische myotonieën op het fysiek functioneren substantieel is en 
dat vooral pijnlijke myotonie en vermoeidheid factoren zijn die het fysiek 
functioneren van patiënten met een niet-dystrofische myotonie negatief beïnvloeden. 
 
In Hoofdstuk 8 beschrijven we een studie waarin middels spierecho de skeletspier-
intensiteit en skeletspier-dikte van patiënten met een niet-dystrofische myotonie 
werden onderzocht. Bij een afwijkende spierecho-intensiteit of afwijkende spierdikte 
werd gekeken of deze afwijkingen correleerden met de eveneens gemeten 
functionele spierparameters. De belangrijkste bevinding van deze studie betreft een 
verhoogde spierecho-intensiteit, welke in de literatuur gecorreleerd is aan 
spierfibrose en spiervervetting, in bijna alle gemeten spieren. Daarnaast vonden we 
hypertrofie in de armspieren en niet in de beenspieren. De spierecho-intensiteits-
waarden waren omgekeerd gecorreleerd met de bewegingsmogelijkheden van het 
overeenkomende gewricht en de spierecho-intensiteit was positief gecorreleerd met 
de leeftijd. Daarnaast waren de gevonden spierecho-intensiteitsafwijkingen ernstiger 
aan de dominante zijde. De spierecho-intensiteit van de voorarm-flexoren was 
omgekeerd gecorreleerd aan de spierkracht. Concluderend kan gesteld worden dat 
kwantitatieve spiermetingen bij patiënten met een niet-dystrofische myotonie 
structurele spierveranderingen suggereren. Deze structurele spierveranderingen zijn 
gecorreleerd aan de mate van spiergebruik. Om de histopathologische origine en de 
mate van aantasting van het spierweefsel verder te onderzoeken dient toekomstig 
onderzoek zich te richten op het afnemen van spierbiopten in de meest aangedane 
spieren of dienen echo-geleide spierbiopten afgenomen te worden. Indien deze 
studies eveneens een zekere mate van spierdystrofie aantonen, dan kan de naam 
niet-dystrofische myotonieën ter discussie worden gesteld.  
 
Concluderend hebben we in dit proefschrift middels een review aangetoond dat er 
geen dubbelblind gerandomiseerde studies naar de behandeling van myotonie bij de 
niet-dystrofische myotonieën zijn uitgevoerd. Onze genetische studie toont aan dat 
het achtereenvolgens testen van CLCN1 en SCN4A tot een zeer hoge mutatie-detectie 
leidt en dat deze methode helpt bij het samenstellen van homogene genetische 
groepen. Verder beschrijft dit proefschrift de klinische herdefinitie van de niet-
dystrofische myotonieën. Hierbij beschrijven we klinische vuistregels voor het 
gerichter aanvragen van genetisch onderzoek. Daarnaast blijkt dat de impact van de 
ziekte op het dagelijks leven groter is dan wellicht werd gedacht. Tevens hebben we 
door een beter klinisch inzicht te krijgen betere omstandigheden gecreëerd voor 
toekomstig op te zetten dubbelblind gerandomiseerde klinische trials voor de 
behandeling van myotonie. Als laatste suggereren spierecho studies dat er bij 
patiënten met niet-dystrofische myotonieën waarschijnlijk toch structurele 
spierafwijkingen ontstaan.  
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Uiteindelijk bediscussiëren we in Hoofdstuk 9 de resultaten van dit proefschrift. Als 
laatste hebben we in dit hoofdstuk de toekomstige mogelijkheden voor 
wetenschappelijk onderzoek op het gebied van de niet-dystrofische myotonieën 
beschreven.
Thesis_Trip_v13.pdf
 Thesis_Trip_v13.pdf
  
 
 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis_Trip_v13.pdf
159
Thesis_Trip_v13.pdf
 Dankwoord⏐161 
Dankwoord 
In de afgelopen vijf jaar heb ik met veel plezier aan dit proefschrift gewerkt. De 
werkzaamheden vonden zowel in Nijmegen, Maastricht of in de trein op weg naar één 
van beide steden plaats en ondanks het feit dat dit het soms tot een complex geheel 
maakte zou ik dit proces niet hebben willen missen en heb ik er veel van geleerd. 
Langs deze weg wil ik dan ook iedereen die in welke vorm dan ook heeft bijgedragen 
aan het tot stand komen van dit proefschrift bedanken. De volgende mensen wil ik in 
het bijzonder noemen.   
 
Allereerst de patiënten met een niet-dystrofische myotonie die aan dit onderzoek 
hebben deelgenomen. Zij zijn vanuit heel Nederland gedurende een dag naar 
Nijmegen gekomen. Ik dank jullie allen oprecht. De Vereniging Spierziekten Nederland 
en alle neurologen in Nederland wil ik bedanken voor het verwijzen van patiënten en 
het Prinses Beatrix Fonds dank ik voor de subsidie van dit project.  
 
Prof. Dr. B.G.M. van Engelen, beste Baziel, dank voor je rol als promotor. Ik heb je 
tijdens mijn onderzoek in Nijmegen leren kennen. Je heldere denken, menselijkheid, 
goede ‘helikopterview’ en eeuwige rustige uitstraling, ook in moeilijke tijden, maken 
je tot een zeer gewaardeerd promotor. Van jou heb ik geleerd dat als je maar integer 
blijft er veel mogelijk  is. Veel dank voor de prettige samenwerking en goede 
begeleiding. 
 
Dr. G. Drost, beste Gea, ook jou heb ik leren kennen tijdens ons wetenschappelijk 
werk in Nijmegen, waar je dagelijks een prettige collega was. Je gastvrijheid blijkt 
alleen al uit het feit dat ik meer dan twee jaar bij je op de kamer mocht werken. Dat je 
af en toe de deur eens op slot deed terwijl Mark en ik nog in jouw kamer zaten doet 
daar absoluut geen afbreuk aan. Verder moet je tijdens deze twee jaar zo nu en dan 
bijna gek geworden zijn van al mijn vragen en onzekerheden. Desalniettemin bleef je 
altijd positief. Ik heb ontzag voor je gedreven en oprechte manier van werken en wil je 
bedanken voor de plezierige en enthousiaste ondersteuning bij het schrijven van dit 
proefschrift. Fijn dat je mijn co-promotor bent. 
 
Dr. C.G. Faber, beste Carin, jij bent degene die mij vlak na mijn komst naar Maastricht 
voor dit promotie-onderzoek heeft gevraagd. Ik heb je vlak daarvoor tijdens mijn 
eerste klinische werkzaamheden in het azM als een prettige supervisor leren kennen. 
Toen je me voor dit onderzoek vroeg wisten we nog niet wat er allemaal op ons af zou 
komen. Ook wisten we toen nog niet dat we pas in januari 2005 zouden gaan starten. 
We hebben er denk ik allebei op ons eigen manier veel van geleerd. Ik wil je bedanken 
voor het vertrouwen dat je altijd in me hebt gehad en gehouden. Verder bewonder ik 
je enthousiasme, arbeidsethos, efficiëntie en scherpe blik. Hoe druk je het verder ook 
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had, ik kon altijd bij je terecht en de te corrigeren manuscripten kreeg ik met de juiste 
adviezen altijd snel weer terug. Ik ben blij dat je mijn co-promotor bent.  
 
Prof. Dr. M. Zwarts, beste Machiel, dank voor je gastvrijheid op de afdeling klinische 
neurofysiologie van het UMC St Radboud. Ondanks het feit dat ik niet alle dagen van 
de week aanwezig was en officieel op de loonlijst van Maastricht stond voelde ik me 
altijd welkom. Tevens bedankt voor het idee om de skeletspieren van patiënten met 
een niet-dystrofische myotonie middels echo te bekijken.  
 
Prof. Dr. J. Troost, prof. Dr. M. Limburg en Dr. M.C.T.F.M. de Krom, beste Jaap, 
Martien en Marc, jullie zijn in Maastricht mijn opleiders geweest. Bedankt voor de 
brede, goede en prettige opleiding die jullie mij samen gegeven hebben. 
 
Iris en Erik, mijn paranimfen. Sinds ik jullie in respectievelijk 2002 te Sittard en 2001 te 
Maastricht heb leren kennen zijn jullie niet alleen mijn directe collega’s neurologie, 
maar ook collega onderzoekers en vrienden geworden. Samen met Margriet, Danitsja, 
Jeroen en inmiddels ook Tijmen en Lenore hebben we vele leuke uren doorgebracht. 
Bedankt dat jullie mijn paranimfen willen zijn. 
 
De laboranten en secretaresses van de afdeling KNF te Nijmegen en in het bijzonder 
Henny, Wilma, José, Mirjam, May en Angelique. Bedankt voor jullie secretariële en 
logistieke ondersteuning. Maar ook bedankt voor jullie gezelligheid, praktische tips en 
persoonlijke interesse.  
 
Medeonderzoekers en collega’s van de afdeling KNF te Nijmegen en in het bijzonder 
Sigrid, Hans, Mark, Nens, Dick, Paul en Nicol. Bedankt voor jullie gastvrijheid, scherpe 
opmerkingen en bij mooi weer de wandelingen in het park.  
 
Medeonderzoekers en (oud) collega’s van de afdeling Neurologie in het azM. Bedankt 
voor de leuke, gezellige en leerzame tijd in Maastricht. 
 
De dames van de polikliniek en het secretariaat van de afdeling neurologie in zowel 
het UMC St Radboud als in het azM. Bedankt voor alles. 
 
Ingemar. Bedankt voor je oprechte interesse. Daarnaast wil ik je natuurlijk bedanken 
voor de opzet en het verrichten van de statistiek van hoofdstuk 7. 
 
Geert-Jan. Bedankt voor de opmaak en het ontwerpen van mijn figuren. 
 
Hanneke. Bedankt voor je correcties en adviezen. Jij hebt de kwaliteit van het Engels 
van dit proefschrift bewaakt. Je flexibele inzet en precieze uitleg en toevoegingen heb 
ik altijd gewaardeerd. 
Thesis_Trip_v13.pdf
 Dankwoord⏐163 
De vakgroep Neurologie van het Diaconessenhuis te Meppel. Beste Bert, Emile, Okki, 
Esther en Liedeke. Bedankt voor de vroege beslissing om bij jullie in de vakgroep te 
mogen komen werken. Dit heeft mij tijdens de laatste werkzaamheden aan dit 
proefschrift veel rust gegeven. 
 
Lieve pap en mam, jullie wil ik bedanken voor de onvoorwaardelijke steun die jullie 
mij altijd op alle vlakken gegeven hebben.  
 
Lieve Margriet, jou wil ik bedanken voor alle steun en liefde die je me tot nu toe 
gegeven hebt. Ik heb het wel eens vaker gezegd, maar zonder jou waren de leuke 
momenten in mijn leven een stuk minder aanwezig geweest. De vele gezellige en 
romantische vakanties, weekendjes en ander momenten die ik samen met je heb zijn 
onmisbaar. Ik blijf de gezamenlijke interesse in sport fantastisch vinden. Maar, de 
leukste, belangrijkste en meest bijzondere dag was voor ons 16 augustus 2008: ons 
huwelijk in Maastricht. Ik hou van je.  
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Curriculum vitae 
Jeroen Trip werd op 25 september 1975 geboren in Veendam. Van 1987 tot 1993 
volgde hij het VWO aan de Rijksscholengemeenschap Winkler Prins te Veendam. Na 
afronding hiervan studeerde hij Geneeskunde aan de Rijksuniversiteit Groningen. In 
1998 werd het doctoraal examen met goed gevolg afgelegd. Na het doctoraal volgden 
de co-schappen in het Academisch Ziekenhuis Groningen. Het keuze-coschap 
neurologie werd onder leiding van Dr. G. de Jong gevolgd in de Isala klinieken, locatie 
de Weezenlanden, te Zwolle. Aansluitend werd in 2000 het arts-examen cum laude 
behaald. Zijn medische carrière begon hij daarna als AGNIO op de afdeling neurologie 
van de Isala klinieken. De opleiding tot neuroloog volgde hij in het Academisch 
Ziekenhuis Maastricht met als opleiders Prof. dr. J. Troost, Prof. dr. M. Limburg en Dr. 
M.C.T.F.M. de Krom. Gedurende deze opleiding kreeg hij door middel van een 
subsidie van het Prinses Beatrix Fonds de ruimte voor het verrichten van klinisch 
wetenschappelijk onderzoek. Dit onderzoek, dat een samenwerkingsverband met de 
afdeling Neurologie van het Universitair Medisch Centrum St Radboud te Nijmegen 
betrof, heeft dit proefschrift als resultaat. Een deel van dit promotieonderzoek werd 
bekroond met de Neurologie Jaarprijs 2007 van de Nederlandse Vereniging voor 
Neurologie en de Pelerinprijs 2007 van het Academisch Ziekenhuis Maastricht. Per 
1 december 2009 is Jeroen begonnen als neuroloog in het Diaconessenhuis te 
Meppel. 
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List of publications 
Stunnenberg BC, Ginjaar HB, Trip J, Faber CG, van Engelen BGM, Drost G. Isolated 
eyelid closure myotonia in two families with sodium channel myotonia. 
Neurogenetics, accepted.  
 
Vermeij J-D, Winogrodzka A, Trip J, Weber WEJ. Parkinson’s disease, levodopa-use and 
risk of melanoma. Parkinsonism and related disorders 2009;15:551-553. 
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measurements and functional muscle parameters in non-dystrophic myotonias 
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Glossary 
Acetazolamide responsive myotonia congenita: potassium sensitive form of myotonia 
with painful myotonia, which responds to acetazolamide 
BP: body pain 
CI: confidence interval 
ClCh: chloride channelopathies (DMC and RMC) 
CMAP: compound muscle action potential 
CLCN1: skeletal muscle chloride channel gene, mapped to chromosome 7q35 
DM1: myotonic dystrophy type 1 
DM2: myotonic dystrophy type 2 (PROMM) 
DMC: dominant myotonia congenita 
Exercise-induced delayed onset myotonia: myotonia appearing after a prolonged 
period of exercise, which is a clinical phenomenon of myotonia fluctuans 
EMG: electromyography 
FAS: fatigue assessment scale 
GPH: general-health perception 
HyperPP: hyperkalemic periodic paralysis 
HYPP: hyperkalemic periodic paralysis with myotonia 
MC: myotonia congenita 
MCS: mental component summary 
MH: mental health 
MRC: medical research council, range 1-5 
MVC: maximum voluntary contraction 
Myotonia: clinical phenomenon, which refers to delayed muscle relaxation after 
voluntary or evoked muscle contraction. It is experienced by patients as muscle 
stiffness 
Myotonia fluctuans: Potassium sensitive form of NDM with fluctuations of myotonia 
and exercise-induced delayed onset myotonia 
Myotonia permanens: postassium sensitive form of NDM with serious and continuous 
myotonia 
NaCh: sodium channelopathies (PAM or SCM and PC) 
NDMs: non-dystrophic myotonic syndromes: skeletal muscle disorders including 
chloride (myotonia congenita) and sodium channelopathies (potassium aggravated 
myotonias or sodium-channel myotonias, paramyotonia congenita and hyperkalemic 
periodic paralysis with myotonia 
NNH: number needed to harm 
NNT: number needed to treat 
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NRS: numerical rating scale, range 1-10 
PAM: potassium aggravated myotonia (myotonia fluctuans, myotonia permanens, 
acetazolamide responsive myotonia congenita) 
Paramyotonia: paradoxical myotonia, i.e. worsening of myotonia after repetitive 
muscle contractions 
PC: paramyotonia congenita 
PCS: physical component summary 
PhF: physical functioning 
PROMM: proximal myotonic myopathy (DM2) 
RCT: randomised controlled trial 
RFE: role functioning emotional 
RFPh: role functioning physical 
RMC: recessive myotonia congenita (M. Becker) 
RNS: repetitive nerve stimulation 
SCM: sodium-channel myotonias: PAM diagnosed without a potassium loading test 
SCN4A: skeletal muscle sodium channel gene, mapped to chromosome 17q 23-25 
SD: standard deviation 
SF: social functioning 
SF-36: 36-item short-form health survey 
Transient paresis: transient decline in muscle force 
Vit: vitality 
Warm-up phenomenon: Improvement of myotonia and transient paresis after 
repetitive muscle contractions 
WMD: weighted mean difference 
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behorende bij het proefschrift 
 
REDEFINING THE NON-DYSTROPHIC  
MYOTONIC SYNDROMES 
Phenotypic characterisation based 
on genetic testing 
 
Jeroen Trip 
Nijmegen, 22 januari 2010 
 
1. Volgens de ‘evidence based medicine’ is er geen klasse I bewijs ten aanzien van 
de medicamenteuze behandeling voor myotonie. (dit proefschrift) 
 
2. Door bij een groep patiënten met een niet-dystrofische myotonie op basis van 
geherdefinieerde klinische kenmerken het CLCN1-gen dan wel het SCN4A-gen op 
aanwezige mutaties te analyseren wordt de diagnostische opbrengst sterk 
vergroot. (dit proefschrift) 
 
3. Voor het onderscheid tussen chloor- en natrium-kanalopathieën heeft het warm-
up fenomeen geen diagnostische waarde. (dit proefschrift) 
 
4. Chloor-kanalopathieën hebben een hoge incidentie en een lange relaxatietijd van 
myotonie in de beenspieren. Natrium-kanalopathieën daarentegen hebben een 
hoge incidentie en een lange relaxatietijd van myotonie in de ooglidspieren. 
 
 
5. De impact op het fysiek functioneren van patiënten met een niet-dystrofische 
myotonie is substantieel. Pijnlijke myotonie en vermoeidheid zijn factoren die dit 
fysiek functioneren in negatieve zin beïnvloeden. (dit proefschrift) 
 
6. Spierecho-intensiteitswaarden en functionele spiermetingen bij een groep 
patiënten met een niet-dystrofische myotonie suggereren structurele 
spierveranderingen. Indien spierbiopten dit bevestigen, dan kan de naam niet-
dystrofische myotonieën ter discussie worden gesteld. (dit proefschrift) 
 
7. Patiënten met een niet-dystrofische myotonie kunnen in een warenhuis beter 
niet de roltrap nemen. 
 
8. La médicine, c’est guérir porfois, souloger souvent, consoler toujours.  
 De geneeskunde, dat is soms genezen, vaak verlichten, altijd troosten.  
 (Ambroise Paré) 
 
9. Wie behouden wil zal steeds verliezen en wie bereid is te verliezen, zal behouden 
ook al behoudt hij iets heel anders dan hij zich oorspronkelijk had voorgesteld. 
 
10. Kritiek krijgen betekent ook dat iemand belangstelling voor je heeft. (Ton Boot) 
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